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ABSTRACT
Interferons and interleukins are induced during the acute phase response to viral infections 
and suppress drug metabolism by down-regulation of cytochrome P450 isoenzymes. Although 
numerous investigators have attempted to explain this phenomenon, the precise interferon-mediated 
molecular mechanism(s) which causes the suppression has yet to be identified.
Previous workers have examined the suppression of clofibrate-induced CYP4A1 mRNA by 
the interferon inducer, poly IC, and indicated that the interferon-mediated inhibitory mechanism acts 
at a pretranslational stage of CYP4A1 expression (Renton et al, 1987, Renton and Knickle, 1990, 
Knickle et al, 1992). The results I present in this thesis have extended these investigations.
1. In preliminary studies I have confirmed the findings of Renton and coworkers 
and also shown that the constitutive (uninduced) expression of CYP4A1 
protein, enzyme activity and mRNA is not down-regulated by poly IC.
2. I have used a cDNA probe for the peroxisome proliferator activated receptor 
(PPAR) to investigate the effects of clofibrate, poly IC and human interferon 
CL on rat PPAR mRNA expression. Down-regulation of CYP4A1 mRNA is 
not preceded by down-regulation of PPAR mRNA synthesis.
3. Neither poly IC nor human interferon a affected the induction of CYP2E1 
protein by isoniazid.
4. The species specificity of the interferon-mediated suppression of rat hepatic 
CYP4A1 expression has been examined using human interferon c l.
5. Using nuclear run-on experiments, I have shown that the interferon-mediated 
suppression of CYP4A1 induction is due to the down-regulation of clofibrate- 
induced synthesis of CYP4A1 pre-mRNA.
I have concluded from these investigations that the suppression of clofibrate-induced CYP4A1 
by type I interferons is caused by an interferon-mediated molecular mechanism(s) which interferes 
with the clofibrate-responsive mechanisms governing the transcriptional induction of the CYP4A1 
gene. In contrast, the induction of CYP2E1 by isoniazid, which occurs through protein stabilisation, 
is not affected by interferons. I have used these results to develop the proposal that the down- 
regulation of other cytochrome P450s in response to interferons or interleukins is most likely to be 
also at the level of pre-mRNA synthesis.
Interferons are often used in conjunction with other drugs in the chemotherapy of a variety 
of diseases. Since many of these drugs have a narrow therapeutic index, their reduced metabolism 
could result in accumulation leading to enhanced toxicity. Clearly, an improvement in our 
understanding of the mechanisms by which interferons affect drug metabolism will help to predict, 
and therefore restrict, any toxicity caused by combination therapy with interferons.
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CHAPTER 1 
INTRODUCTION
CHAPTER 1: INTRODUCTION
1.1 CYTOCHROME P450
Cytochrome P450 is the generic name given to a super-family of haemoproteins which, 
together with the flavoprotein NADPH-cytochrome P450 reductase, constitute the microsomal mixed 
function monooxygenase system. This enzyme system is bound to the membrane of smooth 
endoplasmic reticulum (SER) in the cells of most mammalian tissues. The primary role of 
cytochrome P450 proteins is in the metabolism of xenobiotics and some endogenous substances which 
occurs mainly in the liver.
The term "cytochrome P450" derives from the original identification of a reduced microsomal 
pigment that, when bound to carbon monoxide, gave a major absorbance peak (soret maximum) at 
450nm (Klingenberg, 1958 and Garfinkle, 1958). Further characterization of this protein by Omura 
and Sato in 1964 identified it’s haemoprotein nature, and in the following year the role of cytochrome 
P450 in the mixed function monooxygenase system was demonstrated (Cooper et al, 1965). Extensive 
research in the subsequent 25 years has revealed that cytochrome P450 exists as multiple forms 
(isoenzymes) that are ubiquitous in animal, plant, bacterial and fungal species.
1.1.1 The cytochrome P450 gene superfamily
The proteins, genes and cDNAs of many cytochrome P450 isoenzymes have been isolated 
and sequenced, and new isoenzymes are being discovered with increasing frequency. Using 
computer-aided protein sequence alignment, the degree of homology between the primary amino acid 
sequence of individual isoenzymes has been determined and used as a basis for the classification of 
the cytochrome P450 isoenzymes into families and sub-families. Isoenzymes with less than 25-40%
similarity are assigned to separate families of which there are 36 to date (12 of which are mammalian)
while sequence similarity between 40% and 70% identifies subfamilies within a family (Nelson et 
al, 1993). A similarity of greater than 70% identifies individual isoenzymes within a subfamily.
Most of the cytochrome P450 genes studied to date have been isolated and sequenced from 
the rat liver (reviewed by Soucek and Gut, 1992). However, the clinical application of our 
understanding of the cytochrome P450 isoenzymes will rely on the continuing characterisation of 
human hepatic cytochromes P450 and their differences from their rat orthologues (Wrighton and 
Stevens, 1992, Guengerich, 1992).
1.1.2 Nomenclature
Until recently the nomenclature of the cytochrome P450 genes and their products was 
confusing and disparate. However, apart from the mouse cytochrome P450 isoenzymes (see later), 
the most recent consensus of nomenclature for the P450 isoenzymes of all other species is based 
entirely on upper case letters and arable numerals (Nebert et al, 1991, Nelson et al, 1993). The genes 
are identified by the abbreviation of cytochrome P450, ’CYP’, followed by an arable numeral 
representing the P450 family, then the subfamily represented by a letter and finally, an arable 
numeral designating the individual gene. The entire appellation is italicised e.g. CYP4A1. The 
cDNA, mRNA and proteins are identified in the same way except for the use of regular typeface 
instead of italics. For example, the mRNA expressed by CYP4A1 is termed ’CYP4A1 mRNA’.
The mouse P450 genes are the given the italic root symbol ’Cy/?’, followed by an arable 
numeral representing the family, a lower case letter representing the subfamily, a hyphen, and finally 
an arable numeral representing the individual gene. The protein, cDNA and mRNA are identified in 
the same way but in normal type face. For example, the mouse orthologue of the rat CYPlAl gene 
is denoted "Cypla-1\ These nomenclature will be used throughout this thesis. It should be noted that
at times the general term ’cytochrome P450’ will be shortened to ’P450’ and the plural ’P450s’ will 
refer collectively to the cytochrome P450 isoenzymes.
1.1.3 Evolution of the cytochrome P450 genes
Although the amino acid sequence of most P450 proteins are significantly different, they all 
exhibit a high degree of homology in a 26-residue sequence near the carboxyl-terminus (Gonzalez 
and Nebert, 1990). This similarity is strongly indicative of a common genetic origin of all P450 
genes. Comparison of the substantial data bank of amino acid sequences with the estimated times of 
species divergence (based on fossil evidence) has confirmed the evolutionary relationship between 
P450s and has enabled the construction of phylogenetic trees (Gonzalez and Nebert, 1990). It is 
estimated that the original "ancestral" P450 gene was in existence as early as 2 billion years ago.
A new P450 gene may be generated by a sequence of events which usually begins with gene 
duplication. The duplicate genes then diverge as a consequence of mutations, and the differences in 
the new gene are "fixed" by the selective advantage conferred to the organism by the new gene 
product. It is interesting to note that during the past 800 million years there appears to have been 
a marked escalation in the divergence of P450 genes. This has been attributed to the concurrent 
divergence of animals from plants and the subsequent competition between them. As animals began 
to feed on plants, the latter developed protective strategies including the synthesis of new toxic 
products. In response, animals evolved new cytochrome P450 isoenzymes to metabolize these toxins.
1.1.4 Cytochrome P450 catalysed reactions
The cytochrome P450 monooxygenase system plays a critical role in the first stage of the 
metabolism of endogenous substances such as fatty acids, prostaglandins, steroids, bile acids and 
ketones and also of exogenous compounds (xenobiotics) such as drugs and pesticides. A foreign 
chemical might enter the body by absorption through the skin, through the respiratory tract or by 
ingestion. Metabolism of such essentially hydrophobic substances facilitates their excretion by 
conversion to more polar derivatives.
A range of oxidative reactions are catalysed by the P450s, the nature of the reaction 
depending on the substrate and the specific P450 isoenzyme involved. The reactions include the 
hydroxylation of aromatic, aliphatic, and cyclic compounds, oxidation, dealkylation and deamination. 
Details of these types of reactions and the substrate specific P450 isoenzymes which catalyse them 
are well documented in literature, therefore, a simple overview will be given here. Most cytochrome 
P450-mediated metabolism involves the insertion of a single atom of oxygen, derived from molecular 
oxygen, into a substrate. The essential stages of this type of metabolism are as follows.
V The substrate binds to P450 when the iron in the haem group is in the oxidised state.
The substrate-enzyme complex is then reduced by the transfer of an electron from 
NADPH. This process is catalysed by NADPH-cytochrome P450 reductase. The reduced enzyme- 
substrate complex then binds with molecular oxygen and further reduction of this complex occurs by 
the transfer of an electron either from NADPH-cytochrome P450 reductase or NADH via NADH- 
cytochrome bg reductase and cytochrome bg. Finally, the substrate-enzyme-oxygen complex splits 
into water, oxidised substrate and the oxidised form of the enzyme. The second phase of 
biotransformation involves conjugation of the oxidised compounds to polar, endogenous groups by 
the action of other enzymes such as the glutathione S-transferases.
1.1.5 CYP4A1
CYP4A1 belongs to the CYP4A subfamily of which nine members have been characterised 
to date. These are the rat liver and kidney lauric acid w-hydroxylases, CYP4A1, CYP4A2 and 
CYP4A3 (Hardwick et al, 1987, Kimura et al, 1989a, Kimura et al, 1989b); the rabbit lung 
prostaglandin co-hydroxylase, CYP4A4 (Matsubara et al, 1987); the rabbit liver and kidney fatty acid 
co-hydroxylases, CYP4A5, CYP4A6 and CYP4A7 (Johnson et al, 1990, Yokotani et al, 1989); 
CYP4A8, which has been identified in the rat prostate (Stromstedt et al, 1990); and CYP4A11 the 
human fatty acid co-hydroxylase (Kawashima et al, 1992). Recently, the gene for the human form of 
CYP4A9 has been isolated (personal communication with Steven Hood). In addition, the mouse 
Cyp4a-12, guinea pig CYP4A13, and mouse Cyp4a-10 have also been identified but the sequences 
of these genes are as yet unpublished (Nelson et al, 1993).
CYP4A1 has been selected for study in the present investigations because it is an example 
of. a constitutively expressed P450 isoenzyme which is transcriptionally inducible by a group of 
structurally diverse compounds which cause peroxisome proliferation and hepatocarcinoma in rats 
(Hardwick et al, 1987, Hawkins et al, 1987). This is in contrast to CYP2E1 whose levels are 
modulated by small organic molecules such as ethanol and isoniazid through protein stabilisation. 
Although the constitutive expression of CYP2E1 is pretranslationally enhanced in pathophysiological 
conditions such as diabetes and starvation, the main level of control is post-translational (Koop et al, 
1989).
As will be detailed later (see sections 1.3.1 and 6.3 for references), earlier work has 
demonstrated that a number of cytochrome P450 isoenzymes, including CYP4A1, are modulated in 
vivo by infection or by direct treatment with cytokines, interferons or their inducers. The mechanism 
of this effect has not been elucidated but is thought to occur pretranscriptionally (Renton and Knickle, 
1990, Morgan and Norman, 1990, Craig et al, 1990, Morgan, 1991, Pasco et al, 1992). A
comparison of the effects of interferon on the expression of CYP4A1 and CYP2E1 will improve our 
understanding of the down-regulation of drug metabolism by the acute-phase response.
According to the evolutionary tree constructed for the cytochrome P450 genes, the CYP4A1 
gene was formed approximately 1.25 billion years ago (Kimura et al, 1989a). The gene has 13 exons 
one of which is non-coding and a 19bp sequence, located 42bp upstream from the transcription start 
site, which is highly conserved between the CYP4A1 and CYP4A2 genes (Kimura et al, 1989a). It 
has been proposed that the 19bp conserved upstream element is involved in the transcriptional 
regulation of these genes (Kimura et al, 1989a). Another feature of the CYP4A1 gene is that it does 
not contain a consensus TATA sequence upstream of the transcription start site, neither does the 
promoter region contain a consensus sequence in common with other genes lacking a TATA box 
(Kimura et al, 1989a).
In addition to being transcriptionally inducible, evidence suggests that CYP4A1 may also be 
regulated through differential splicing of the pre-mRNA (Eamshaw et al, 1988). Transcription of the 
CYP4A1 gene produces a pre-mRNA which is alternately spliced in intron 12 generating two mRNA 
species one of which has a 75 nucleotide insert in the 3’ non-coding region. The biological 
significance of differential splicing to the regulation of CYP4A1 expression is not yet known.
The induction of CYP4A1 expression appears to be sex specific. It was shown recently that 
the clofibrate-induced expression of CYP4A1 mRNA in the male rat liver was much more 
pronounced, approximately 12 fold greater, than in the female rat liver (Sundseth et al, 1992).
In the studies described above and in the present investigations, clofibrate was used to induce 
the expression of CYP4A1. Clofibrate is one of a group of structurally diverse chemicals which have 
been shown to induce the proliferation of rat hepatic peroxisomes (Hawkins et al, 1987). Other such 
peroxisome proliferators include analogues of clofibrate such as ciprofibrate, bezafibrate and 
nafenopin; plasticisers such as di-(2-ethylhexyl)phthalate; pesticides such as dimethrin, drugs such 
as aspirin; and industrial solvents such as trichloroethylene (Hawkins et al, 1987, Reddy and
Lalwani, 1983).
Another property of clofibrate, which is shared with it s analogues and some other 
peroxisome proliferators, is an ability to lower high levels of lipids in the blood resulting from 
hyperlipidaemias which have been associated with ischemic heart disease (Hawkins et al, 1987). 
Although clofibrate appeared to be successful as a hypolipidaemic drug in clinical trials, an increase
in non-cardiac mortality in treated patients, possibly related to latent side effects of clofibrate,
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compared with the control group has raised doubts about its therapeutic /  (Oliver, 1978,
Strandberg et al, 1991, Editorial in the Lancet, 1991).
CYP4A1 specifically catalyses the w-hydroxylation, and to a lesser extent w-1 hydroxylation, 
of lauric acid, arachidonic acid and palmitic acid indicating a physiological role for this isoenzyme 
in lipid homeostasis (Bains et al, 1985, Sharma er al, 1988a, Sharma et al, 1988b). An understanding 
of the mechanism of CYP4A1 induction is critical to an examination of how interferons down- 
regulate the expression of this P450 isoenzyme. Two hypotheses have been proposed for the 
induction of CYP4A1 expression and peroxisome proliferation.
In the ’lipid overload’ theory, the initial stimulus is a perturbation of normal hepatocellular 
fatty acid metabolism induced by peroxisome proliferators and non-chemical factors such as 
starvation, diabetes, cold adaptation and high fat diets (Sharma et al, 1988a, Sharma et al, 1988b, 
Hawkins et al, 1987). Peroxisome proliferators have been shown to inhibit the mitochondrial /?- 
oxidation of fatty acids in the hepatocyte (Eacho and Foxworthy, 1988, Foxworthy and Eacho, 1988). 
In particular, long chain unsaturated fatty acids, which are poor substrates of mitochondrial j8- 
oxidation, have been shown to cause mitochondrial enlargement and loss of function (Osmundsen and 
Bjomstad, 1985).
According to this hypothesis, the resultant accumulation (or ’overload’) of intracellular fatty 
acids in hepatocytes causes peroxisome proliferation and the transcriptional induction of CYP4A1 by 
unidentified mechanisms. Following the enhanced w-hydroxylation of long chain fatty acids to
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medium and long chain dicarboxylic acids by microsomal CYP4A1, subsequent /3-oxidation by 
peroxisomal enzymes generates short chain fatty acids which are more readily oxidised further by 
the mitochondria.
The alternative hypothesis to this is a ligand-receptor mediated mechanism. In 1983, Lalwani 
and coworkers identified a rat liver cytosolic protein which displayed stereospecific binding to 
nafenopin, an analogue of clofibrate (Lalwani et al, 1983). They later purified the protein, which 
they named the peroxisome proliferator binding protein (PPbP), and demonstrated that it also bound 
to clofibrate and ciprofibrate (Lalwani et al, 1987). Considering the structural diversity of peroxisome 
proliferators, it was postulated that either the PPbP possesses more than one binding site or that more 
than one type of PPbP exists in the liver.
When similar ligand binding studies carried out by others failed to detect a PPbP, the 
existence of a cytosolic protein receptor for peroxisome proliferators was disputed (Milton et al, 
1988). Subsequent work conducted by this group showed that the induction of CYP4A1 occurred 
before that of peroxisomal j3-oxidation and therefore supported the sequential mechanism proposed 
in the ’lipid overload’ hypothesis.
The molecular mechanisms of peroxisome proliferation were somewhat clarified recently with 
the identification of a novel member of the nuclear steroid hormone receptor family which is 
activated by peroxisome proliferators (Issemann and Green, 1990). The mouse peroxisome 
proliferator activated receptor (PPAR) gene was cloned and the probable ligand-binding domain 
identified. A chimeric receptor cDNA containing the DNA-binding domain of a steroid 
(glucocorticoid or oestrogen) receptor gene and the PPAR ligand-binding domain was then 
constructed. This cDNA construct was transfected (into an expression plasmid) into COSl cells in 
order to express the hybrid protein. Following treatment of the cells with a range of peroxisome 
proliferators, this chimeric protein was able to bind to a steroid response element linked to a 
chloroamphenicol acetyltransferase (CAT) reporter gene in a second transfected plasmid. An increase
in CAT activity was observed for a range of structurally dissimilar peroxisome proliferators 
suggesting that a single PPAR protein species might be involved in the induction of peroxisome 
proliferation.
The nuclear receptor-mediated hypothesis has been strengthened by the identification in the 
5’ flanking regions of the CYP4A6 and acyl Co A oxidase genes of response elements which are 
recognized by the activated mouse PPAR (Tugwood et al, 1992, Muerhoff et al, 1992a, Muerhoff 
et al, 1992b). Acyl Co A oxidase is a rate-limiting enzyme in peroxisomal j3-oxidation and is often 
used as a marker for peroxisome proliferation. The response elements (to which the PPAR binds) 
have been denoted the ’peroxisome proliferator response elements’ (PPREs). Although a PPRE 
associated with the promoter of CYP4A1 has not yet been identified, it is possible that the regulatory 
element might be located in the 5’ flanking region further upstream to that which has been sequenced 
thus far (Kimura et al, 1989a). A rat cDNA for a PPAR gene, which encodes a protein that is 97% 
homologous to the mouse PPAR, has also been identified (Gottlicher et al, 1992).
It has been suggested that the two hypotheses outlined above are not mutually exclusive (Lock 
et al, 1989). It is possible that specific lipid accumulation may be an important factor in peroxisome 
proliferation but an inhibition of /3-oxidation may not be a prerequisite for this. Additional 
mechanisms might be involved, such as the activation of PPAR by a peroxisome proliferator. This 
combined theory is supported by the activation of the rat PPAR by saturated fatty acids (Gottlicher 
et al, 1992). Therefore, in addition to activation by peroxisome proliferators, the PPAR might also 
be activated by an accumulation of lipids.
Recent studies involving other members of the nuclear receptor superfamily including the 
thyroid hormone receptor (TR) and the vitamin Dg receptor (VDR) suggest that the PPAR might 
heterodimerise with the retinoid X receptor (RXR) prior the transcriptional induction of peroxisome 
proliferator responsive genes ((Carlberg et al, 1993, Green, 1993, Thomas et al, 1993, Umesono et 
al, 1991). These implications and a more detailed review of the recent progress made in the
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elucidation of the mechanisms which control CYP4A1 induction and other peroxisome proliferator- 
inducible genes are detailed later (section 6.4).
1.1.6 CYP2E1
In 1982, Koop and coworkers purified a cytochrome P450 isoenzyme from the hepatic 
microsomes of rabbits which had been treated with ethanol. They called this protein LM3a. Since 
then, immuno-related cytochrome P450 orthologues have been identified in the rat, hamster and in 
man among other animal species (Ryan et al, 1985, McCoy and Koop, 1988, Lasker et at, 1987). 
Although the nomenclature of this P450 isoenzyme varies in literature, it is now also designated the 
term CYP2E1. It appears that the constitutively expressed CYP2E1 is differentially expressed in the 
tissues of the animals studied so far. While CYP2E1 has been identified in the rabbit liver, kidney 
and nasal mucosa, it has not been detected in microsomes from the brain, lung, adrenal, heart, 
intestine, spleen, ovaries, testes, or uterus even after ethanol treatment (Ding et at, 1986). However, 
very small levels of CYP2E1 have been measured in the rat lung, ovaries and testes as well as in the 
liver and kidney (Thomas et al, 1987).
Like m ^y of the other P450 isoenzymes, CYP2E1 metabolises a range of xenobiotics such 
as drugs and environmental pollutants. Structurally diverse chemicals have been shown to induce 
CYP2E1 and, like ethanol, some of these substances are also substrates of the isoenzyme. The 
known inducers and substrates of CYP2E1 are indicated in figure 1.1.
Constitutive expression of CYP2E1 is transcriptionally activated by déméthylation of specific 
sites around the gene during development of the rat (Song et al, 1986, Umeno et al, 1988). The 
CYP2E1 gene is inactive in newborn rats. Transcriptional activation of the CYP2E1 gene, by specific 
5’ cytosine déméthylation, occurs (in both male and female rats) within one week of birth (Song et 
al, 1986, Umeno et al, 1988).
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INDUCERS SUBSTRATES
Ethanol
Isoniazid
Pyridine
Acetone
■ Imidazole
Ethanol
Paracetamol
Glycerol
Acetone
Chloroform
Aniline
CCI4
Nicotine
N-Nitosomethylamine
Figure 1.1 , Some chemical inducers and substrates of CYP2E1
(Koop et al, 1989)
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In the adult rat, the induction of CYP2E1 protein by small organic molecules (such as 
ethanol, acetone and isoniazid) is not accompanied by an increase in CYP2E1 mRNA indicating that 
the induction of this isoenzyme by small organic molecules occurs at the translational or post- 
translational levels (Song et al, 1986). This type of CYP2E1 induction has been attributed to an 
increase in protein stabilisation caused by the organic molecules acting as ligands thereby preventing 
degradation of the protein (Song et al, 1989, Eliasson et al, 1988, Eliasson et al, 1990).
The elevation of the catalytic activities associated with CYP2E1 in response to certain 
nutritional and pathophysiological states has given rise to a number of hypotheses about the 
endogenous function(s) of this enzyme. Studies conducted to elucidate the mechanisms of these 
postulated roles have also revealed that the regulatory mechanisms controlling CYP2E1 expression 
vary depending on the nature of the inducing stimuli.
It has been demonstrated that starvation is accompanied by an induction in the activity of 
CYP2E1 and an increase in CYP2E1 mRNA (Hong et al, 1987, Miller and Yang, 1984). 
Spontaneous and chemically-induced forms of diabetes in rats have also been shown to be associated 
with an elevation in the levels of CYP2E1 protein and mRNA (Song et al, 1987). However, nuclear 
run-on experiments demonstrated that the increase in mRNA was not due to an increase in 
transcriptional activity but was more likely to be the result of either an increase in CYP2E1 mRNA 
stabilisation or a decreased degradation of the mRNA.
It is known that fasting and diabetes are associated with an increase in ketone body formation 
indicative of a change in lipid metabolism (Peng et al, 1983). It has been suggested that under such 
circumstances, the higher concentration of acetone is metabolised mainly by CYP2E1, rather than 
via the gluconeogenic pathway that occurs under normal physiological conditions (Landau and 
Brunengraber, 1987). Obesity is another physiological condition which is accompanied by an 
elevation of CYP2E1 activity although the biological significance of this is not yet clear (Salazar et 
al, 1988).
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1.2 INTERFERONS
1.2.1 Historical background
The term ’interferon’ originates from the observation of an interference between inactive and 
active influenza viruses in the developing chick embryo which attenuated the growth of the active 
virus (Henle and Henle, 1943). The basic nature of this mysterious phenomenon was established by 
Isaac, Lindenmann and coworkers (Isaac and Lindenmann, 1957, Isaac et al, 1957). After incubating 
chick chorioallantoic membrane with heat-inactivated influenza virus, they isolated the cell- and virus- 
free medium and incubated this with fresh membranes and live virus. The inability of the fresh virus 
to grow suggested that the interfering factor was produced in the original membrane in response to 
the inactive virus and then secreted into the medium. Their studies revealed that the interfering factor 
(which they named ’interferon’) was a protein, stable in the pH 2-10 range and at 60*C for 1 hour.
It soon became evident that more than one type of interferon exists. Although the 
nomenclature of these proteins varies in literature, in recent times the three interferon types have 
been designated the lower case Greek letters ot, ^  and 7 . The interferons are sometimes referred to 
as cytokines, the general term for a group of polypeptide mediators which are released by a variety 
of activated immune and non-immune cells. The other mammalian cytokines include the interleukins 
(IL), tumour necrosis factor a. (TNFœ), lymphotoxin (LT or TNF/3), granulocyte colony stimulating 
factor (G-CSF), macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF) and 
transforming growth factor (TGF-/3) (Beck and Habicht, 1991, Durum and Mealy, 1990, Durum et 
al, 1991). Elucidation of the molecular nature and properties of interferons is rapidly progressing. 
The multiplicity of the effects of interferons on cell structure and function have been well documented 
and in-depth reviews exist which can supplement the overview described here (Pfeffer, 1987a, 
Pfeffer, 1987b, Mannering and Deloria, 1986, Pestka and Langer, 1987).
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1.2.2 General properties of interferons
There are at least 24 human and 12 murine nonallelic human genes, which do not contain 
introns, encoding the a  interferons. The human interferon a genes belong to two subfamilies denoted 
IFN-tti (at least 18 genes) and IFN-an (at least 6 genes). Whereas the coding sequences of the intra­
subfamily human interferon a genes differ by upto 8%, the differences between the subfamilies are 
approximately 30% (De Maeyer and De Maeyer-Guignard, 1991, Pestka and Langer, 1987). The 
molecular size of human a interferon subtypes range from 16,000- 27,000 and several of the 
subtypes are glycosylated, however, the function of this carbohydrate moiety is unknown. The main 
cellular sources of a interferons are B and null lymphocytes.
Unlike the a interferons, the human and murine interferon /3 genes exists as a single copy. 
Human interferon jg is a glycosylated protein with a molecular size of approximately 20,000 and, in 
common with the a  interferons, it can be induced by a wide range of viruses and double-stranded 
RNA. The human a interferon and interferon P genes are clustered on the short arm of chromosome 
9 while the murine type II interferon genes are located on chromosome 4. There is approximately 
48% similarity between the amino acid sequences of human and murine interferon p proteins. These 
similarities suggest an evolutionary relationship between the two interferon types and form the basis 
of their classification as type I interferons. However, several important differences distinguish 
interferon jg as a separate type. Firstly, the gene encoding human interferon p has no more than 30% 
sequence homology with the a interferon genes (Pestka and Langer, 1987). Moreover, interferon p 
is induced mainly in epithelial and fibroblast cells. In the early days of interferon research, the 
difference in their main cellular sources was used to classify the cx interferons and interferon P as 
leucocyte and fibroblast interferons respectively. In addition to a strong induction by viruses and 
double-stranded RNA, the type I interferons are also weakly induced by microbes, their products and 
low molecular weight chemicals such as tilorone (Mannering and Deloria, 1986).
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The synthetic double stranded polynucleotide, polyriboinosinic- polyribocytidilic acid (poly 
IC) induces both type I interferons in cultured human cells. In*diploid fibroblast cell cultures, 
interferon P is predominantly induced by poly IC whereas interferon a is the main type induced in 
human lymphoblastoid cells (Knight, 1976, Tamura et al, 1983). It is not clear what proportion of 
each interferon type is induced by poly IC in rats. Where the induction of interferon by poly IC has 
been reported in literature, it is expressed in terms of antiviral activity, a property shared by both 
type I interferons. Therefore, it is assumed that poly IC induces a combination of the a interferons 
and interferon p. Due to higher levels of serum ribonuclease, poly IC is a poor interferon-inducer 
in monkeys and humans (Pfeffer, 1987a). For this reason and due to its toxicity (exhibited as nausea, 
lethargy and fever among other symptoms), the clinical uses of poly IC have been restricted. 
Although the precise mechanism(s) by which poly IC induces type I interferons is not yet known, it 
is thought to involve a trans-2ictmg transcription factor (Enoch et al, 1986).
The single copy human gene encoding the type II interferon y  has three introns, is located 
on chromosome 12 and has no sequence homology with the type I interferons (Pestka and Langer, 
1987). Interferon y, is induced mainly in T lymphocytes in response to mitogen or antigen 
stimulation and is an important immunomodulator (see section 1.2.4.1).
1.2.3 Interferon receptors
The cell surface receptors which recognize interferons display a marked specificity for 
interferon type. Type I interferons (a and P) bind to a common receptor, whereas interferon y  
interacts with a different receptor. The specificity of interferon receptors for interferon type was 
demonstrated by competition experiments (Branca and Baglioni, 1981).
Unlabelled HuIFN a and HuIFN P abolished the binding of ^^I-labelled HuIFN a  to its 
receptor, while HuIFN y  was unable to compete with the radiolabelled HuIFNa for receptor
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occupancy. In addition, the type I interferon receptors show a further specificity for the different 
subtypes of interferon a  which have been shown to bind with variable affinity to a common receptor 
on human cells (Aguet et al, 1984).
The genes for the receptors of type I and II human interferons are located on the distal 
segment of the long arm of chromosome 21 (Epstein, 1981, Epstein and Epstein, 1982). It is 
interesting to note that in children with Down’s syndrome, who have three copies of chromosome 
21, there is an exaggerated sensitivity to the effects of interferon (Epstein and Epstein, 1982).
Although very little is known about the signal transduction mechanism(s) induced by the 
binding of interferons to their cell surface receptors, it is generally accepted that interferons do not 
have to be internalized to act. A decrease in interferon-receptor binding at the surface of bovine 
kidney cells, which had been pre-exposed to HuIFN a, was shown to be due to a decrease in the rate 
of appearance of new HuIFN a  receptors to the plasma membrane rather than due to occupied- 
receptor internalization (Zoon et al, 1986).
In addition to the specificity of interferon receptors for interferon type, receptor-binding is 
also thought to govern the species specificity of interferon action. In general, the closer the 
phylogenetic relationship between the animal species of the cells treated and the species source of the 
interferon, the greater are the antiviral effects of the interferon (Chany et al, 1982). One exception 
to this general rule appears to be human interferon a. which has been shown to express antiviral 
activity in primate, bovine, porcine, feline and rabbit cells (Gresser et al, 1974, Paucker et al, 1975, 
Stewart and Desmyter, 1975, Jameson et al, 1977, Week et al, 1981).
1.2.4 The biological effects of interferons
The induction and activities of interferons in certain pathophysiological conditions, such as 
viral infections and malignancies, belie the fact that these proteins have regulatory roles in normal
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cellular and physiological processes. The following is an overview of the main activities of 
interferons.
1.2.4.1 The role of interferons in immunomodulation
The major immunoregulatory role of type I interferons is in the establishment of an antiviral 
state in infected cells (see section 1.2.4.3). In addition, the type I interferons have also been shown 
to exhibit some of the immunomodulatory activities of interferon 7  which plays an integral role in 
the complex, dynamic interactions which comprise the immune system.
The production of interferon 7 , mainly by T cells and natural killer (NK) cells, in response 
to mitogen or antigen stimulation is regulated by the interactions between T helper cells (Tg), T 
suppressor cells (Tg), macrophages and the interferon producing cells. Although the precise molecular 
mechanisms controlling interferon 7 production are not known, the current understanding of the 
process indicates an important role for interleukin-2 (produced by Tg cells in response to interleukin- 
1 (IL-1) secretion by macrophages) in the stimulation of interferon 7  synthesis (Male et al, 1991).
Interferons a, P and 7 have been implicated in the maturation of B cells. The production of 
antibodies is differentially regulated by interferons depending on the stage of development of the B 
cells. While they appear to suppress antibody production before the B cells have undergone clonal 
expansion, interferons enhance antibody production in B cells which have been terminally 
differentiated (Johnson and Baron, 1976).
Interferon 7 enhances the cytotoxic activities of NK cells, cytotoxic T lymphocytes (Tc) and 
the tumour cell killing activity of macrophages. All three interferon types have been shown to induce 
NK cell cytotoxicity (Weigent et al, 1983). Synergism between interferon 7  and TNF augments this 
immune response by increasing the susceptibility of target cells to the cytotoxic activities of Tc and 
NK cells.
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One of the most important immunoregulatory roles of interferon 7  is in the induction of the 
major histocompatibility complex (MHC) class I and II antigens on the surface of antigen presenting 
cells (including macrophages). The MHC class I antigens recognize specific Tc cell responses while 
the class II antigens are necessary for Tg cell-dependent functions. Interferon 7  also enhances the 
expression of some T cell membrane receptors. These include the Fc receptors (which are important 
in the recognition of antibodies) and IL-2 receptors which, when stimulated, promote proliferation 
of the T cells (Male et al, 1991).
1.2.4.2 Interferons in cell differentiation and proliferation
Interferons inhibit cell proliferation mainly by decreasing the rate of transition of cells from 
the GO/Gl phases to the S phase of the cell cycle (Sokawa et al, 1977). This effect is thought to be 
due to an interferon-mediated down-regulation of the expression of certain proto-oncogenes which 
are involved in directing cell division. In one of the studies supporting this proposal, a decrease in 
myc mRNA correlated with an inhibition in the proliferation of an interferon-treated cell culture 
(Einat et al, 1985).
In addition, several studies have demonstrated that interferons (interferon p in particular) are 
induced by colony stimulating factor I (CSF I), platelet derived growth factor (PDGF) and tumour 
necrosis factor (TNF) (Moore et al, 1984, Zullo et al, 1985, Van Damme et al, 1985, Kohase et al, 
1986). These observations have suggested a role for interferon in the negative feed-back control of 
these growth factors some of which are known to promote cell division through an induction of proto­
oncogene expression.
It has been shown that interferon a and interferon P inhibit the proliferation of human 
prostate carcinoma cell lines grown in culture suggesting that the antiproliferative activity of 
interferons may be responsible for their antitumour effects in man and in animal models (Sica et al,
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1989). The antitumour mechanisms mediated by interferons are not understood and are likely to be 
complex. Inhibition of cell proliferation may be just one of the multiple mechanisms involved 
(Gresser, 1990).
In addition to a role in cell proliferation, interferons also play a part in the differentiation of 
some cells types. The effects of interferons on cell differentiation vary depending on the cell type, 
interferon type and on the stage of development of the cell (Romeo et al, 1989). For example, 
MuIFN OL, P and y  have different effects on erythroid differentiation of Friend leukaemia cells (FLC) 
where MuIFN p enhanced differentiation but MuIFN a  and y  inhibited it (Coccia et al, 1990). A 
clear picture of how interferons modulate differentiation and developmental processes has not yet 
emerged.
1.2.4.3 The antiviral activities of interferons
A model representing the current understanding of the antiviral mechanisms mediated by type 
I interferons is shown in figure 1.2. Essentially, two enzyme systems which exhibit antiviral activities 
are stimulated by the binding of type I interferons to specific receptors on the surface of infected 
cells.
One of these pathways is initiated by the interferon-mediated induction of the gene expressing 
inactive 2’ ,5’-oligoadenylate synthetase (Pfeffer, 1987a). Following activation by double-stranded 
RNA (the genome of RNA viruses or the replicative intermediate of DNA viruses), the 2’,5’- 
oligoadenylate synthetase catalyses the synthesis of a family of oligonucleotides of the general 
structure ppp(A2’p5’)nA with n>2 (abbreviated to 2,5A). The 2,5A activates a latent 
endoribonuclease (denoted RNase L) which in turn degrades viral and cellular RNA molecules by 
cleaving single stranded RNA molecules on the 3’ side of -UpXp- sequences (with X = A, C or G).
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Figure 1.2 The antiviral activities induced by type I interferons
(Pfeffer, 1987a)
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A third enzyme, 2’,5’-phosphodiesterase, catalyses the degradation of 2,5A to regenerate AMP and 
ATP. The other antiviral mechanism is stimulated by the interferon-mediated induction of the inactive 
form of a cAMP-dependent protein kinase. Activation of the enzyme by double- or single-stranded 
RNA enables it to phosphorylate the a subunit of the protein synthesis initiation factor eIF-2, thereby 
inactivating it and preventing the synthesis of viral proteins.
1.2.5 Interferon-mediated signal transduction
The activities of interferons are initiated by their binding to saturable, high-affinity cell- 
surface receptors. The correlation between interferon receptor-binding at the cell surface and the 
subsequent transcriptional regulation of gene expression has been reported in numerous studies 
(Fertsch-Ruggio et al, 1988, Hannigan and Williams, 1986, Caplen and Gupta, 1988, Gupta, 1990, 
Shan and Lewis, 1989, Rutherford, 1988).
Interferon a  and interferon y  have been shown to induce transcription by different 
mechanisms (Caplen and Gupta, 1988, Gupta, 1990). Cycloheximide treatment inhibited the 
transcriptional induction of the C5-4 gene by interferon y  but did not affect its induction by interferon 
a, indicating that transcriptional activation by interferon y  requires the synthesis of a new protein 
while interferon «-mediated induction does not.
Little is known about the signal transduction mechanism(s) induced by interferon y. Much 
of the research to date focuses on interferon a, and since type I interferons bind to the same cell 
surface receptors, it is assumed (at this stage) that they trigger the same signal transduction pathways. 
The following is a summary of the current information available (reviewed more extensively by 
Pfeffer and Tan, 1991 and Williams, 1991).
Many independent studies have identified the involvement of at least two regulatory protein 
factors in the interferon « mediated regulation of transcription. Lamer and coworkers showed that
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interferon « treatment for 4 hours resulted in the transcriptional induction of two genes, IFN-IND-1 
and -2, in human fibroblasts (Lamer et al, 1986). This was not prevented by cycloheximide 
indicating that transcriptional induction by interferon a. does not require the synthesis of new 
proteins. However, continuous interferon a treatment for up to 8 hours resulted in a decline in the 
transcription rate of IFN-IND-1 and -2. This latter response was termed ’desensitization’. When 
desensitized fibroblasts were washed in the presence of cycloheximide, a time-dependent increase in 
the transcription rate of the genes was observed suggested that desensitization involves a negative 
regulatory factor(s) whose expression requires the synthesis of new proteins.
Levy and coworkers have confirmed this finding and identified the DNA binding site of these 
proteins (Levy et al, 1988, Kessler et al, 1988). They studied two genes, ISG54 and ISG15, 
belonging to a set of genes, termed interferon-stimulated genes (ISGs), which are transcriptionally 
activated by type I interferons. Deletion analysis and point mutagenesis of ISG54 and ISG15, and 
comparison of the 5’ flanking region of these and other ISGs, revealed a 15bp consensus element 
with the sequence YAGTTTC(A/T)YTTTYCC (with Y = A, T, C or G).
Gel-shift protein-DNA binding assays revealed that two protein complexes, denoted B2 and 
B3, were involved in the transcriptional regulation of ISGs by interferon «. B2 appeared after 1.5 
hours of interferon ol treatment, reaching a maximal level at about 4 hours and declining at about 10 
hours after continuous interferon treatment. The appearance of B2 was blocked by cycloheximide 
suggesting that this protein might be involved in the down-regulation of transcription described by 
Caplen and Gupta (1988). B3 bound to the same DNA sequence as B2, but did not exhibit the same 
sensitivity to cycloheximide treatment. Therefore B3 was identified as the putative latent cellular 
protein responsible for the transcriptional induction of ISGs by interferon ct.
Other groups confirmed the existence of a latent cellular DNA-binding protein, which they 
called E, in human foreskin fibroblast cells treated with interferon « (Dale et al, 1989a, All Iman 
et al, 1990). This protein was necessary for the transcriptional induction of the human gene 6-16 in
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HeLa cells (Dale et al, 1989b). Another protein complex, C1/C2, was also observed. Point 
substitution mutation analysis and competition band-shift assays indicated that the two protein 
complexes had overlapping binding sites on the 6-16 ISRE.
Different footprinting techniques revealed that E interacted closely with DNA on only one 
face of the helix, over the 5’ part of the ISRE, making contact with both the major and minor 
grooves while the C1/C2 complex probably wrapped around the DNA. According to these three- 
dimensional models, the binding of the two complexes with the ISRE should be mutually exclusive. 
It has been established that E is necessary for transcriptional induction, therefore the repression of 
transcription might occur by competition of the regulatory binding site by the C1/C2 complex.
The cycloheximide-sensitive appearance of another protein, denoted M, occurred at a maximal 
level when the transcription rate was maximal (All hnan et al, 1990). The rate of transcription 
declined more rapidly when M was absent than when it was present suggesting a role for M as a 
positive regulatory factor that maintains a low level of transcription.
Some interferon-induced regulatory proteins recognize a 29bp cis-acting sequence called the 
interferon consensus sequence (ICS) which shares a degree of homology with the ISRE (Roy and 
Lebleu, 1990). Roy and Lebleu showed that a protein factor, which does not itself interact with the 
ICS, increased the DNA-binding properties of other nuclear proteins by enhancing their capacity to 
be phosphorylated.
The phosphorylase, protein kinase C (PKC), has been implicated in the signal transduction 
pathway induced by interferon a  (Reich and Pfeffer, 1990, Pfeffer et al, 1990). The inhibition of 
PKC activity by staurosporine in HeLa cells was shown to prevent the ability of interferon « to 
establish an antiviral response to infection by vesicular stomatis virus. In addition, the inhibition of 
PKC activity correlated with an inhibition of the transcriptional activation of the ISGs studied. 
Immunochemical analysis revealed a specific translocation of the isoform of PKC from the cytosol 
to the particulate fraction of HeLa cells after interferon a. treatment, while other isoforms of PKC
24
remained unaffected (Reich and Pfeffer, 1990). This suggests that an interferon-mediated mechanism 
selectively activates thei soform of PKC.
Clearly, interferon a  regulates the expression of different interferon-responsive genes via 
different, perhaps related, pathways. The following model of one such pathway emerges from the 
observations described above. The binding of interferon a  to its specific cell surface receptor 
generates an intracellular signal which involves the activation, possibly due to phosphorylation by 
the j3-isoform of PKC, of a latent cytoplasmic protein. Thus activated, the protein then migrates to 
the nucleus where it binds to the ISRE or ICS of ISGs inducing the transcription of these genes. A 
second protein, whose activity requires the de novo synthesis of proteins, subsequently binds to the 
same consensus sequence in such a way that the induction of transcription initiated by the first 
regulatory protein is suppressed to a low level. This reduced rate of transcription may then be 
maintained by an additional regulatory factor.
1.2.6 The clinical use of interferons
The use of interferons in early clinical trials was restricted by the expense and paucity of 
purified interferons. The advent of recombinant technology enabled the production of large quantities 
of pure interferons facilitating subsequent clinical studies. The therapeutic efficacy of interferons has 
been complicated by the unpredictability of the outcome of treatment. This has been attributed to the 
differences in the properties of the interferon types and sub-types and the problems associated with 
their tolerance, toxicity and interaction with other chemotherapeutic drugs, hi addition, the down- 
regulation of drug metabolism by interferons and their inducers in animals and humans has been well 
documented (Mannering and Deloria, 1986 and section 1.3).
From the existing literature it is clear that interferon a is the most widely used interferon type 
in the treatment of infectious diseases. A wide range of viral infections including infiuenza, herpes
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virus, Epstein-Barr virus and hepatitis B virus, have been treated with interferon a  with varying 
degrees of success (hnanishi et al, 1980, Sandmacher et al, 1976, Cheeseman er a/, 1980, Weimar 
et al, 1980).
More recently, interferons have been used in the treatment of patients infected with the human 
immunodeficiency virus (HIV). Although it has been demonstrated that type I interferons reduce HIV 
replication in vitro, their antiviral activity in infected patients has not been effective (Crespi, 1989, 
Michaelis and Levy, 1989, Hadden, 1991). However, the antitumour activity of interferon « has been 
beneficial to HIV-infected patients who have developed the acquired immunodeficiency syndrome 
(AIDS). The administration of high dose levels of interferon « has been shown to induce regression 
of Kaposi’s sarcoma, the most common AIDS-related malignancy (Krown et al, 1986). Other 
malignancies, including melanomas, renal cell carcinoma, breast carcinoma and hairy cell leukaemia, 
have also been treated with interferons (Borden, 1988). For instance, interferon « treatment was 
successful in inducing the regression of malignant melanoma in about 10-15 % of patients (Legha, 
1986).
The adverse side effects of interferons are the major drawback to their clinical effectiveness. 
The typical side effects of interferon « treatment are fever, chills, headache, malaise and loss of 
appetite (Wills, 1990). Recently, interferon «-2b treatment of a patient suffering from chronic 
myelogenous leukaemia resulted in her death due to liver failure (Wandl and Kloke, 1992). In another 
case, 5 out of 38 metastatic renal cell carcinoma patients suffered mental deterioration 3 weeks to 
13 months after the start of treatment with recombinant interferon «-C (Merimsky et al, 1990).
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1.3 INTERFERON-MEDIATED SUPPRESSION OF DRUG METABOLISM
1.3.1 Historical background
In 1972, Morahan and coworkers conducted a study to investigate the effect of the molecular 
size of poly IC on its ability to induce serum interferon (Morahan et al, 1972). Their results revealed 
that a decrease in molecular size of the double stranded RNA correlated with a decrease in its ability 
to induce interferon.
In addition to this outcome, they also observed that poly IC administration prolonged the sleep 
time induced by hexobarbital and reduced the metabolism of aminopyrine. These seemingly incidental 
observations formed the basis of the growing area of research concerned with elucidating the 
mechanisms governing the interferon-mediated suppression of cytochrome P450.
Soon after this initial finding, two separate groups lead by Renton and Mannering (1976a) 
and Leeson (1976) demonstrated that the treatment of rats with tilorone, a drug thought to exert its 
antiviral activity through its induction of interferon, resulted in a marked depression of the 
metabolism of ethylmorphine, aniline and benzo(a)pyrene. In the same year Renton and Mannering 
(1976b) went on to show that this effect is consistent following the administration of twelve known 
inducers of interferons to rats, including an RNA virus, a fungal my cophage, poly IC and E.coli 
endotoxin.
These observations lead Renton and Mannering (1976b) to propose that if the suppression of 
drug metabolism in response to viral infection (and interferon inducing agents) seen in rats is as great 
in humans, then the treatment of patients with antiviral chemotherapy including interferon might 
result in an accumulation of the medication due to the suppression of drug metabolism. Such an 
accumulation of drugs, which might have a narrow therapeutic index, would be expected to lead to 
cellular toxicity and tissue damage.
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This prediction was soon realized with reports of patients receiving theophylline for the 
treatment of respiratory disorders, who suffered toxicity following influenza infection or vaccination 
(Chang et al, 1978, Kraemer et al, 1982). The theophylline toxicity was exhibited as nausea, 
diarrhoea, malaise, cold sweats and chest pains.
This mounting body of evidence demonstrating the depression of drug biotransformation by 
interferon-inducing agents lead Renton to propose that the inhibitory effect might be directed 
specifically at the cytochrome P450 isoenzymes (Renton, 1978). Thereafter, it was not long before 
the involvement of both interferons and the cytochrome P450s in this phenomenon was demonstrated. 
Renton showed that in mice infected with encephalomyocarditis virus, the time course for the 
induction of interferons correlated directly with the suppression of cytochrome P450 (Renton, 1981).
In the same year, this evidence was reinforced with studies conducted on mice infected with 
the Newcastle disease virus (Singh and Renton, 1981). The CjH/HeJ strain of mouse, which produces 
a high titre of interferon after infection, also exhibited a suppression of P450 while the viral infection 
of C57BL/6J mice, which do not produce interferon, was not associated with a decrease in 
cytochrome P450.
The advent of recombinant DNA technology during that time enabled the most conclusive 
demonstration of the involvement of interferons in the down-regulation of cytochrome P450. 
Following the administration of recombinant interferon ol to mice, the level of hepatic cytochrome 
P450 was markedly suppressed (Singh et al, 1982). Since this report, recombinant interferons have 
been applied to numerous studies confirming the initial finding and showing that the ability to depress 
drug metabolism is common to all the interferon types, albeit with varying potency (Parkinson et al, 
1982, Smith et al, 1983, Renton et al, 1984, Taylor et al, 1985, Franklin and Finkle, 1985, Bertini 
et al, 1988, Moochhala et al, 1989, Craig et al, 1989, Okuno et al, 1990, Craig ar al, 1990, Craig 
et al, 1992, Ansher et al, 1992).
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The treatment of mice, rats and hamsters with human interferons in these studies highlighted 
the varied effects of the human interferons on drug metabolism in different rodent species. The 
species specificity of the interferon-mediated down-regulation of drug metabolism has not yet been 
clarified and is ongoing.
It is interesting to note that the interferon-mediated suppression of drug metabolism does not 
always cause an adverse effect. In certain cases the reverse is true. For example, the coadministration 
of poly IC and acetaminophen to mice protected them from the severe toxicity (fatal centrilobular 
necrosis in the liver) caused when acetaminophen was administered alone (Renton and Dickson, 
1984). This was due to a reduction in the formation of highly reactive metabolites of acetaminophen 
which covalently bind with cellular macromolecules, thus initiating toxicity.
More recent studies have attempted to elucidate the mechanism(s) by which interferons exert 
their inhibitory effect on cytochrome P450. For instance, it has been demonstrated that the down- 
regulation of drug metabolism by interferon requires the de novo synthesis of an intermediate 
protein(s) (Moochhala et al, 1989). Therefore, the inhibitory mechanism is likely to be mediated by 
a signal transduction pathway (stimulated by the binding of interferon molecules with specific cell 
surface receptors) rather that through a direct action by the interferons.
Evaluation of the suppressive effects of interferons on cytochrome P450 is complicated by 
the fact that human recombinant interferon « has been shown to differentially depress cytochrome 
P450 isoenzymes. For example, while the constitutive protein levels of Cypla-2 and Cyp2c-6 were 
significantly suppressed by interferon a. in the mouse, the same effect was not seen with respect to 
Cypla-1 and Cyp2b-1 (Stanley e/ al, 1991). In addition, the induced protein levels of Cypla-1 and 
Cyp2b-1 were not depressed by coadministration of interferon « with the inducers (3MC and PB 
respectively). It appears from this and other studies (discussed in section 6.3) that interferons 
differentially down-regulate cytochrome P450 isoenzymes.
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Several investigators have explored the possibility that the interferon-induced molecular 
mechanisms which confer antiviral activity in cells might also be involved in the down-regulation of 
drug metabolism (Parkinson et al, 1982, Renton et al, 1984). This and other proposed interferon- 
mediated mechanisms for the inhibition of drug metabolism are reviewed in more detail later (in 
section 1.3.3).
Interferons are not the only cytokines that suppress drug metabolism. Several studies have 
indicated that interleukin 1 (IL-1) down-regulates P450 (Bertini et al, 1988, Pous et al, 1990, 
Kurokohchi et al, 1992, Pasco et al, 1992). In particular, IL-1 has been shown to suppress the 
transcriptional activation by TCDD of the CYPlAl and CYP1A2 genes in rat hepatocytes (Pasco et 
al, 1992). IL-1 also down-regulates the protein and mRNA levels of CYP2D (Kurokohchi et al, 
1992). In addition, interleukin 6 (IL-6) has been shown to suppress the PB-induced level of CYP2B1 
in rat hepatocytes (Williams et al, 1991, Chen et al, 1992). The implication from these reports seems 
to suggest that cytokines in general have a suppressive effect on cytochrome P450. However, this 
suggestion was recently contradicted by the observation that interleukin 2 (IL-2) actually induced the 
expression of rat hepatic CYP2D1 (Kurokohchi et al, 1993). Evidently, the differential effects of 
these cytokines on cytochrome P450 isoenzymes suggest that the mechanisms governing the 
modulation of drug metabolism by cytokines are complex and may be integral to the overall acute 
phase response to virall infection; in which these cytokines are involved. These implications are 
explored further in section 6.5.
1.3.2 Clinical implications of the use of interferons in combination chemotherapy
Interferons, mainly interferon o l, have been used extensively in combination therapy in recent 
years. Numerous encouraging experiments in cell culture and in animal models have supported the 
progression to combination therapy in clinical trials. For example, the combination of interferon o l
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with retinoids (which also modulate cell growth) inhibited the proliferation of human transformed cell 
lines to a greater extent than treatment with either agent alone and a clinical trial with 13-cis-retinoic 
acid and interferon a  used in the treatment of cutaneous T cell lymphoma produced favourable results
(Frey et al, 1991, Knobler et al, 1991). In another study, the concomitant administration of
‘ rifampicin :
interferon 7  and X' to nude mice infected with human leproma-derived Mycobacterium leprae 
resulted in a significant reduction of bacterial growth (Banerjee and McDermot-Lancaster, 1990).
Clinical trials of interferons in combination with other drugs have resulted in varying degrees 
of success. The treatment of HIV and AIDS-related tumours has received a great deal of attention 
recently (Smith and Read, 1990). In preliminary trials, the combined use of interferon « with 
zidovudine has exhibited both antiviral and antitumour activities (Kovacs et al, 1989, Stadler et al, 
1990, Berglund et al, 1991).
In other clinical trials, the combination of vinblastine and interferon « in the treatment of 
renal cell carcinoma did not show an improvement in the disease compared with interferon treatment 
alone whereas the response to the combined treatment of interferon a  and the cytotoxic drug 
dacarbazine in advanced cutaneous melanoma appeared to be promising (Figlin et al, 1985, Schuster 
et al, 1990, Bajetta et al, 1990).
Although some of the published reports of combined chemotherapy make note of side effects 
and toxicity, the causes of these adverse reactions are not clear and may be due to drug-drug 
interactions or a response to the individual therapeutic agents. Interestingly, the possibility of 
interferon-mediated suppression of drug metabolism is rarely raised. While it is recognized that the 
cytochrome P450 monooxygenase system is not responsible for the metabolism of all 
chemotherapeutic drugs, the possibility remains that other metabolizing enzymes might also be subject 
to a similar, suppressive effect by interferons.
When adenine arabinoside and interferon « were used in conjunction to treat chronic hepatitis 
B infection, the patients suffered neurotoxicity at lower doses of the former drug than when it was
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used alone at a higher dose level. This potentiated toxicity was attributed to an accumulation of the 
major metabolite of adenine arabinoside, arabinofiiranosylhypoxanthine, in the serum (Sacks et al, 
1982). It was proposed that, although the breakdown of adenine arabinoside and its metabolite does 
not involve the cytochrome P450 monooxygenase system, other metabolic pathways (not yet 
described for the drug) may have been affected by interferon.
In many instances, the drugs used in conjunction with interferons have a narrow therapeutic 
index. Therefore, the possibility of a marginal improvement afforded by combination therapy might 
be outweighed by the possibility of enhanced toxicity due to an accumulation of the potent drug. An 
improvement in our understanding of the mechanisms by which interferons affect drug metabolism 
would help to predict, and therefore restrict, the toxicity caused by combination therapy including 
interferons.
1.3.3 Proposed interferon-mediated mechanisms for the down-regulation of drug metabolism
The precise mechanism(s) by which type I interferons mediate the suppression of drug 
metabolism is not clear. However, a number of hypothetical mechanisms, acting at successive stages 
of cytochrome P450 expression (presented here in reverse order), have been postulated.
1.3.3.1 Stability of the cytochrome P450 apoprotein
Xanthine oxidase is one of many proteins induced by interferons (Ghezzi et al, 1984). It has 
been suggested that a causal link might exist between the ability of interferons to increase the activity 
of hepatic xanthine oxidase and the destruction of cytochrome P450 by oxygen radicals generated by 
xanthine oxidase (Ghezzi et al, 1985, Deloria et al, 1985, Koizumi et al, 1986). However, the results 
of several studies have contradicted this theory. Firstly, the suppression of cytochrome P450 by poly
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IC has been shown to be accompanied by a depression of superoxide anion generation (Ischiropoulos 
et al, 1989). In another experiment, the suppression of cytochrome P450 was not prevented by 
eliminating the interferon-induced xanthine oxidase activity (Mannering et al, 1988).
1.3.3.2 Formation of the cytochrome P450 apoprotein-haem complex
The interferon-inducing agents poly IC and tilorone have been shown to increase the rate of 
cytochrome P450 haem breakdown (El Azhary et al, 1980) suggesting an explanation for the 
interferon-mediated down-regulation of cytochrome P450 haemoproteins. However, Singh and Renton 
have argued that the slight decrease in haem following interferon administration cannot account for 
the much greater reduction in P450 (Singh and Renton, 1984).
1.3.3.3 Translation of cytochrome P450 mRNA to the apoprotein
The effect of poly IC on MC-induced total cytochrome P450 expression has been analyzed 
by pulse labelling with ^H- and '^‘C-labelled leucine (Matsunaga et al, 1986). The de novo synthesis 
of hepatic, microsomal cytochrome P450 apoproteins was depressed by approximately 66% compared 
with that in rats treated with MC alone. This result concurred with the results of a similar study 
conducted by Gooderham and Mannering in 1986 and suggested that the suppression of cytochrome 
P450 by interferons might be due to a down-regulation at the level of translation of cytochrome P450 
apoprotein. Renton and coworkers demonstrated, using ^^S-labelled methionine, that the in vitro 
translation of clofibrate-induced CYP4A1 mRNA was inhibited by poly IC (Renton et al, 1987). 
Since a pretranslational down-regulation of cytochrome P450 would give the same results as those 
outlined above, these studies indicate that the interferon-mediated mechanism(s) which suppresses 
cytochrome P450 acts at the translational or pretranslational levels.
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One of the antiviral activities mediated by interferons is the inactivation of eIF-2a (see section 
1.2.4.3). In addition to preventing the translation of viral proteins, the translation of host proteins, 
including the cytochrome P450 isoenzymes, might also be affected. This possibility has been explored 
in a study using two hybrid recombinant interferons, IFN-aAD(Bgl) and IFN-aAD(Pvu), which 
differed from each other by three amino acids (Renton et al, 1984). The antiviral activity of the 
interferons did not correlate with their ability to suppress drug metabolism suggesting that the 
mechanism(s) causing the down-regulation of cytochrome P450 is probably independent of the 
antiviral activities of interferon.
1.3.3.4 Regulation of cytochrome P450 mRNA levels
Recent studies have reported a decrease in the mRNA level of the cytochrome P450 
isoenzymes CYP4A1, CYP2C11, CYP2C12 and CYP3A2 following treatment of rats with poly IC 
(Morgan and Norman, 1990, Morgan, 1991, Renton and Knickle, 1990, Craig et al, 1990). 
However, these reports did not indicate whether the suppressed mRNA level was due to the 
transcriptional down-regulation of the CYP genes, an inhibition of the processing of specific pre- 
mRNA, an inhibition in the translocation of the mRNA from nucleus to cytoplasm or an increase in 
mRNA degradation.
If the down-regulation occurs by an enhanced degradation of the cytochrome P450 mRNA, 
a possible candidate for this putative action would be the endoribonuclease activated by an interferon- 
mediated mechanism in response to viral infection (see section 1.2.4.3). However, it is not known 
whether RNase L specifically digests viral RNA or whether host cellular RNA might also be affected.
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1.3.3.5 Transcriptional regulation of the CYP4A1 gene.
As described earlier, the administration of poly IC to clofibrate treated rats results in the 
suppression of the induction of CYP4A1 apoprotein, lauric acid w-hydroxylase activity and mRNA 
(Renton et al, 1987, Renton and Knickle, 1990, results presented in this thesis). The results presented 
in this thesis demonstrate that induced transcription of the CYP4A1 gene is down-regulated by an 
interferon-mediated mechanism. No published studies to date conclusively demonstrate a similar 
transcriptional down-regulation of CYP4A1 or any of the other cytochrome P450 genes. It is possible 
that the interferon-mediated mechanism(s) which suppresses the transcription of CYP4A1 also down- 
regulates the production of other drug metabolising enzymes in a similar manner.
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1.4 OBJECTIVES OF THE PRESENT INVESTIGATION
The most effective clinical trials with interferons appear to be those which combine interferon 
a with other chemotherapeutic agents. However, increasing evidence that cytochrome P450 
isoenzymes are down-regulated by interferons calls for the safety evaluation of interferons in 
combination therapy. An essential aspect of this evaluation is an understanding of the precise 
molecular mechanism(s) involved in the interferon-mediated suppression of cytochrome P450.
So far, the research conducted by other workers has determined that the interferon-mediated 
mechanism(s) which down-regulates cytochrome P450 acts at a pretranslational level of gene 
expression. The preliminary aim of the present investigation was to demonstrate that the induction 
of CYP4A1 protein and mRNA by clofibrate was suppressed by concomitant treatment with poly IC, 
confirming the findings of Renton and coworkers (Renton et al, 1987, Renton and Knickle, 1990). 
Having demonstrated that the down-regulation of CYP4A1 occurred at a pretranslational level, 
nuclear run-on experiments were to be conducted to determine whether the suppressed levels of 
CYP4A1 protein and mRNA reflect a transcriptional down-regulation of CYP4A1.
In addition to these central objectives, the effects of poly IC and human interferon a on the 
constitutive versus induced levels of CYP4A1 and CYP2E1 were also evaluated. This was first, to 
compare the effects of interferons on two cytochrome P450 isoenzymes which are chemically-induced 
by different mechanisms; second, to analyze the effects of interferon a  and poly IC on the 
constitutive (as well as the induced) expression of cytochrome P450; and finally, to compare the 
effects of endogenous rat type I interferons (induced by poly IC) versus exogenous human interferon 
a as this might expand our current knowledge regarding the species specificity of the interferon- 
mediated down-regulation of cytochrome P450.
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CHAPTER 2 
MATERIALS AND METHODS
37
2.1 MATERIALS
2.1.1 Chemicals
Aldrich Chemical Company Ltd. U.K.: 4-nitrocatechol, Tween 20
Amersham International. U.K.: streptavidin biotinylated horse radish peroxidase conjugate.
BDH Chemical Ltd. Poole. Dorset. U.K.: ammonium persulphate, L-ascorbic acid, calcium chloride, 
EDTA (ethylenediamine tetraacetic acid), formaldehyde, formamide, gelatin, glycine, lithium 
chloride, magnesium chloride, perchloric acid, phenol, potassium chloride, di-potassium hydrogen 
phosphate, potassium dihydrogen phosphate, sodium acetate, sodium carbonate, sodium dithionite, 
sodium dodecyl sulphate, sodium hydrogen phosphate, sodium potassium tartrate, sodium 
pyrophosphate, sucrose, Triton X 100, TCA (trichloroacetic acid).
Beta Lab. U.K.: yeast extract.
Boehringer Mannheim Ltd U.K. : proteinase K, RNase-free DNase I, RNase A, ATP, CTP, GTP. 
Difco Laboratories. U.S.A.: bacto-agar, bactotryptone.
FSA Laboratories Supplies Ltd. U.K.: glycerol, methanol, hydrochloric acid, diethyl ether, glacial 
acetic acid, chloroform.
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Gibco. BRL Life Technologies Ltd. U.K. : agarose, guanidinium isothiocyanate, low-melting-point 
agarose, T4 DNA ligase, TEMED (N,N,N’,N’-tetramethylethylene diamine).
Honkin and Williams. U.K.: paranitrophenol.
KOA Atlas Company. Japan: Emulgen 911.
May and Baker Ltd U.K. : sulphuric acid, sodium hydroxide.
National Diagnostics. Avlesburv. U.K.: acrylamide, bis-acrylamide
Pharmacia. Upsalla. Sweden: ficoll
Sigma Chemical Company. U.K.: ampicillin, BSA (bovine serum albumin), bromophenol blue, 4- 
chloronaphthol, cholate, citric acid, clofibric acid, copper sulphate, cytochrome c, DEPC 
(Diethylpyrocarbonate), DTT (dithiothreitol), ethidium bromide, donkey anti-sheep horse radish 
peroxidase, donkey anti-rabbit biotin conjugate, EGTA (ethyleneglycol-bis-(/5-aminoethyl ether) 
N,N,N’,N’-tetraacetic acid), Folin-Ciocalteu phenol, HEPES (N-[2-hydroxyethylj piperazine-N*-[2- 
ethanesulphonic acid]), hydrogen peroxide, isoniazid, isoamyl alcohol, lauric acid, 2- 
mercaptoethanol, MOPS (3-[N-morpholino] propanesulphonic acid), NADH (reduced nictinamide 
adenine dinucleotide), NADPH (reduced nicotinamide adenine dinucleotide phosphate), 4- 
nitrocatechol, OPD (orthophenylenediamine), polyvinylpyrrolidone, salmon sperm DNA, spermidine 
(N- [3-aminopropy 1] -1,4-butanediamine), spermine tetrahydrochloride(N,N’-bis[3-aminopropyl]-l,4- 
butanediamine), TES (N-tris [hydroxymethy 1] methyl-2-aminoethanesuphonic acid), tris 
(tris[hydroxymethy 1] aminomethane), xylene cyanole, yeast tRNA,
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2.1.2 Radiochemicals
All the radiochemicals detailed below were obtained from Amersham International. U.K.
(i) Deoxycytidine 5’-[a^^P] triphosphate ([5-a^^]-dCTP), triethylammonium salt. 
Specific activity 3000Ci/mmol, lOmCi/ml.
(ii) Uridine 5’-pH] triphosphate ([5-^H]-UTP), ammonium salt. Specific activity 
9.2Ci/mmol, ImCi/ml.
(iii) Uridine 5’-[a^^P] triphosphate ([5-a^^P]-UTP), triethylammonium salt. Specific 
activity 800Ci/mmol, 20mCi/ml.
2.1.3 Antibodies against CYP4A1 and CYP2E1
The primary antibody to CYP2E1 was kindly donated by Dr. J. B. Schenkman, University 
of Connecticut Health Centre (Favreau et al, 1987). The primary antibody to CYP4A1 was kindly 
provided by Dr. R. Sharma, University of Surrey (Sharma, 1988).
2.1.4 cDNA probes and plasmid vectors
The expression of CYP4A1 pre-RNA and mRNA were analyzed using a 2.1kb cDNA probe. 
The cDNA, which was isolated from a clofibrate-induced rat liver poly A"*" Xgtll cDNA library and 
ligated into pUC19 (Eamshaw et al, 1988), was kindly donated by Dr. D. Eamshaw (University of 
Surrey). The recombinant plasmid pUC19 (Norrander et al, 1983) containing the human actin cDNA 
was also provided by Dr. D. Eamshaw (University of Surrey). The CYP2E1 l.lkb  cDNA probe 
(ligated into pUC19) was kindly donated by Dr. T. Richardson (University of Surrey) who isolated
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it from a Xgtll rat liver cDNA library probed with a monospecific antibody raised against RLM6. 
The 1.8kb mouse PPAR cDNA insert in the plasmid pBluescript (Stratagene catalogue, 1988) was 
a kind gift from Dr. S. Green (Issemann and Green, 1990).
2.1.5 Bacterial strain
The Ecoli bacterial strain used throughout as a host for recombinant plasmids was TBl which 
has the following genotype: ara hsd R. thi, str A  A lac-pro rK+
2.1.6 Restriction endonucleases
Table 2.1 Restriction enzymes used in tbe preparation of probes for tbe analysis of mRNA
(see section 2.4.5.4) and pre-RNA (section 2.5.3.2). The symbol (’) indicates the site 
at which the enzyme cuts the DNA
Restriction enzymes Recognition site
Eco RI G’AATTC
Hind III A’ACGTT
Raw HI G’GATCC
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2.2 ANIMAL HUSBANDRY AND TREATMENT PROCEDURES
2.2.1 Animal husbandry
The hepatic tissues used throughout these investigations were from male Wistar albino rats, 
obtained from the University of Surrey breeders. The rats, weighing between 200 and 250g, were 
allowed an unlimited supply of water and chow (LAD2), and were housed in cages with sawdust 
bedding (RS Services Ltd) and subjected to a 12 hour light/dark cycle at 22*C.
2.2.2 Animal treatment
Dosing regimes for specific studies will be detailed in the results chapters (3, 4 and 5). The 
dosing vehicle used throughout was 0.9% saline administered at a volume of Iml/kg body weight.
Sodium clofibrate was prepared by the reaction of equimolar concentrations of sodium 
hydroxide and clofibric acid, followed by freeze-drying. Daily treatments by i.p. injection of sodium 
clofibrate at a dose level of 250mg/kg body weight were carried out for three days. Four consecutive 
daily treatments of isoniazid were administered by gavage at a dose level of lOOmg/kg.
Polyriboinosinic. polyribocytidilic acid (poly IC) was administered by i.p. injection at a dose 
level of lOmg/kg 24 hours prior to sacrifice. Lyophilised human lymphoblastoid interferon a, kindly 
donated by the Wellcome Research Laboratories (Kent, U.K.), was solubilised in 0.9% saline (w/v) 
and administered by i.p. injection 24 hours prior to sacrifice. The doses of interferon a  used are 
specified in the following chapters where appropriate.
The human lymphoblastoid interferon (obtained as 1.7 x 10^  lU/vial) consisted of a mixture 
of 22 human interferon a  subtypes derived from human lymphoblastoid cells, Namalwa line, 
stimulated with Sendai virus. Although the human lymphoblastoid interferon a preparation described
42
above consisted of a number of interferon a  subtypes, further references to the preparation will be 
given the simple term ’interferon a ’.
One international unit (lU) of interferon is defined as that dilution of a sample that results 
in the protection of a cell sheet from virus infection. In other words, the titre of interferon used at 
the point at which viral infection ceases is taken as 1 lU. The purity of the interferon a  preparation, 
determined by SDS PAGE and staining with Coomassie blue dye followed by densitometric scanning, 
was estimated at 93%. The impurities were considered to be other cellular proteins and background 
’noise’ in the densitometry scan (personal communication with Dr Garnet Lewis, Wellcome Research 
Laboratories).
Following treatment, the rats were sacrificed by cervical dislocation and the liver from each 
rat was removed. Liver tissue for the preparation of RNA was immediately excised, flash frozen in 
liquid nitrogen and stored at -80'C until required. The remainder of the liver was placed in ice cold 
saline solution (0.9% w/v).
2.3 METHODS RELATING TO PROTEIN CHARACTERIZATION
2.3.1 Preparation of rat liver microsomes
Microsomes were prepared by a modification of the method of Omura and Sato (1964). The 
livers were perfused with ice cold 0.9% (w/v) saline to displace contaminating haemoglobin. The 
livers were then blotted dry and placed separately in ice cold 0.25M sucrose such that each liver 
constituted 25% (w/v). Each of the subsequent steps were carried out at 4* C.
The livers were scissor-minced and homogenised in a motor driven Potter Elvehjem glass 
teflon homogeniser (3 return strokes). The homogenates were centrifuged at 13,800g for 30 minutes 
at 4*C. The supernatant was decanted and centrifuged at 50,700g for 1 hour at 4*C. The microsomal
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pellet was very gently resuspended in 4ml ice cold 50mM potassium phosphate buffer, pH 7.25 using 
a motor driven Potter Elvehjem glass teflon homogeniser. The phosphate buffer included 20% (v/v) 
glycerol throughout except when resuspending microsomes from rats used in the study of CYP2E1 
since glycerol is a substrate of this enzyme. The microsomal suspension was stored as 0.5ml aliquots 
in eppendorf tubes at -80* C.
2.3.2 Determination of microsomal protein concentration
The protein concentrations of microsome samples were routinely determined by a modification 
of the method of Lowry et al (1951). A series of duplicate dilutions, between 0-40/xg, of bovine 
serum albumin (BSA) was prepared using a2()mg/ml stock solution. Where microsomal samples 
contained glycerol, appropriate additions of glycerol (in ImM potassium phosphate buffer, pH7.25) 
were made to the BSA standards. Test samples were diluted 1:49 with 50mM potassium phosphate 
buffer, pH7.25. The BSA standards and samples (0.4ml) were mixed with 2.5ml of a buffer prepared 
by combining 1% (w/v) hydrated copper sulphate, 2% (w/v) sodium potassium tartrate, and 2% (w/v) 
sodium carbonate in O.IM sodium hydroxide (1:1:100 by volume respectively). The tubes were 
allowed to stand at room temperature for 10 minutes. Folin-Ciocalteu phenol reagent was diluted 1:1 
with distilled water and 0.25ml was added to each tube followed by immediate vortexing. After 30 
minutes incubation at room temperature the absorbance was recorded at 750nm using a Kontron- 
Uvikon 860 spectrophotometer.
2.3.3 Determination of total cytochrome P450 content
Total cytochrome P450 content was measured spectrophotometrically by the method of Omura 
and Sato (1964). Microsomes were diluted 1:9 with 50mM potassium phosphate buffer (pH 7.25)
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containing 20% (v/v) glycerol to a final volume of 5ml. A few grains of sodium dithionite were 
added to reduce the cytochrome P450 from the ferric to the ferrous form. The reduced sample was 
divided between two cuvettes and the baseline recorded between 400-500nm using a Kontron-Uvikon 
860 spectrophotometer. Carbon monoxide was gassed (30 bubbles at approximately 1 bubble per 
second) through the sample cuvette only and the spectrum was scanned repetitively until there was 
no further absorbance development at 450nm. The concentration of cytochrome P450 was calculated 
using the difference millimolar extinction coefficient (450-490 nm) of 91 mM^cm'\
2.3.4 Determination of CYP4A1 apoprotein content by ELISA
The enzyme linked immunoabsorbent assay (ELISA) as described by Voiler et al (1978) has 
been modified by Sharma et al (1988a) for the quantitation of CYP4A1 apoprotein content.
Microsomes were solubilised by the addition of Img cholate and 0.2mg Emulgen 911 per mg 
protein with stirring for 20 minutes on ice. The solubilised microsomes were diluted as appropriate 
(0.5-2ptg protein/ml) with O.IM sodium carbonate/bicarbonate buffer (pH 9.6) and 200^1 aliquots 
were loaded in triplicate onto microtitre plates (Alpha laboratories, U.K.). Pure CYP4A1 protein was 
used as the standard at a series of concentrations between 0-0.2pmol/ml. The plates were left 
overnight at 4*C in a humid environment. The plates were then washed with phosphate buffered 
saline (pH7.4) containing 0.1% (w/v) gelatin and 0.05% (v/v) Tween 20 (PBS-GT). The CYP4A1 
antibody and pre-immune serum were diluted 1:20,000 using PBS-GT buffer and 200^1 applied to 
duplicate test and standard wells.
The plates were incubated at 37*C for 2 hours and rewashed with PBS-GT buffer. Following 
application of 200/d per well of donkey anti-sheep (horseradish peroxidase) enzyme label conjugate 
diluted 1:15,000 in PBS-GT buffer, the plates were further incubated at 37 *C for 2 hours and 
rewashed with PBS-GT buffer. The substrate was prepared immediately prior to use as follows:
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0.025M citric acid, 0.05M sodium hydrogen phosphate buffer (pH5.6), 30mg orthophenylenediamine 
(OPD) and 30fi\ (30% v/v) hydrogen peroxide. Then 150/d substrate was applied to each well. 
Following a final incubation at 37*C for 30 minutes, the colorimetric I  reaction was terminated by
the addition of 2.5M sulphuric acid (50/d per well). The plates were read at 492nm using a Titertek 
plate reader (Flow Laboratories, UK). The values obtained for wells treated with pre-immune serum, 
representing non-specific binding, were used to adjust the calculation of microsomal CYP4A1 
apoprotein content.
2.3.5 Determination of lauric acid hydroxylase activity
The microsomal lauric acid hydroxylase activity was determined by the method of Parker and 
Orton (1980). Triplicate reactions at a final volume of 2ml contained '^^C-labelled lauric acid (0.1/iCi 
in 10/d methanol), O.lmM lauric acid (prepared from a 200mM stock solution in methanol 
diluted to ImM in 0.5M Tris-HCl buffer, pH 7.4) and 0.5mg (clofibrate-induced) or Img (control) 
liver microsomal protein. The tubes were pre-incubated at 37 *C for 5 minutes after which the 
reaction was initiated by addition of 40/d of 40mM NADPH. Microsomal blanks, to which distilled 
water was added instead of NADPH, and control samples (from rats not treated with clofibrate) were 
incubated for 10 minutes while clofibrate-induced samples were incubated for 5 minutes. The reaction 
was terminated by the addition of 0.2ml 3M HCl.
Extraction of the lauric acid and its metabolites was achieved by the addition of 10ml diethyl 
ether to each incubation mixture. The tightly sealed tubes were rotated end over end for 20 minutes 
then allowed to stand for 10 minutes to clarify the phases. The upper (diethyl ether) layer was 
transferred to a glass test tube and evaporated to dryness under a stream of nitrogen. The test tubes 
were sealed with parafilm and stored at -20*C prior to analysis.
The dried extracts were reconstituted in 150/d eluting solvent which was prepared by the
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combination of water, methanol and glacial acetic acid (45:55:0.5 by volume) and lOO/il were then 
injected onto a Microbondapak MCH-10 column with dimensions 30 x 4.4 cm (Varian Associates 
Ltd, Walton on Thames, U.K.). Elution of the products was achieved by using a linear gradient of 
water: methanol: glacial acetic acid (45:55:0.5 by volume) to 100% methanol over a 40 minute 
period at a flow rate of 1.5ml/minute. A pressure of 350-500 psi was maintained. The levels of 
radiolabelled lauric acid and the 11- and 12-hydroxymetabolites eluted were detected by a Berthold 
LB 506 C-1 HPLC Radioactivity Monitor (Laboratory Impex Ltd., U.K.) which was interfaced with 
a PC IV 286 AT-Compact Computer. The Berthold HPLC Program version 1.44 was used to detect 
the time of elution and relative amounts of the "^^ C-labelled parent lauric acid, 11-hydroxylaurate and 
12-hydroxylaurate.
2.3.6 Détermination of paranitrophenol hydroxylase activity
The paranitrophenol hydroxylase activity of microsomal samples was measured by a 
modification of the method described by Reinke et al (1985). A series of standards was set up 
containing 0-50nmol 4-nitrocatechol and 50/d microsomal suspension made up to 1ml with 0.2M 
potassium phosphate (pH 6.8). Triplicate 0.9ml incubation reactions included 0.65ml 0.2M potassium 
phosphate (pH 6.8), 0.1ml ImM paranitrophenol, 0.1ml ImM ascorbate and 50/d microsomal 
suspension (approximately Img).
The reaction mixtures were pre-incubated at 37’C for 3 minutes, then enzyme activity was 
initiated in the test samples by the addition of 0.1ml lOmM NADPH (in 1 % sodium carbonate w/v). 
The tubes were further incubated at 37 *C for 10 minutes. The reaction was terminated by the 
addition of 0.5ml 0.6M perchloric acid which was also added to the standard samples and all tubes 
were centrifuged at 2000g for 10 minutes at room temperature. Following the addition of 0.1ml lOM 
sodium hydroxide to 1ml of supernatant in a cuvette, the amount of 4-nitrocatechol in the samples
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was determined by recording the absorbance at 536nm using a Kontron-Uvikon 860 
spectrophotometer.
2.3.7 Determination of NADPH-cytochrome c reductase activity
The activity of NADPH-cytochrome c reductase was determined by the method described by 
French and Coon (1979).
Sample and reference cuvettes were prepared as follows :
Sample Reference
lOOmM Tris-HCl (pH7.5) 0.8ml 0.85ml
O.lmM cytochrome c 0.5ml 0.5ml
Microsomal sample 50/d 50/d
The cuvettes were placed in a Kontron-Uvikon 860 spectrophotometer at 37‘C and the 
baseline was recorded at 550nm. The reaction was initiated by addition of 50/d 2% NADPH (w/v 
in 1 % sodium carbonate (w/v)) to the sample cuvette. The reaction was followed for 2 minutes at 
550nm. The NADPH-cytochrome c reductase activity was calculated using the initial linear rate of 
reaction, the protein content (mg/ml), and the extinction coefficient of 19.6 mM'^cm'  ^at 550nm.
2.3.8 Determination of cytochrome b$ content
Cytochrome b^  content was measured using a modification of the procedure described 
originally described by Kajihara and Hagihara (1968). Microsomes were diluted 1:49 by the addition 
of 20/d to 0.98 ml 0.05M potassium phosphate buffer (pH 7.25) in each of two cuvettes. The 
cuvettes were placed in a Kontron-Uvikon spectrophotometer and the baseline was recorded between
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400 and 500nm. After the addition of 25pi 2% NADH (w/v in 1% sodium carbonate w/v), the 
sample cuvette was scanned repetitively until there was no further development at 424nm. The 
concentration of cytochrome bg was calculated using the difference millimolar extinction coefficient 
(424 minus 490nm) of 112 mM'^cm ^
2.3.9 SDS polyacrylamide gel electrophoresis of microsomal proteins and Western blotting
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was employed to 
separate solubilised microsomal proteins according to the method described by Laemmli (1971). 
Electrophoretic transfer of the separated proteins onto nitrocellulose sheets and subsequent 
immunoblotting was achieved by the method of Burnette (1981).
Liver microsomes were solubilised by dilution with sample buffer (62.5mM Tris-Cl, pH 6.8, 
containing 2.3% (w/v) SDS, 15% (v/v) glycerol, 5% (v/v) 2-mercaptoethanol and 0.001% (w/v) 
bromophenol blue) to give a protein content of Img/ml. The solubilised proteins were boiled for 
approximately 3 minutes. Electrophoresis was performed at room temperature using the Sturdier slab 
gel electrophoresis unit (Hoefer Scientific Instruments, San Fransisco). The separating gel was 
prepared by mixing acrylamide, bis-acrylamide and 1.5M Tris-Cl, pH 8.8, containing 0.4% (w/v) 
SDS with distilled water to give a 10% (w/v) acrylamide/ 0.27% (w/v) bis-acrylamide gel containing 
0.1% (w/v) SDS. Ammonium persulphate (10% w/v) and TEMED were added to initiate the 
polymerisation process. This solution was poured into the glass cassette to approximately 2/3 of its 
height. The stacking gel was prepared by mixing acrylamide, bis-acrylamide and 0.5M Tris-Cl pH 
6.8, containing 0.4% (w/v) SDS with distilled water to give a 3% (w/v) acrylamide/ 0.08% (w/v) 
bis-acrylamide gel containing 0.1% (w/v) SDS. Polymerisation was initiated as before and the wells
were formed by placing a perspex comb at the top of the cassette.
A 10% separating gel was used for immunodetection with the anti-CYP2El antibody j
whereas a 7% gel was prepared for detection with the anti-CYP4Al antibody. I
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The solubilised proteins were loaded on an equivalent protein (20/ig) basis using a Hamilton 
syringe. Prestained molecular weight markers (Sigma Chemical Company, U.K.) were used as 
standards to determine the size of proteins of interest. Electrophoresis was carried out under a 20mA 
constant current which was increased to 40mA when the bromophenol indicator entered the separating 
gel. The samples were run in electrophoresis buffer (2.5mM Tris-Cl pH 8.3, containing 192mM 
glycine and 1 % (w/v) SDS) until the indicator dye was approximately 0.5cm from the bottom of the 
gel.
Following gel electrophoresis, the separating gel was immersed in transfer buffer (20mM 
Tris-Cl, pH 8.3, 150mM glycine, 20% (v/v) methanol) for 30 minutes. Electrophoretic transfer was 
achieved by the use of a plastic sandwich apparatus in which the gel was placed next to a sheet of 
nitrocellulose (Anderman and Co Ltd, U.K.). The transfer was carried out overnight at 20mV in 
transfer buffer.
After electrophoretic transfer, the nitrocellulose sheet was immersed in phosphate buffered 
saline (PBS) containing 1% (w/v) BSA and 0.2% Triton X-100 (PBSBT) for 2 hours at room 
temperature. The nitrocellulose was then incubated for 60 minutes in fresh PBSBT containing the 
primary antibody (1:1000 dilution). The sheet was then washed three times for 5 minutes with PBST 
(omitting the BSA). The subsequent procedure differed as follows (depending on the primary 
antibody used).
Anti-CYP4A1 primarv antibodv:
The nitrocellulose was incubated with the second antibody (donkey anti-sheep) labelled with 
horseradish peroxidase (1:1000 dilution) in PBSBT for 90 minutes.
Anti-CYP2E1 primary antibody:
The nitrocellulose was incubated with the second antibody (donkey anti-rabbit) labelled with a biotin 
conjugate (1:660 dilution) in PBSBT for 90 minutes. Following three 5 minute washes in PBST the
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nitrocellulose was incubated with an enzyme-labelled antibody, streptavidin-biotinylated horseradish 
peroxidase (1:660 dilution), in PBSBT for 60 minutes.
Following each of the above procedures the final stages were identical. After three 5 minute 
washes in PBS (omitting both BSA and Triton) the immunochemical stain was developed by adding 
substrate (30mg 4-chloronaphthol tablet dissolved in 5ml methanol then added to 45ml PBS 
containing 30/d 30% (v/v) hydrogen peroxide). Development of the stain was stopped at the 
appropriate intensity by thorough washing with distilled water.
2.4 METHODS RELATING TO THE ANALYSIS OF mRNA
For all nucleic acid procedures described in sections 2.4 and 2.5, the solutions, glassware, 
and plasticware used were sterilised for 20 minutes at 120 *C in a Rodwell automatic autoclave in 
order to destroy nucleases. Unless otherwise stated, solutions were sterilised by the addition of 0.1% 
(v/v) diethylpyrocarbonate (DEPC) approximately 20 minutes prior to autoclaving. Solutions 
containing SDS were sterilised by autoclaving the solution prepared without SDS, followed by the 
addition of an appropriate volume of a 20% (w/v) stock solution prepared in sterile water.
2.4.1 Preparation of total cellular RNA and determination of its concentration and purity
Total cellular RNA was extracted from hepatic tissue by a modification of the method 
described by Cathala et al (1983). Hepatic tissue, previously frozen in liquid nitrogen and stored at 
-80 *C, was ground up in liquid nitrogen with a pestle and mortar. To Ig of tissue, 8ml of RNA lysis 
buffer (5M guanidinium isothiocyanate (not autoclaved), 50mM Tris-Cl pH 8.0) and 0.5ml 2- 
mercaptoethanol was added. The mixture was homogenised using a polytron (Kinematica GmbH,
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Switzerland). Following addition of 50ml 4M LiCl, the homogenate was incubated at 4*C for at least 
20 hours. The mixture was centrifuged at ll,000g for 90 minutes at 4*C after which the supernatant 
was discarded. The pellet was rinsed by resuspension in 30ml 3M LiCl and recentrifuged for 30 
minutes as above. The pellet was resuspended in 5ml TE (lOmM Tris-Cl pH 7.5, ImM EDTA pH 
8.0) containing 0.1% (w/v) SDS.
An equal volume of TE-saturated phenol was added to the aqueous solution which was then 
thoroughly mixed. The resultant emulsion was centrifuged at 12,900g at 4 ’C for 10 minutes. The 
top (aqueous) phase was removed and the phenol extraction procedure was repeated as above, using 
fresh phenol, until the white (protein) interface had disappeared. Further extraction with 
phenol/chloroform/ isoamyl alcohol (25:24:1 by volume) and then chloroform/isoamyl alcohol (24:1 
by volume) was carried out to remove residual phenol.
The RNA was precipitated from the aqueous solution by the addition of 0.1 volume of 3M 
sodium acetate, pH 5.2 and 2.5 volumes 100% ice cold ethanol and incubation of this mixture at 
-20’C overnight. The mixture was then centrifuged at 16,000g for 20 minutes at 4*C. The 
supernatant was discarded and the RNA pellet was washed with 70% (v/v) ethanol. The pellet was 
dried in a Univap centrifugal evaporator (Uniscience Ltd.) under vacuum. Finally the pellet was 
resuspended in an appropriate volume of sterile water.
For the determination of RNA purity and concentration, RNA aliquots were diluted 1:499 
with sterile water in 0.5ml quartz cuvettes. The samples were scanned between 220 and 300nm using 
a Kontron-Uvikon 860 spectrophotometer. RNA and protein absorb maximally at 260nm and 280nm 
respectively. A ratio of absorbance at 260nm:280nm between 1.9 and 2 was indicative of pure RNA. 
The concentration of RNA was determined using the absorbance at 260nm where 1 absorbance unit 
is equal to 40/ng/ml (Sambrook et al, 1989).
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2.4.2 Application of RNA to nylon membranes by slot blotting
Slot blotting was carried out routinely using a modification of the method of White and 
Bancroft (1982). Total RNA was diluted in sterile water to give a stock solution of 0.2mg/ml. This 
was serially diluted to give 20, 10, 5, 2.5, 1.25, 0.625/tg/100/tl water. To each dilution was added 
300/d of denaturing solution (a 1:1 mixture of 6.15M formaldehyde/ 20 x SSC (3M sodium chloride 
and 0.3M sodium citrate, pH 8.0)). Yeast tRNA (lO/ig/50/tl) was prepared in the same way as the 
samples and was used as a negative control. The samples and tRNA were incubated at 65*C for 15 
minutes.
The slot blot apparatus (Millipore Corporation, U.K.) was assembled with a nylon membrane 
(Hybond-N, Amersham International pic) placed on 3MM Whatman paper (presoaked in 10 x SSC) 
sandwiched within the apparatus. The denatured RNA samples were applied to the wells of the 
apparatus and a vacuum was applied such that 400/d took approximately 5 minutes to pass through 
the apparatus. After the RNA samples had been loaded, the wells were washed with 400/d 10 x SSC. 
The apparatus was dismantled and the nylon membrane was placed on a piece of 3MM Whatman 
paper. The tRNA was applied in a concentrated spot to the bottom right hand comer of the nylon 
membrane which was then air dried and wrapped in cling film. The RNA side of the membrane was 
subjected to UV irradiation at 305nm for 3 minutes to fix the RNA to the membrane. The membrane 
was stored at 4*C until required.
2.4.3 Agarose gel electrophoresis of RNA
RNA electrophoresis was carried out by adaptation of the method originally described by 
Lehrach et al (1977). Formaldehyde denaturing gels were prepared by heat-dissolving 1.05g agarose 
in 50.4ml sterile water and addition of 12.6ml 37% (v/v) formaldehyde and 7ml 10 x running buffer
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(4M MOPS pH 7.0, O.IM sodium acetate, lOmM EDTA pH 8.0). The solution was poured into a 
perspex gel former and wells were formed by the introduction of a perspex comb. When the agarose 
had set the gel was transferred to an electrophoresis tank filled with 1 x running buffer.
The RNA samples were prepared by the combination of 20/tg RNA, 2/tl 10 x running buffer, 
10/tl deionised formamide, 3.5/tl formaldehyde, 2/il (0.5/tg/ml) ethidium bromide and 3/tl loading 
buffer (4% (w/v) bromophenol blue, 4% (w/v) xylene cyanole, lOmM EDTA pH 8.0, 50% (w/v) 
glycerol). The samples were incubated at 65*C for 15 minutes then loaded into the wells. The gel 
was run at 100mA constant current until the indicator dye had run approximately 3/4 the length of 
the gel. The separation of the 28S, 18S and 5S ribosomal RNA bands in the gel were visualised 
under UV illumination. This is possible since the fluorescent dye ethidium bromide intercalates with 
nucleic acids and irradiation by dye at 300nm is re-emitted at 590nm in the red/orange region of the 
visible spectrum.
The UV irradiated gel was photographed with a polaroid land speed MP-4 camera and type 
65 positive/negative film. The film was exposed for approximately 30 seconds with an aperture of 
f4.5 and an orange filter.
2.4.4 Northern blotting
Following agarose gel electrophoresis of the RNA samples as described in section 2.4.3, the 
RNA was transferred to a nylon membrane by modification of the method originally described by 
Alwine et al (1977).
The gel was rinsed for 5 minutes in sterile water, then for 20 minutes in 0.05M sodium 
hydroxide followed by a further 5 minute wash in sterile water. The Northern blotting apparatus was 
set up as follows. A glass plate was positioned on top of 4 large rubber bungs in a glass tray 
containing 600ml 20 x SSC. A sheet of 3MM Whatman paper soaked in 20 x SSC was placed over
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the plate to act as a wick. The gel was placed on the Whatman paper and the edges of the gel were 
covered with plastic strips which extended over the edge of the glass tray. The gel was then covered 
by a sheet of nylon membrane (of the same dimensions as the gel) which was in turn covered by 
three sheets of Whatman paper presoaked in 20 x SSC. A stack of paper towels was placed on top 
and covered by another glass plate. Finally a weight of approximately 1kg was placed on the glass 
plate.
Transfer of the RNA species from the gel to the nylon membrane by capillary action usually 
takes at least 24 hours. The apparatus was dismantled on completion of transfer and the RNA was 
fixed to the membrane as described in section 2.4.2.
2.4.5 Preparation of cDNA probes
2.4.5.1 Transformation of bacterial cell with plasmid
The CYP4A1, CYP2E1, and actin cDNA inserts in (separate) pUC19 (see section 2.1.6) 
plasmids were available in TBl cells (see section 2.1.5) stored as glycerol stocks. However the 
PPAR cDNA was originally obtained as 5/tg of the cDNA inserted in pBluescript plasmid (see 
section 2.1.5). Therefore it was necessary to transform competent TBl cells with this plasmid for 
subsequent large scale preparation of the plasmid DNA. Preparation and transformation of competent 
cells was carried out essentially as described by Sambrook et al (1989).
Preparation of competent cells:
A 10ml culture of TBl cells in TYN (lOg tryptone,10g yeast extract, 5g sodium chloride in 
IL distilled water) was prepared by inoculation with a glycerol stock and incubated overnight at 
37 *C. Addition of 0.5ml of this overnight culture to 50ml prewarmed TYN was followed by
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incubation at 37*C with vigorous shaking. The growth of the culture was monitored at 30 minutes 
intervals by measuring absorbance at 600nm. When the absorbance reached between 0.35-0.4 units 
the growth of the culture was terminated by placing the conical flask on ice for 60 minutes.
The cells were harvested by centrifugation at 8820g for 10 minutes at 4 ’C then resuspended 
in 50ml lOOmM magnesium chloride. The mixture was placed on ice for 5 minutes after which the 
cells were recentrifuged as above and the pellet was resuspended in 25ml 50mM calcium 
chloride/lOmM Tris-Cl, pH8.0. Following a further incubation on ice for 40 minutes, the cells were 
pelleted by centrifugation at 1500g for 5 minutes. Finally the pellet was resuspended in 2ml lOOmM 
calcium chloride/ lOmM Tris-Cl, pH8.0.
Transformation of competent cells:
The plasmid DNA was diluted to 0.1/ig//tl with sterile water and 25/tl was added to 100/d 
competent cells. This mixture was placed on ice for 30 minutes then heat shocked for 45 seconds at 
43 ’ C and immediately returned to the ice. Following addition of 875/d prewarmed TYN to the cells, 
the mixture was incubated at 37’C for 60 minutes. Finally, lOO/il of the culture was spread on 
freshly prepared hard agar plates (5g bactotryptone, 7.5g agar, 5g sodium chloride diluted to 500ml 
with distilled water containing 150/tg/ml ampicillin). The plates were incubated at 37’C overnight 
and the resultant colonies were used to inoculate TYN/Amp for subsequent large scale plasmid 
preparation and storage as glycerol stocks.
2.4.S.2 Large scale preparation of plasmid DNA
Plasmid DNA was prepared on a large scale using the SDS-lysis method described by 
Sambrook et al (1989). Routinely 5ml TYN/Amp (containing 150/ig/ml ampicillin) was inoculated 
with a glycerol stock of the bacterial culture. This was incubated, with vigorous shaking, at 37’C
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for approximately 6 hours. The culture was then added to 500ml TYN/Amp in a IL conical flask 
stoppered with sterile cotton wool. This larger culture was grown overnight with vigorous shaking.
The cells were harvested by centrifugation at 2000g for 30 minutes at 4 ’ C. The plasmid DNA 
was extracted from the culture by using the Qiagen Maxi plasmid preparation kit (Qiagen Inc, U.K.). 
The resultant DNA pellet was dissolved in an appropriate volume of sterile water and the 
concentration of the DNA was determined using the absorbance at 260nm as described in section
2.4.1 with the following modification. One absorbance unit at 260nm is equal to 50/tg/ml DNA.
2.4.5.S Restriction digestion of plasmid DNA.
Appropriate restriction endonucleases were chosen to isolate the cDNAs from their respective 
plasmids. CYP4A1, CYP2E1 and PPAR cDNAs were restricted from their plasmids with Eco RI, 
and the actin DNA was restricted from its plasmid with Bam HI (see Table 2.1).
A digestion mixture was set up by combining 30/ig plasmid DNA, 30 units of restriction 
enzyme, 60/tl 10 x reaction buffer (appropriate to the enzyme), 60/d 40mM spermidine and sterile 
water to a final volume of 600/d. The mixture was incubated at 37’C overnight.
2.4.S.4 Agarose gel electrophoresis of DNA
Standard and preparative 1.0% (w/v) low melting point(LMP)-agarose gel electrophoresis was 
routinely carried out by the procedure described by Sambrook et al, (1989). The agarose was heat- 
dissolved in TAE-buffer (40mM Tris.acetate, 20mM sodium acetate, lOmM EDTA, pH 8.0) and 
poured into a perspex gel former. A long well was created in the LMP-gel by taping the teeth of the 
perspex comb. Once set, the gel was transferred to an electrophoresis tank filled with TAE-buffer. 
The digestion mixture was prepared for electrophoresis by the addition of loading buffer (30% (w/v)
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Ficoll, 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanole, 0.2M EDTA, pH 8.0 in 10 x 
TAE) then loaded evenly in the long well. The LMP-gel was run at 100mA constant current in the 
cold room (at approximately 4 ’C) until the indicator dye had reached 1cm from the end of the gel. 
Standard agarose gels are routinely run at 150mA constant current at room temperature. Lamda DNA 
(digested with Hind III) markers were used to determine the size of the DNA species of interest.
The gel was immersed in distilled water containing 0.5/tg/ml ethidium bromide for 
approximately 20 minutes and destained in water alone for a similar period. The DNA bands were 
visualised under UV illumination as described in section 2.4.3.
2.4.S.5 Purification of cDNA insert from LMP-agarose
LMP-agarose gel electrophoresis separated the plasmid and cDNA insert bands each of which 
was identified by size. The cDNA band was dissected from the gel using a sterile scalpel and placed 
in a 15ml polypropylene tube. When the PPAR cDNA was separated from pBluescript in a LMP- 
agarose gel, the plasmid band was also cut out of the gel and purified in the same way as the cDNAs. 
The linear pBluescript DNA was later ligated and prepared in bulk for the nuclear run-on assay (see 
section 2.5.3.1). The cDNAs and pBluescript plasmid were purified from the agarose by using the 
Geneclean kit (Stratech Scientific Ltd).
Firstly 2.5 volumes of sodium iodide was added to the tube and the gel was dissolved by 
incubation at 55 ’ C for 5 minutes. Glassmilk™ was added (1/tl glassmilk to each fig of DNA using 
a minimum volume of 5/tl), the solution was mixed and incubated at 55’C for 5 minutes during 
which the cDNA was adsorbed onto the silica matrix in the glassmilk. The solution was then placed 
on ice for 5 minutes followed by centrifugation at top speed in a microcentrifiige for 5 seconds. The 
supernatant was decanted and the glassmilk pellet was washed by resuspension in 500/il of ice cold 
NEW™ solution (a sodium chloride/ethanol wash) and recentrifuged for 5 seconds. The washing
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procedure was repeated twice and the glassmilk pellet was resuspended in an equal volume of sterile 
water. The mixture was incubated at 55*C for 5 minutes to elute the cDNA from the silica matrix 
then centrifuged for 30 seconds. The supernatant, containing pure cDNA, was transferred to a sterile 
1.5ml polypropylene tube and stored at -20’C until required.
The purity of the cDNA was checked by agarose gel electrophoresis (see section 2.4.5.5) of 
a small aliquot. In addition, a ratio of absorbance at 260nm:280nm between 1.8 and 1.9 was 
indicative of pure DNA.
2.4.6 Radioactive labelling of cDNA probes
The cDNAs isolated as described in section 2.4.5 were routinely radiolabelled immediately 
prior to hybridisation by using the Multiprime DNA labelling kit (Amersham International, U.K.) 
based on the random priming method described by Feinberg and Vogelstein (1983,1984). The cDNA 
was denatured and bound by random sequence hexanuleotides which act as primers for DNA 
synthesis. Incubation of the radioactive label [a-^^]-dCTP and the "Klenow" fragment of DNA 
polymerase I with the DNA lead to DNA synthesis incorporating the radiolabelled nucleotide. The 
labelled DNA was purified to remove unincorporated nucleotides by passing through a Nick™ 
colunm of DNA grade Sephadex G50 (Pharmacia, Sweden). The unincorporated nucleotides and 
unlabelled DNA was washed through with the first 400/il application of Nick buffer (20mM Tris, 
20mM sodium chloride, 2mM EDTA, 0.25% (w/v) SDS). The second AOOfil application of Nick 
buffer to the colunm eluted the labelled cDNA. Further heat-denaturation released the labelled cDNA 
probe which was ready for hybridisation to RNA bound to a nylon membrane.
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2.4.7 Hybridisation and membrane washing procedures
The RNA slot and Northern blot nylon membranes were pre-wet with 5 x SSC and placed 
on a sheet of nylon mesh immersed in 5 x SSC in a tray. Two membranes could be placed side by 
side and a second sheet of nylon mesh was placed over the membranes to keep them separate and 
allow for the even flow of buffer. The mesh was rolled into a cylinder and placed inside a Hybaid™ 
bottle (Hybaid Ltd, U.K.) to which was added approximately 50ml prehyb/hyb buffer (from a 200ml 
stock solution containing 100ml deionized formamide, 20ml 50 x Denhardts, 50ml 20 x SSC, 5ml 
(lOmg/ml) boiled and sonicated salmon sperm DNA and 25ml sterile water). The membranes were 
incubated at 42* C in a rotating Hybaid™ oven overnight.
The buffer from the Hybaid bottle was removed to a 50ml polypropylene tube. The cDNA 
probe (see section 2.4.6) was boiled for 5 minutes and after cooling on ice for a further 5 minutes 
was added to the prehyb/hyb buffer. The buffer was returned to the Hybaid bottle and incubated with 
the membranes again at 42'C overnight.
Following hybridisation the membranes were washed. The washing conditions varied 
depending on the experiment being conducted. Unless otherwise stated the following high washing 
stringencies were used.
(i) 5 X SSC/ 0.1% (w/v) SDS at 42*C for 30 minute
(ii) 1 X SSC/ 0.1% (w/v) SDS at 42*C for 20 minutes twice
(iii) 0.1 X SSC/ 0.1% (w/v) SDS at room temperature for 20 minutes.
(iv) 5 X SSC at room temperature for 15 minutes.
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2.4.8 Autoradiography
After washing the nylon membranes following hybridisation, the extent of hybridisation was 
visualised by autoradiography. This procedure is standard for RNA slot blots and Northern blots, and 
for nuclear run-on membranes (see section 2.5.6.4).
Nylon membranes were placed between thin plastic sheets in a cassette containing an 
intensifying screen. Kodak X-Omat AR 5 high speed film was placed over the membranes in a dark 
room and the film was exposed at -70 "C and developed in a Fuji RGII Medical Film Processor. The 
duration of film exposure was usually 24 hours for RNA slot and Northern blots and 14 days for 
nuclear run-on membranes.
2.4.9 Scanning densitometry
The results generated by Northern blotting, slot blotting, nuclear-run-on experiments and 
Western blotting were quantified by scanning densitometry using a CS-9001PC DUal Wavelength 
Flying-Spot Scanner (Shimadzu Europa, Germany). The bands on autoradiographs or photographs 
(of Western blots) were scanned using the parameters and procedures recommended in the instruction 
manual. The data was generated graphically as absorbance peaks corresponding to the intensities of 
the bands. The areas under the peaks were used to represent the band intensities. Since the relative 
intensities of the bands between treatment groups were required, the unit of the number representing 
the area under each peak was arbitrary. Therefore, the data was converted to a percentage of the 
control value(s) (from rats treated with saline alone in each study) and then presented in a histogram 
format.
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2.5 METHODS RELATING TO THE DETERMINATION OF TRANSCRIPTION RATE
2.5.1 Isolation of rat hepatic nuclei
Nuclei were isolated from rat liver tissue using a modification of the method of Schibler et 
al (1983) which was based on the procedure described by Hewish and Burgoyne (1973).
Fresh rat liver was perfused with ice cold 0.9% (w/v) saline to remove contaminating 
haemoglobin and then blot-dried. The liver tissue from individual rats within a group were pooled 
and then immersed in 10 volumes of 0.3M sucrose in buffer A (60mM potassium chloride, ISmM 
sodium chloride, 0.5mM spermidine, O.lSmM spermine, O.lSmM HEPES (acid), 0.5mM EGTA, 
2mM EDTA, 14mM 2-mercaptoethanol). The tissue was scissor-minced and gently homogenized in 
a Potter-Elvehjem homogenizer using a hand held Teflon pestle (with at least 0.2mm clearance) with 
10 return strokes.
The homogenate was filtered through a nylon mesh (125jLtm aperture) which was secured over 
a glass beaker with an elastic band. Approximately 10ml of the filtrate was then layered with a 
syringe over an equal volume of 0.88M sucrose in buffer A and centrifuged at 1300g for 10 minutes 
at 4*C. The supernatant was discarded and the pellet resuspended in 3ml 2M sucrose in buffer B 
(same as buffer A, but O.lmM EGTA and O.lmM EDTA). The suspension was layered over 15ml 
2M sucrose in buffer B then centrifuged at 60,000g. Finally, after discarding the supernatant, the 
pellet of nuclei was resuspended by gently pipetting up and down in 1ml nuclei storage buffer (50mM 
Tris-Cl, pH 8.3,5mM magnesium chloride, O.lmM EDTA, 40% (v/v) glycerol). The nuclei derived 
from pooled liver tissue from any one treatment group were combined and after lO/il was removed 
(for determination of concentration) the homogeneous suspension was stored as 0.5ml aliquots in 
NUNC cryotubes (Intermed) under liquid nitrogen until required.
The concentration of the nuclei was determined by viewing in a haemocytometer (Weber
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Scientific International Ltd, U.K.) with a phase contrast microscope following the appropriate dilution 
of the 10^1 sample in sterile water.
2.5.2 Preparation of DNA probes
The cDNA probes used in the nuclear run-on assay were the same as those used to probe 
RNA (section 2.4). In the latter case the cDNAs were isolated from their respective plasmids and 
hybridised with RNA immobilized on nylon membranes. For the purposes of the nuclear run-on 
assay, the cDNAs were retained in their plasmids and the whole plasmids were linearised, 
immobilised on nylon membranes and hybridised with ^ ^-labelled pre-RNA. In this case the negative 
controls were provided by the plasmids without their cDNA (i.e. pUC19 and pBluescript alone).
2.5.2.1 Ligation of pBluescript plasmid
The pBluescript plasmid (without a cDNA) was not available for large scale preparation. 
Therefore the linear plasmid generated during the isolation of the PFAR cDNA (see section 2.4.5.5) 
was ligated for transformation of TBl cells and subsequent bulk preparation.
Ligation reactions were set up according to the procedure described by Berger and Kimmel 
(1987). The test reaction contained 2/il (5ng/^l) pBluescript DNA (cut with Eco RI), 4^15 x ligase 
buffer (0.4M Tris-Cl, pH 7.6, O.IM magnesium chloride, lOmM dithiothreitol), l/il T4 DNA ligase 
(0.5U//a1) and 16fil sterile water. The control reactions contained different combinations of the above, 
omitting one of the constituents in each control, maintaining the final volume at 20/d by the addition 
of sterile water.
The ligation mixtures were incubated at 14'C overnight. The reaction was terminated by the 
addition of 1/d 0.5M EDTA (pH 8.0) and 10/d of the mixture was combined with 40/d TE (pH 7.2).
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From this solution, 25/il were used to transform competent TBl cells (see section 2.4.5.1) and the 
resultant cultures were plated onto prewarmed TYN/Amp plates. After incubation at 37*C overnight, 
only the culture containing plasmid DNA from the test ligation reaction mixture developed into 
colonies. This culture was used to inoculate TYN/Amp for large scale preparation of the plasmid 
DNA.
2.S.2.2 Large scale préparation of probes and restriction digestion
The cDNAs of interest in their respective plasmids (CYP4A1, CYP2E1 and actin cDNAs in 
pUC19, PPAR cDNA in pBluescript) were prepared on a large scale using the method described in 
section 2.4.5.2. The plasmids pUC19 and pBluescript (see section 2.5.2.1) without cDNAs were also 
prepared in the same way and used as negative controls in the nuclear run-on assay.
Each plasmid containing a cDNA of interest was linearised by restriction digestion with an 
enzyme that cut the plasmid at only one position, which was not within the cDNA. The restriction 
enzyme Hind III was used to digest CYP4A1 cDNA/pUC19, CYP2E1 cDNA/pUC19, actin 
cDNA/pUC19 and pUC19 alone. The PPAR cDNA/Bluescript and Bluescript alone were digested 
with Bam HI. The digestion mixtures containing 60/tg DNA were prepared as described previously 
(in section 2.4.5.3) in a final volume of 1ml.
2.5.3 DNA slot blotting
The volume of each digestion mixture was made up to 4.8ml with sterile water. This was 
heated for 5 minutes at 95 * C then chilled on ice for 2 minutes. The slot blot apparatus was assembled 
as described in section 2.4.2. The DNA solution was applied to six adjacent wells in aliquots of 
5/tg/400/il per well. The probes were applied to the membrane in consecutive rows such that each
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column (to be cut into strips eventually) contained each of the probes of interest.
The slot blot apparatus was dismantelled and the nylon membrane was immersed in 
denaturing solution (1.5M sodium chloride, 0.5M sodium hydroxide) for 1 minute. The membrane 
was then transferred to neutralising solution (1.5M sodium chloride, ImM EDTA, pH 8.0, 0.5M 
Tris-Cl pH 7.2) for 1 minute. The membrane was allowed to air dry on a piece of 3MM Whatman 
paper. The DNA was then fixed to the nylon membrane by UV illumination as described in section 
2.4.2. The columns of DNA probes described above were cut into strips and stored at 4 ’C until 
required.
2.5.4 Determination of the duration of linear rate of transcription
For valid comparison of the rate of transcription of a particular RNA species between 
different treatment groups, the transcription rate in each group of nuclei must be linear during the 
nuclear run-on reaction. Therefore, a preliminary experiment was conducted to follow the 
incorporation of pHJ-UTP into elongating transcripts which had already been initiated. This 
experiment also ensured the viability of the nuclei.
The nuclear run-on assay outlined in this section and in section 2.5.5 was comprised by 
modifications of the methods described by Ausubel et al (1987), Schibler et al (1983), Scheutz et al 
(1990) and McKnight and Palmiter (1979).
The following procedure was carried out using the nuclei from each treatment group. The 
nuclei were thawed on ice then 5 x 10^  nuclei were transferred to each of two 1.5ml polypropylene 
tubes on ice. The volume of the nuclear suspension was made up to 200/tl with nuclei storage buffer 
and to this was added an equal volume of 2 x transcription reaction buffer which was prepared 
immediately prior to use by combining 2ml 2 x standard buffer (lOmM Tris-Cl, pH 8.0, 5mM 
magnesium chloride, 0.3M potassium chloride), 20/d lOOmM ATP, 20/d lOOmM CTP, 20/d lOOmM
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GTP, lO/il dithiothreitol. To the duplicate tubes, 10/tCi [5-^H]-UTP (10-30/tCi/mmol, Amersham 
International) was added and the tubes were immediately transferred to a 30’C waterbath for 
incubation for 4 minutes.
At the end of the incubation period 0.5ml 10% (w/v) TCA was added to each tube and after 
thorough mixing the solution was placed on ice for 15 minutes. At this stage the entire procedure was 
repeated 4 times, increasing the duration of incubation at 30* C by 4 minutes each time. When all the 
tubes had been on ice for at least 15 minutes they were centrifuged at top speed in a microcentrifuge 
for 5 minutes. The supernatant was discarded and the pellet was resuspended in 1ml ice cold 100% 
ethanol. The tubes were incubated for 60 minutes at -20 *C then recentrifuged as above for 10 
minutes. Finally the pellet was resuspended in 150/d sterile water and transferred to a scintillation 
vial to which was added 4.5ml OptiPhase "Safe" scintillant (LKB Scintillation Products Ltd.). The 
relative extent of [5-^H]-UTP incorporation into total pre-RNA was measured in a LKB Wallace 1217 
rack liquid scintillation counter.
2.5.5 Nuclear run-on transcription assay
2.5.5.1 Radiolabelling of pre-RNA
A linear rate of transcription in rat liver nuclei was found to occur up to approximately 20 
minutes of incubation with [5-^H]-UTP (see section 2.5.4). Therefore, this incubation time was 
subsequently used in the nuclear run-on transcription assay described below.
For each treatment group, duplicate transcription reactions were setup as described in section
2.5.5 except that following the combination of nuclei and 2 x transcription reaction buffer, 150/iCi 
[5-^^P]-UTP (800Ci/mmol, 20Ci/ml, Amersham International) was added to each reaction (instead 
of [5-^H]-UTP). In addition, 14mlpolypropylene tubes were used instead of eppendorf tubes to
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minimize contamination and ensure safer handling of the greater amount of radioactivity. Following 
incubation at 30*C for 20 minutes in a shaking waterbath, the transcription reaction was terminated 
by the addition of 0.6ml DNase/HSB solution, prepared immediately prior to use by the combination 
of 14/il RNase free DNase I (27U//tl, Boehringer Mannheim, U.K. Ltd) and 0.6ml HSB buffer 
(0.5M sodium chloride, 50mM magnesium chloride, 2mM calcium chloride, lOmM Tris-Cl pH7.4) 
per reaction.
2.S.5.2 Extraction and purification of total nuclear RNA
The suspension, slightly viscous at this stage due to the rupture of the nuclear membrane and 
digestion of DNA, was mixed by pipetting up and down. After further incubation at 30 *C for 5 
minutes, 200/il Tris/SDS buffer (0.5M Tris, pH 7.4, 0.125M EDTA, pH 8.0, 5% (w/v) SDS) and 
lO/il proteinase K (20mg/ml) were added. The solution was incubated at 42*C for 30 minutes then 
extracted with 1ml phenol/chloroform/isoamyl alcohol (25:24:1 respectively). The organic and 
aqueous phases were clarified by centrifugation at 8000g for 5 minutes. The aqueous phase was 
removed to a fresh tube and following the addition of 2ml sterile water, 3ml 10% (w/v) TCA/ 60mM 
sodium pyrophosphate and 10/tl E.coli tRNA (lOmg/ml), the tube was placed on ice for 30 minutes.
The TCA precipitate was layered onto a GF/A glass fibre filter disc (Whatman Paper Ltd) 
placed on top of a Millipore filter attached to suction pump. The precipitate was washed with 30ml 
5 % (w/v) TCA/ 30mM sodium pyrophosphate then the filter disc was transferred to a scintillation 
vial to which was added 14/d RNase free DNase I and 1.5ml DNase buffer (20mM HEPES (free 
acid), 5mM magnesium chloride, ImM calcium chloride).
After incubation at 37*C for 30 minutes in a shaking waterbath, 45/tl 0.5M EDTA (pH 8.0) 
and 68/tl 20% (w/v) SDS were added to the solution in the scintillation vial, making sure the glass 
fibre filter disc was completely immersed in the solution. The scintillation vial was incubated at 65 * C
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for 10 minutes after which the solution was removed and transferred to a 14ml polypropylene tube. 
Following the addition of 1.5ml elution buffer (lOmM Tris-Cl, pH7.5, 5mM EDTA, pH 8.0, 1% 
(w/v) SDS) to the solution it was further incubated at 65*C for 10 minutes. The RNA was extracted 
by the addition of 3ml TE-saturated phenol and centrifugation at 800g for 5 minutes. The aqueous 
phase was further extracted as above with phenol/chloroform/isoamylalcohol (25:24:1 respectively) 
then chloroform/ isoamylalcohol (24:1 respectively) to remove contaminating phenol.
In a fresh 14ml polypropylene tube, 0.75ml IM sodium hydroxide was added to the aqueous 
RNA solution which was then placed on ice for 10 minutes followed by addition of 1.5ml IM 
HEPES (free acid). The RNA was precipitated by the addition of 0.1 volume 3M sodium acetate and
2.5 volumes ice cold 100% ethanol and incubation at -20*C overnight. The RNA precipitate was 
pelleted by centrifugation at 13,800g for 30 minutes at 4*C. The RNA pellet was washed with TES 
solution (lOmM N-tris(hydroxymethyl)methyl-2-aminoethanesulphonic acid, pH 7.4, lOmM EDTA, 
pH 8.0, 0.2% (w/v) SDS) then resuspended in 100/tl TES solution.
2.5 5.3 Hybridisation of labelled RNA with cDNA probes
The amount of ^^P-labelled RNA in the solution was determined by spotting 5/il of the 
solution onto duplicate GF/F glass fibre filter discs (Whatman Paper Ltd, U.K.) which were placed 
in scintillation vials with 4.5ml OptiPhase scintillant followed by scintillation counting as described 
in section 2.5.4. The amount of ^ ^-labelled RNA in the duplicate RNA solutions from each treatment 
group was standardised to 5 x 10® cpm/ml by dilution with appropriate volumes of TES solution. 
Finally 1ml of RNA solution was combined with an equal volume of TES/sodium chloride solution 
(TES including 0.6M sodium chloride).
For each RNA solution, a nylon membrane strip (the treatment group clearly labelled in 
pencil), prepared as described in section 2.5.3., was rolled and placed into a scintillation vial to
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which was added to the 2ml ^^-labelled RNA solution. After securing the tightly fitting lids of the 
scintillation vials with tape, the scintillation vials were placed in Hybaid™ bottles for incubation in 
a Hybaid™ oven at 42*C for 96 hours.
2.5.S.4 Nylon membrane washing conditions
Following hybridisation, the nylon strips were removed from the scintillation vials and 
washed together in 100ml 2 x SSC at 65’C for 60 minutes. The strips were then placed in separate 
scintillation vials containing 4ml 2 x SSC and 4/d RNase A for incubation without shaking at 37*C 
for 30 minutes. The nylon strips were then washed together in 100ml 2 x SSC at 36'C for 60 
minutes. The nylon strips were allowed to air-dry on 3MM Whatman paper and placed in a cassette 
with a Kodak X Omat AR 5 high speed film which was exposed at -70*C for 14 days. Finally the 
film was developed as described in section 2.4.8.
2.6 Statistical analysis
All statistical analyses were carried out using the software SPSS/PC + V3.0 (Marija. J. 
Norusis, SPSS. Inc. Chicago, Illanois). The Komolgorov-Smimov goodness of fit test was used to 
determine the frequency of distribution of the data (Sokal and Rohlf, 1969). This is a non-parametric 
test which is based on the absolute differences between observed and expected cumulative frequency 
distributions. This particular test was used because it is appropriate when sample sizes are small. 
When the distribution of the data was found to be normal, the significance of the differences between 
treatment groups was determined by a one way analysis of variance and the Duncan’s multiple range 
test which enabled all pair-wise comparisons among thé group means (Ott, 1988).
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These procedures were straight-forward when applied to the data generated from the 
determination of protein levels and enzyme activities (chapter 3). However, the analysis of slot blot 
results (chapters 4 and 5) was somewhat more complicated. In some instances, the group data was 
shown to have unequal variances (identified where appropriate). This was evident when the 
minimum/maximum variance, exceeded the critical tabulated value (table for the critical point 
of Bartlet’s F^^. Such data is said to be heteroscedastic (Ott, 1988). Equal variances are usually 
obtained by carrying out a transformation of the data, a process which converts the measurements 
on the original scale to a new scale of measurement. A logarithmic transformation of the data was 
found to reduce the F^ ax values to within the acceptable range.
The statistical analysis of data generated by the determination of specific mRNA levels by slot 
blotting was hampered by a number of problems encountered with the experimental technique. These 
are discussed in sections 4.3, 4.4 and 4.7.
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CHAPTERS
THE EFFECTS OF POLY IC AND 
INTERFERON of ON CYP4A1 AND CYP2E1 PROTEINS
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3.1 INTRODUCTION
Increasing evidence shows that the immunomodulating proteins, interferons, and their 
inducers differentially down-regulate some cytochrome P450 isoenzymes (Moochhala et a/,1989, 
Morgan and Norman, 1990 and Craig et al, 1990). The precise molecular mechanism(s) which 
mediates the observed inhibition is as yet unknown, although numerous theories have been proposed 
with varying degrees of supporting evidence. These have been outlined elsewhere (section 1.3.3).
One recent study carried out by Renton and coworkers showed that the coadministration of 
poly IC (an inducer of endogenous interferons a and j8) and the CYP4A1 inducer, clofibrate, resulted 
in suppression of the induced level of lauric acid co-hydroxylase activity of CYP4A1 by 
approximately 60%. This was attributed to a decrease in the synthesis of the apoprotein as measured 
by SDS PAGE and Western blotting following in vitro cell free translation (Renton et al, 1987). This 
result suggested that the reduced level of CYP4A1 apoprotein was due to a decrease in the amount 
of CYP4A1 mRNA. This was confirmed by a subsequent study in which it was demonstrated that 
poly IC significantly suppressed the clofibrate-induced level of rat hepatic CYP4A1 mRNA (Renton 
and Knickle, 1990).
The results presented in this chapter confirm this observation and extend the investigations 
further. The dose of clofibrate chosen to induce CYP4A1 was reduced from 400mg/kg to 250mg/kg 
since this has been found to be sufficient to induce the levels of this isoenzyme approximately eight 
fold above the control level (Sharma et al, 1988a). The dose level of poly IC was maintained at 
lOmg/kg, administered in accordance with the procedure adopted by Renton and coworkers (1987), 
24 hours before the rats were killed.
The investigations have now been advanced by the use of human lymphoblastoid interferon 
a  (a 93% pure combination of the 22 subtypes). The reason for administering interferon ol in place 
of poly IC is twofold. Firstly, to determine whether the inhibitory effect observed is a reflection of
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the direct action of interferons on cytochrome P450s rather than the consequence of an unrelated, 
either direct or induced, effect generated by poly IC.
The second reason for the use of human interferon a  in this study is to determine the species 
specificity of the interferon-mediated inhibition of drug metabolism. The species specific nature of 
interferons in relation to the down-regulation of drug metabolism has not yet been clarified, although 
one recent report suggests that human interferons do not inhibit drug metabolism in rats (Craig et al, 
1989). However, the results presented here indicate that, contrary to the conclusion drawn by Craig, 
human interferon a does decrease the content of at least one cytochrome P450 isoenzyme in rats.
In addition, clofibratetreated rats were administered a range of doses of interferon a to 
determine whether there is a dose-dependent effect on the clofibrate-induced protein level and 
catalytic activity of CYP4A1. The dose levels used were selected on the basis of those reported in 
other similar studies (Craig et al, 1989, Craig et al, 1990, Moochhala et al, 1989).
The constitutively expressed CYP4A1 is regulated primarily at the level of transcription 
(Hardwick et al, 1987, Eamshaw et al, 1988). This is discussed more fully in sections 1.1.5 and 
6.4). In order to compare the effects of poly IC and interferon a on this isoenzyme with that on a 
post-transcriptionally regulated isoenzyme, additional experiments examined the induction and 
evaluation of the effects of poly IC and interferon a on CYP2E1. A variety of substances and 
conditions such as treatment with some small organic molecules, high fat diets and diabetes increase 
the level of CYP2E1 activity without a corresponding transcriptional induction of the CYP2E1 gene 
(Koop et al, 1985, Favreau and Schenkman, 1988, Yang and Yoo, 1988, Song et al, 1986). One 
such organic inducer is isonicotinic acid hydrazine (abbreviated to isoniazid or INH), a drug used 
in the treatment of tuberculosis. A dose of 0.1 % (w/v) administered to rats in drinking water for 10 
days increases the level of hepatic CYP2E1 apoprotein four-fold above the constitutive, control level 
(Ryan et al, 1985). In the present study, isoniazid was administered at a dose level of l(X)mg/kg for 
4 days by gavage. The daily dose and duration of treatment were reduced from previously used levels
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to limit the deleterious effects of giving a single, large daily doses instead of a gradual treatment in
the drinking water.
The main objectives of the studies presented in this chapter are summarized below.
1. To confirm that poly IC administration to clofibrate treated rats suppresses the induced levels
of CYP4A1 protein and catalytic activity in accordance with the observations of Renton and 
coworkers (1987).
2. To ensure that the observed effect is mediated by interferons and is not the result of other
poly IC-related activities. This was accomplished by the administration of exogenous human 
a interferons.
3. The treatment of rats with human lymphoblastoid interferon a  was an attempt to initiate the 
elucidation of the species specificity of interferon a  with respect to its action on drug 
metabolism.
4. To investigate the effect of poly IC and interferon a  on the protein level and catalytic activity
of CYP2E1, an example of the P450 isoenzymes which are post-transcriptionally regulated.
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3.2 Hepatomegaly
Hepatomegaly is defined as an enlargement of the liver due to either (or both) hyperplasia 
and hypertrophy and is associated with a large increase in phospholipid and total protein levels 
(Azamoff et al, 1965). This condition is a common adaptive response to treatment with peroxisome 
proliferators, a class of compounds of which clofibrate is a member (Reddy et al, 1980, Lake et al, 
1975). Hepatomegaly is expressed as an increase in the liver/body weight ratio relative to the control 
ratio (Beckett et al, 1972).
Following the administration of clofibrate for three days, a significant increase in liver/body 
weight ratio was observed relative to the control ratio (figure 3.1). The coadministration of poly IC 
significantly reduced the extent of hepatomegaly induced by clofibrate. In addition, the control 
liver/body weight ratio was reduced by treatment with poly IC treatment alone. These observations 
indicate that poly IC, or the interferons induced by poly IC, inhibit the process leading to 
hepatomegaly.
In the second study (figure 3.2) the administration of clofibrate did not elicit the same 
response as seen previously. There was no significant increase in liver/body weight ratio in clofibrate 
treated rats compared with the control group. Concomitant treatment with the three dose levels of 
interferon a. did not affect the control liver/body ratio. An additional control group with interferon 
a  treatment alone was omitted through oversight, however this control group was included in the 
study involving isoniazid treatment (see later).
Administration of isoniazid, alone or in combination with either poly IC or interferon a. 
(figure 3.3), did not change the control liver/body weight ratio. Neither poly IC or interferon a 
treatment alone affected the control liver/body weight ratio.
75
Figure 3.1
The effect of poly IC on clofibrate-induced hepatomegaly in rats
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CONTROL POLY IC CLOFIBRATE CLOFIBRATE
+ POLY IC
TREATMENT GROUP
Error bars represent the standard deviation where n=4
* p < 0.01 significant difference from the control group 
** p < 0.01 significant difference from the clofibrate group
Treatment
Control 
Clofibrate 
Poly IC
0.9% saline x 3 days
250 mg/kg X 3 days
10 mg/kg 24 hours before sacrifice
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Figure 3.2
Rat liver/body weight ratio after administration of clofibrate 
alone and with interferon a
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Figure 3.3
Rat liver/body weight ratio after administration of isoniazid and 
poly IC or interferon a
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Error bars represent the standard deviation where n = 4
No two groups are significantly different
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1(X) mg/kg
X 3 days 
X 3 days
2 X 1Q6 lU/kg 24 hours before sacrifice 
10 mg/kg 24 hours before sacrifice
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3.3 Effects of poly IC and interferon a on hepatic microsomal cytochrome P450 enzymes
3.3.1 Cytochrome P450 specific content
The induction of cytochrome P450 (i.e. total carbon monoxide discernible) specific content 
following clofibrate treatment was found to be significant at the 5 percent level (figure 3.4). 
Cotreatment with poly IC significantly suppressed this clofibrate-induced level of total cytochrome 
P450. While interferon a was also found to suppress the induction of cytochrome P450 content 
(figure 3.5), this effect was only apparent at the two higher dose levels of interferon. Furthermore, 
the inhibitory effect of interferon on clofibrate-induced cytochrome P450 does not appear to be dose- 
dependent.
Treatment with isoniazid has the reverse effect on cytochrome P450 specific content to that 
of clofibrate, causing a significant decrease in the level of total cytochrome P450 (figure 3.6). This 
effect is in agreement with the observations of Ryan and coworkers (1985). Neither poly IC nor 
interferon a  treatment alone had an effect on the level of cytochrome P450 specific content relative 
to control.
3.3.2 CYP4AI apoprotein content determined by ELISA
Other studies investigating the effects of poly IC and recombinant interferon a  on CYP4A1 
have measured the apoprotein content of this isoenzyme by Western blotting alone (Renton et al, 
1987, Renton and Knickle, 1990). While this technique is valuable, and indeed it has been used in 
the present investigation (see sections 3.3.3 and 3.3.5), it is largely a qualitative measurement of the 
relative levels of a protein in comparative samples. Densitometric scanning of the bands on the 
Western blots has enabled a more quantitative assessment of the relative protein levels they represent.
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Figure 3.4
Suppression of clofibrate-induced rat hepatic cytochrome P450 
specific content by poly IC
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Poly IC 10 mg/kg 24 hours before sacrifice
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Figure 3.5
Suppression of clofibrate-induced rat hepatic cytochrome P450 
specific content by interferon a
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Figure 3.6
Effect of isoniazid with poly IC or interferon a on rat hepatic 
cytochrome P450 specific content
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Additional, corroborating results have been obtained by using the enzyme-linked 
immunoabsorbent assay (ELISA) which allows for a quantitative analysis of the apoprotein of 
CYP4A1 in hepatic microsomes. A polyclonal antibody, raised in sheep to purified CYP4A1, was 
used. Western blotting has shown that this antibody cross-reacts with CYP4A1 and a heavier protein 
which is thought to be a closely related CYP4A isoenzyme (Sharma et al, 1989).
Clofibrate treatment markedly induced the level of CYP4A1 apoprotein (fig. 3.7 and fig. 3.8). 
The difference in the extent of induction of the isoenzyme, by the same treatment, in the two separate 
studies may be due to a physiological variation in the two groups of rats.
Cotreatment with poly IC significantly suppressed the induction of CYP4A1 to approximately 
half the induced level and close to the control level. Only the highest dose of interferon a  was 
sufficient to significantly reduce the induced level of CYP4A1. Treatment with poly IC alone did not 
affect the CYP4A1 apoprotein content relative to the control level.
All the ELISA data is presented in terms of "nmol CYP4AI/mg protein", rather than "nmol 
CYP4A1/ nmol P450 specific content", because total P450 content changes with clofibrate and poly 
IC treatment (section 3.3.1). Each sample assayed contained the same amount of microsomal protein, 
therefore, this parameter provides a reference for comparison of the level of specific proteins in the 
different treatment groups.
3.3.3 CYP4A1 apoprotein level measured by Western blotting
Until recently the analysis of protein levels in samples by Western blotting was limited by 
the strictly qualitative interpretation of the relative intensities of the bands on the blot (generated by
the colorimetric endpoint of the reaction catalysed by the specifically bound enzyme label). 
However, densitometric scanning of the bands provides a semi-quantitative means of presenting this 
data.
83
Figure 3.7
Clofibrate-induced rat hepatic CYP4A1 apoprotein suppression 
by poly IC (measured by ELISA)
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Figure 3.8
Effect of interferon a on clofibrate-induced rat hepatic CYP4A1 
apoprotein (measured by ELISA)
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** p < 0.05 significant difference from clofibrate group
Treatment
Control 0.9% saline X 3 days
Clofibrate 250 mg/kg X 3 days
IFN (l) 2.5 X 104 lU/kg 24 hours before sacrifice
IFN (2) 2.5 X 105 lU/kg 24 hours before sacrifice
IFN (3) 2.5 X 106 lU/kg 24 hours before sacrifice
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Each microsomal sample analyzed was representative of a separate treatment group and was 
composed of an equivalent amount of hepatic microsomal protein from the individual animals within 
the group. Therefore, each band in figures 3.9, 3.11 and 3.13 represents the level of CYP4A1 
apoprotein in the identified treatment groups. The use of composite group samples, however, limits 
the quantitative expression of the relative intensities of the bands such that statistical analysis of the 
group data is not possible.
The first four bands in figure 3.9 represent the level of CYP4A1 apoprotein in hepatic 
microsomal samples. Although it is difficult to distinguish them, there are in fact two bands very 
close to one another. The lower, more intense band has a molecular weight of 51,500 and represents 
CYP4A1, while the upper band (with a molecular weight of52,000) is thought to represent CYP4A3 
(Sharma et al, 1989, Aoyama et al, 1990). (It is more easy to differentiate the two bands in the 
Western blot shown in figure 3.11). Unfortunately, due to their close proximity, the two bands were 
not discernible by densitometric scanning. Therefore, the quantitation of these results was based on 
the relative intensity of the combination of the two bands between the comparative samples. Track 
5 contains purified CYP4A1 protein which provides a positive reference for the identification of 
CYP4A1 in the experimental samples.
The intensity of the band in track 2 (figure 3.9) shows a marked induction of CYP4A1 protein 
by clofibrate treatment relative to the control group represented by the band in track 1. Concomitant 
treatment with poly IC (track 3) appears to decrease the induced level of CYP4A1 protein. However, 
this suppression is not as pronounced as that seen when the level of the isoenzyme was determined 
by ELISA (figure 3.7). The control level of CYP4A1 appears to be reduced by poly IC treatment 
alone (tracks 1 and 4 respectively in figure 3.9). However, this is inconsistent with the ELISA data 
which indicates that poly IC treatment did not suppress the control CYP4A1 level.
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Figure 3.9
Western blot analysis of the effect of poly IC on clofibrate-induced rat 
hepatic CYP4A1
CYP4A1
Track Treatment
1 Control 0.9% saline X 3 days
2 Clofibrate 250 mg/kg X 3 days
3 Clofibrate + poly IC (as for tracks2 and 4)
4 Poly IC 10 mg/kg 24 hours before sacrifice
5 Pure CYP4A1
Each ‘treatment group sample’ was obtained by combining the 4 microsomal samples 
within a group on an equivalent protein basis. 20pg protein was loaded in each track. 
The relative intensities of the bands were determined by densitometric scanning 
(as described in Materials and Methods) and are presented in figure 3.10.
Figure 3.10
Relative levels of rat hepatic CYP4A1 in Western blot shown in figure 3.9
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O 200-
ou
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CONTROL POLY IC CLOFIBRATE CLOFIBRATE
+ POLY IC
TREATMENT GROUP
Values, expressed as a percentage of the control level, were obtained by densitometric 
scanning of the bands in figure 3.9 as described in Materials and Methods.
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Figure 3.11
Effect of interferon a  on the level of clofibrate-induced CYP4A1 measured by 
Western blotting
CYP4A1
1 2 3 4 5 6
Track Treatment
1 Pure CYP4A1
2 Control 0.9% saline X 3 days
3 Clofibrate 250 mg/kg X 3 days
4 Clofibrate + IFN (1) 2.5xl04lU /kg IFN administered 24 hours before sacrifice
5 Clofibrate + IFN (2) 2.5 X 105 lU/kg IFN administered 24 hours before sacrifice
6 Clofibrate + IFN (3) 2.5 X 105 lU/kg IFN administered 24 hours before sacrifice
Each ‘treatment group sample’ was obtained by combining the 4 microsomal samples 
within a group on an equivalent protein basis. 20pg protein was loaded in each track 
The relative intensities of the bands were determined by densitometric scanning 
(as described in Materials and Methods) and are presented in figure 3.12.
Figure 3.12
Relative levels of rat hepatic CYP4A1 in Western blot shown in figure 3.11
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o
g  200-
S
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CONTROL CLOFIB CLOHB CLOHB CLOHB
+ IFN(1) +IFN(2) +IFN(3)  
TREATMENT GROUP
Values, expressed as a percentage of the control level, were obtained by densitometric 
scanning of the bands in figure 3.11 as described in Materials and Methods. The doses of 
interferon (1, 2 and 3) are given above in the legend for figure 3.11.
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Figure 3.13
Suppression of CYP4A1 by isoniazid measured by Western blotting
CYP4A1
4
Track
1
2
3
4
5
6
Treatment 
Control 
Poly IC 
IFN
Isoniazid (INH) 
INH + poly IC 
INH + IFN
0.9% saline 
10 mg/kg 
2 X 106 lu/kg 
100 mg/kg 
(as for 2 and 4) 
(as for 3 and 4)
X 3 days
24 hrs before sacrifice 
24 hours before sacrifice 
X 3 days
Each ‘treatment group sample’ was obtained by combining the 4 microsomal samples 
within a group on an equivalent protein basis. 20pg protein was loaded in each track 
The relative intensities of the bands were determined by densitometric scanning 
(as described in Materials and Methods) and are presented in figure 3.14.
Figure 3.14
Relative levels of rat hepatic CYP4A1 in Western blot shown in figure 3.13
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I
u
o
INHCONTROL POLY IC IFN INH INH
+ POLY IC +IFN 
TREATMENT GROUP
Values, expressed as a percentage of the control level, were obtained by densitometric 
scanning of the bands in figure 3.13 as described in Materials and Methods.
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The clofibrate-induced level of CYP4A1 apoprotein was found to be reduced by interferon 
a at each of the three dose levels used (figure 3.11). This observation does not concur fully with the 
ELISA results (figure 3.8) where cotreatment with only the highest dose of
interferon a  was found to significantly suppress the clofibrate-induced level of CYP4A1.
The discrepancies between the relative levels of CYP4A1 protein when measured by ELISA 
and Western blotting may be due to the different attributes and weaknesses of the two techniques. 
The ELISA is in some respects a more sensitive assay, since it (initially) requires a much smaller 
amount of microsomal protein (0.1-0.5/^g as opposed to 20/zg required for Western blotting) for 
analysis and was designed specifically for quantitative analysis. However, although the two bands 
detected on the Western blot are not easily distinguished (due to their close proximity) by 
densitometry, the ELISA does not allow even for a qualitative distinction between the two protein 
species.
Treatment with isoniazid alone appears to cause a decrease in the control level of CYP4A1 
(figure 3.13, tracks 4 and 1 respectively)]
3.3.4. CYP4A1 lauric acid w-hydroxylase activity
Clofibrate and other peroxisome proliferators have been shown to markedly induce the level 
of hepatic CYP4A1 and other members of the CYP4A subfamily with an associated elevation of 
lauric acid oj-hydroxylation in rats (Tamburini et al, 1984, Hardwick et al, 1987a, Sharma et al, 
1988b). A very slight induction of w-1 hydroxylation also occurs. This process is thought to be 
catalysed by a number of CYP4A isoenzymes although it is not yet clear which of the isoenzymes 
are responsible (Aoyama et al, 1990). In the present investigations, clofibrate treatment resulted in
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a five fold induction of co-hydroxylation of lauric acid in one study (figure 3.15) and a ten fold 
induction in another study (figure 3.16). In each case co-1 hydroxylation was also induced but to a 
much smaller extent. In the first study, cotreatment of clofibrate with poly IC caused a significant 
reduction of lauric acid co-hydroxylase activity by poly IC cotreatment (figure 3.15). Poly IC 
treatment alone did not alter the control levels of either co- or co-1 hydroxylase activities.
Although cotreatment of interferon a (at its highest dose level) with clofibrate appeared to 
cause a significant reduction in CYP4A1 apoprotein, relative to the level induced by clofibrate alone, 
this effect was not reflected in the lauric acid co-hydroxylase activities in the comparative treatment 
groups (figure 3.16). There appears to be no significant difference in lauric acid co-hydroxylase 
activity between the group treated with clofibrate alone and the group cotreated with the highest dose 
of interferon a.
The inconsistencies in these results have been investigated by double-checking the initial 
experimental protocols (for the ELISA and lauric acid hydroxylation assays) and the subsequent 
calculations of the data generated. However, there is no apparent error in either procedure. 
Unfortunately, the microsomal samples had been used up during the course of the experiments, 
therefore it was not possible to repeat either assay. Therefore, discussions will focus on the results 
outlined above.
The lauric acid co-hydroxylase activity is expressed in terms of "nmol 12- 
hydroxylaurate/min/mg protein", rather than "nmol 12-hydroxylaurate/min/nmol P450 specific 
content", because total P450 content changes with clofibrate and poly IC treatment (section 3.3.1). 
The microsomal protein content is used as a reference for comparison of the activity of the lauric acid 
co-hydroxylase activity in the different treatment groups, since the amount of microsomal protein 
included in each sample assayed was equal.
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Figure 3.15
The suppression of clofibrate-induced rat hepatic lauric acid 
©-hydroxylation by poly IC
20 1
0  11-hydroxylaurate
0  12-hydroxylaurate15"■t
II 1 0 -
CONTROL POLY IC CLOFIB CLOFIB
+ POLY IC
TREATMENT GROUP
Error bars represent the standard deviation where n=4
* p < 0.01 significant difference from the control group 
** p < 0.05 significant difference from the clofibrate group
Treatment
Control 0.9% saline x 3 days
Clofibrate 250 mg/kg x 3 days
Poly IC 10 mg/kg 24 hours before sacrifice
92
Figure 3.16
The effect of interferon a on hepatic lauric acid hydroxylation in clofibrate 
treated rats
S  11 -hydroxy laurate 
□  12-hydroxylaurate
12 1
1 0 -
CLOFIBCONTROL CLOHB CLOHB CLOHB
+ IHSr (1) + IFN (2) + IFN (3)
TREATMENT GROUP
Error bars represent the standard deviation where n=4
* p < 0.01 significant difference from the control group
Treatment
Control 
Clofibrate 
IFN (l) 
IFN (2) 
IFN (3)
0.9% saline 
250 mg/kg
2.5 X 104 lU/kg
2.5 X 105 lU/kg
2.5 X 106 lU/kg
X 3 days 
X 3 days
24 hours before sacrifice 
24 hours before sacrifice 
24 hours before sacrifice
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3.3.5 Regulation of CYP2E1 apoprotein.
Previous investigations which have focused on the effects of interferons on rat cytochrome 
P450 isoenzymes have shown that the protein level or activity of the isoenzyme in each case has 
been, to varying degrees, suppressed by interferons (Morgan and Norman, 1990, Moochhala and 
Renton, 1989, Craig et al, 1990). In the present study, immunoblotting with an antibody to CYP2E1 
has shown that this effect is not universal among the rat cytochrome P450 isoenzymes.
The Western blot in figure. 3.17 demonstrates that the induced level of CYP2E1 (track 4) was 
not affected by cotreatment with either poly IC or interferon a (tracks 5 and 6 respectively). This 
observation is supported by results from the analysis of CYP2E1 catalytic activity (see section 3.3.6). 
It is interesting to note that poly IC treatment alone (track 2) appears to decrease the constitutive level 
of CYP2E1 (track 1). Clearly, there is at least one rat cytochrome P450 isoenzyme whose induction 
is not inhibited by interferon.
The constitutive level of CYP2E1 protein (figure 3.19, track 1) appears to be suppressed by 
clofibrate-treatment (track 2). This effect mirrors that seen previously (figure 3.13) where isoniazid 
treatment (track 4) resulted in a decrease in the control CYP4A1 level (track 1). Cotreatment of 
clofibrate with poly IC (figure 3.19, track 3) does not alter the repression of CYP2E1 elicited by 
clofibrate, while poly IC treatment alone (track 4) appears to cause an inhibition of the level of 
CYP2E1 apoprotein.
A Western blot of the hepatic microsomes from clofibrate treated and interferon a  cotreated 
groups probed with the antibody to CYP2E1 (figure 3.21) also shows a reduction in the level of this 
isoenzyme by the action of clofibrate (track 2). Concomitant treatment with human interferon a  at 
each of the three dose levels (tracks 3,4 and 5) appears to release the repression (caused by 
clofibrate) such that the CYP2E1 content returns to control level.
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Figure 3.17
Western blot analysis of the effect of poly IC and interferon a  on isoniazid- 
induced CYP2EI
Track
1
2
3
4
5
6
Treatment
Control 
Poly IC 
IFN
Isoniazid (INH) 
INH + poly IC 
INH + IFN
4
0.9% saline 
10 mg/kg 
2 X 10^  lU/kg 
100 mg/kg 
(as for 2 and 4) 
(as for 3 and 4)
X 3 days
24 hrs before sacrifice 
24 hours before sacrifice 
X 3 days
Each ‘treatment group sample’ was obtained by combining the 4 microsomal samples 
within a group on an equivalent protein basis. 20pg protein was loaded in each track 
The relative intensities of the bands were determined by densitometric scanning 
(as described in Materials and Methods) and are presented in figure 3.18.
Figure 3.18
Relative levels of rat hepatic CYP2E1 in Western blot shown in figure 3.17
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100-
CONTROL POLY IC IFN INH INH INH
+ POLY IC +IFN  
TREATMENT GROUP
Values, expressed as a percentage of the control level, were obtained by densitometric 
scanning of the bands in figure 3.17 as described in Materials and Methods.
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Figure 3.19
Western blot analysis of the effect of poly IC on hepatic CYP2E1 in 
clofihrate treated rats
Track
1
2
3
4
Treatment 
Control 
Clofibrate 
Clofibrate + poly IC 
Poly IC
0.9% saline 
250 mg/kg 
(as for 2 and 4) 
10 mg/kg
X 3 days 
X 3 days
24 hrs before sacrifice
Each ‘treatment group sample’ was obtained by combining the 4 microsomal samples 
within a group on an equivalent protein basis. 20pg protein was loaded in each track 
The relative intensities of the bands were determined by densitometric scanning 
(as described in Materials and Methods) and are presented in figure 3.20.
Figure 3.20
Relative levels of rat hepatic CYP2E1 in Western hlot shown in figure 3.19
1201
j  100-
Î  80 : 
I
2 0 -
CONTROL POLYIC CLOFIBRATE CLOFIBRATE
+ POLY IC
TREATMENT GROUP
Values, expressed as a percentage of the control level, were obtained by densitometric 
scanning of the bands in figure 3.19 as described in Materials and Methods.
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Figure 3.21
Effect of clofibrate alone or with interferon a rat hepatic CYP2E1 measured 
by Western blotting
Track Treatment
1 Control
2 Clofibrate
3 Clofibrate + IFN (1)
4 Clofibrate + IFN (2)
5 Clofibrate + IFN (3)
4
0.9% saline 
250 mg/kg
2.5 X 104 lU/kg
2.5 X 105 lU/kg 
2.5xl06lU /kg
X 3 days 
X 3 days
IFN administered 24 hours before sacrifice 
IFN administered 24 hours before sacrifice 
IFN administered 24 hours before sacrifice
Each ‘treatment group sample’ was obtained by combining the 4 microsomal samples 
within a group on an equivalent protein basis. 20pg protein was loaded in each track 
The relative intensities of the bands were determined by densitometric scanning 
(as described in Materials and Methods) and are presented in figure 3.22.
Figure 3.22
Relative levels of rat hepatic CYP2E1 in Western blot shown in figure 3.21
1501
t  100-
I  ■
U
to 5 0 -  O
CONTROL CLOFIB CLOFIB CLOFIB CLOFIB
+ IFN (1) + IFN (2) + IFN (3)
TREATMENT GROUP
Values, expressed as a percentage of the control level, were obtained by densitometric 
scanning of the bands in figure 3.21 as described in Materials and Methods. The doses of 
interferon (1, 2 and 3) are given above in the legend for figure 3.11.
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3.3.6 Regulation of CYP2E1 paranitrophenol hydroxylase activity
CYP2E1 catalyses the metabolism of a variety of compounds some of which are also inducers 
of the isoenzyme (examples are shown in figure 1.1). From the range of substrates of CYP2E1, 
hydroxylation of the aromatic compound paranitrophenol to 4-nitrocatechol was chosen as an assay 
for the catalytic activity of this isoenzyme. Inhibition studies, using an antibody to rabbit CYF2E1 
have shown that under induced conditions, approximately 85% of the paranitrophenol 
hydroxylase activity in rat hepatic microsomes is attributed to the activity of CYF2E1 (Koop et al, 
1989).
Treatment with isoniazid significantly elevated the paranitrophenol hydroxylase activity in 
hepatic microsomes by approximately 300% (figure 3.23). Concomitant treatment with either poly 
IC or interferon a  had no effect on this induced level of activity. These observations are in agreement 
with the results of the Western blot of the corresponding samples which show that the induction in 
the level of CYP2E1 protein by isoniazid is unaffected by the coadministration of poly IC or 
interferon a  (figure 3.17). Administration of poly IC or interferon a. alone did not alter the control 
rate of paranitrophenol hydroxylase activity. However, the Western blot shows that the level of 
CYP2E1 apoprotein appears to be slightly reduced by the administration of poly IC, (although it is 
not possible to ascertain whether this difference is significant).
As mentioned earlier, the substrate specificity of CYP2E1 for paranitrophenol has been shown 
to be about 85% under induced conditions. That is, 85% of the hydroxylation of paranitrophenol can
be attributed to CYP2E1. However, in the uninduced state, only 40% of paranitrophenol is due to
Ihydroxylation i
CYP2E1 (Koop et al, 1989). Therefore, in uninduced samples, hydroxylation of paranitrophenol jis ' 
not an effective indication of CYP2E1 catalytic activity. This may explain the discrepancy between
the paranitrophenol hydroxylase activity and the CYP2E1 protein level in the groups that had not
been treated with isoniazid.
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Figure 3.23
Hepatic paranitrophenol hydroxylase activity rats treated with isoniazid
alone and in combinbation with poly IC or interferon a
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CONTROL POLY IC IFN INH INH INH
+ POLYIC +IFN
TREATMENT GROUP
Error bars represent the standard deviation where n=4
* p < 0.01 significant difference from control group
Treatment
Control
Isoniazid (INH)
IFN
PolylC
0.9% saline x 3 days
100 mg/kg X 3 days
2 X 106 lU/kg 24 hours before sacrifice
10 mg/kg 24 hours before sacrifice
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In view of the finding that isoniazid appears to suppress the expression of CYP4A1 (figure 
3.13) and clofibrate appears to down-regulate CYP2E1 expression (figure 3.21), it would have been 
useful to verify this result by measuring the catalytic activities of CYP4A1 and CYP2E1 in isoniazid 
treated and clofibrate treated samples respectively. However, as mentioned earlier, the microsomal 
samples from the studies involving treatment with clofibrate, poly IC and interferon a  had been used 
up at this stage of the investigations. Therefore, it was not possible to determine the effect of these 
treatments on paranitrophenol hydroxylase activity. Similarly, and for the same reason, it was not 
possible to investigate the effects of isoniazid treatment, alone or in combination with poly IC or 
interferon a on lauric acid w-hydroxylase activity.
3.3.7 NADPH-cytochrome c reductase activity
The flavoprotein NADPH-cytochrome P450 reductase catalyses electron transfer from 
NADPH to cytochrome P450 and is an integral component of the mixed function monooxygenase 
system. A change in protein level or activity of this enzyme would be expected to dramatically alter 
the activity of the cytochrome P450s.
In view of this, it is possible that the suppressive effects of poly IC and interferon o; on the 
induction of CYP4A1 by clofibrate are caused by the action of the former substances on 
NADPH-cytochrome P450 reductase. _ ,
The control rate of microsomal NADPH-cytochrome c reductase activity remained 
unperturbed by clofibrate treatifient, either alone or in combination with interferon a (figure 3.24). 
Microsomal samples from the study in which clofibrate treated rats were cotreated with poly IC had 
been used up, therefore, it was not possible to analyze the effect of the combined treatment of 
clofibrate and poly IC on the activity of NADPH-cytochrome c reductase.
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Figure 3.24
Hepatic NADPH-cytochrome c reductase activity in rats treated
with clofibrate alone or with interferon a
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No two groups are significantly different
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X 3 days 
X 3 days
24 hours before sacrifice 
24 hours before sacrifice 
24 hours before sacrifice
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Figure 3.25
Hepatic NADPH-cytochrome c reductase activity in rats treated
with isoniazid alone and with poly IC or interferon a
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No two groups are significantly different
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Treatment with isoniazid, either alone in conjunction with poly IC or interferon a did not 
affect the control level of NADPH-cytochrome c reductase activity (figure 3.25). Furthermore, 
treatment with poly IC or interferon a alone did not affect the constitutive level of activity of the 
reductase. Clearly, the activity of the NADPH-cytochrome c reductase (and by association, NADPH- 
cytochrome P450 reductase) was not modified by treatment with poly IC or interferon a.
3.3.8 Cytochrome bg
As an extension of the investigation into the effects of poly IC and interferon a  on the 
cytochrome P450 monooxygenase system, the protein level of cytochrome bg was determined in the 
hepatic microsomal samples.
Cytochrome bg is thought to play an important role in the oxidation of some substrates by 
some of the cytochrome P450 isoenzymes (Oshino, 1978). A brief description of its putative function 
in the context of the oxidative process is given below.
Following reduction of the cytochrome P450-substrate complex by transfer of an electron 
from NADPH via NADPH-cytochrome P450 reductase, the reduced complex binds with molecular 
oxygen. At this stage in the oxidation of the substrate, a second reduction event occurs which may 
result from the donation of an electron by NADH, catalysed by cytochrome bs and NADH- 
cytochrome bg reductase. In the final step, the complex dissociates to form water, oxidised substrate 
and the oxidised form of cytochrome P450.
The cytochrome bg level in the hepatic microsomes of rats treated with isoniazid alone or in 
combination with either poly IC or interferon a did not differ significantly from that in control 
microsomes (figure 3.26).
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Figure 3.26
Hepatic cytochrome bs content in rats treated with isoniazid alone 
and with poly IC or interferon a
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No two groups are significantly different
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100 mg/kg X 3 days
2 X 106 lU/kg 24 hours before sacrifice
10 mg/kg 24 hours before sacrifice
104
At this stage of the investigations, the microsome samples from two of the studies conducted 
(those involving treatment with clofibrate) had been used up. Therefore, the cytochrome bg assay was 
only conducted on the third study in which isoniazid was used to induce CYP2E1. However, since 
poly IC and interferon a  have been shown to suppress the induction of CYP4A1 but not that of 
CYP2E1, this does not allow for the evaluation of the cytochrome bg status in a system where the 
induction of a cytochrome P450 isoenzyme has been suppressed by poly IC or interferon a.
3.4 Discussion
The hepatic changes that occur in rats following administration with hypolipidaemic agents, 
such as clofibrate, have been well documented. These include hepatomegaly, peroxisome 
proliferation, proliferation of the smooth endoplasmic reticulum (SER) and transcriptional induction 
of CYP4A1 (Lake et al, 1975, Gibson at at, 1982, Hawkins et al, 1987, Hardwick et al, 1987, 
Sharma et al, 1988b).
A hypothesis, based on a substrate overload mechanism, has been proposed to explain an 
interrelationship between these and other physiological responses to hypolipidaemic agents (Sharma 
et al, 1988a). An account of the supporting evidence for this hypothesis is given elsewhere (section 
1.1.5).
In the first study conducted, as expected, clofibrate treatment resulted in a small, but 
significant increase in liver/body weight ratio. The associated proliferation of SER and peroxisomes 
by clofibrate treatment account for the hepatomegaly. Coadministration of poly 1C with clofibrate 
repressed the hepatomegaly, the levels of CYP4A1, its catalytic activity and cytochrome P450 
specific content.
There was also a marked elevation in microsomal CYP4A1 protein level and lauric acid w- 
hydroxylase activity following clofibrate administration in the second study (interferon a  dose range).
105
However, in this study the induction of CYP4A1 was not accompanied by an increase in liver/body 
weight ratio.
In their study, following the administration of the same dose level and duration of treatment 
of rats with clofibrate (by gavage), Sharma and coworkers observed a 127% increase in liver/body 
weight ratio relative to the control group (Sharma et al, 1988a). This compares well with the 
hepatomegaly observed in the first study (123% increase in liver/body weight ratio). It appears 
therefore, that the hepatomegaly observed in the first study is a more typical response to acute 
clofibrate treatment in rats. The reason for the anomalous result in the interferon dose range study 
is not clear.
Despite the conflicting results with respect to hepatomegaly, in each of the two studies 
mentioned above, clofibrate treatment resulted in a significant increase in the specific content of 
cytochrome P450. This is thought to be due to the selective induction of CYP4A1, which constitutes 
approximately 45 % of the total hepatic cytochrome P450 population following treatment of rats with 
peroxisome proliferators (Sharma, 1988c). This evidence and the observed suppression of clofibrate- 
induced cytochrome P450 specific content by poly IC and interferon a. suggest that these compounds 
may selectively inhibit the induction of CYP4A1.
Poly IC treatment alone did not depress the control levels of total cytochrome P450 content 
or more specifically, CYP4A1. Based on these results, it appears that the inhibitory effect elicited 
by poly IC on CYP4A1 is only directed at the isoenzyme in its induced state. This result was 
unexpected since in a similar study, Morgan and Norman demonstrated that the control level of 
cytochrome P450 specific content was significantly suppressed by poly IC in Sprague-Dawley rats 
(1990). However, this evidence does not negate the above proposal, since the response to poly IC 
may be different in different strains of rats.
Human interferon ot also significantly suppressed the clofibrate-induced levels of cytochrome 
P450 specific content (when administered at the higher dose levels of 2.5x10^ lU/kg and 2.5x10®
106
lU/kg) and CYP4A1 apoprotein (at the highest dose level of 2.5x10® lU/kg). While coadministration 
of the lowest dose of interferon a with clofibrate did not elicit this effect, the relative extents of 
inhibition caused by the higher doses of interferon a  did not reveal a dose dependent relationship 
between interferon and its suppressive effect on CYP4A1. However, these results do not preclude 
the possibility of a dose-dependent relationship, and indeed, suggest that one might exist. 
Administration of a higher dose range of interferon a to clofibrate treated rats might clarify this 
question.
In addition to the absence of hepatomegaly following the clofibrate treatment of rats in the 
interferon dose-range study, a second unusual observation was made in this study. Although 
concomitant treatment of clofibrate and interferon a resulted in reduced levels of cytochrome P450 
specific content and CYP4A1 protein relative to those following clofibrate treatment alone, this down- 
regulation was not evident with respect to the lauric acid w-hydroxylase activity of CYP4A1. It can 
be argued that a decrease in the protein level of an enzyme would necessarily result in the attenuation 
of its catalytic activity. For this reason these conflicting results remain inexplicable.
In spite of the anomalies evident in the results of this study, the previously reported 
suppression of rodent cytochrome P450 isoenzymes by human interferon a (Moochhala et al, 1989) 
supports the indication from this study that human interferon a suppresses the induction of CYP4AI 
by clofibrate in rats.
One explanation for the similar effect generated by exogenous human interferon a  and 
endogenous type I interferons (induced by poly IC) in rats is that the interferon ot/p receptors on the 
surface of rat liver cells may have some degree of amino acid sequence homology with the interferon 
cell surface receptors in humans. This explanation is supported by the weak species specificity of 
human interferon a with respect to its ability to induce antiviral activities.
In general, the species specificity of the antiviral activities of interferons depends on the 
phylogenetic relationship between the animal species of cells treated and the species source of the
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interferon (Pfeffer, 1987a). This relationship is thought to arise from the degree of amino acid 
sequence homology between the interferon cell surface receptors of the animal species of the cells 
treated and that of the source of the interferon.
An exception to this rule, human interferon a can elicit an antiviral activity in bovine, 
porcine, feline and rabbit cells as well as in primate cells (Gresser et al, 1974, Paucker et al, 1975, 
Stewart et al, 1975, Jameson et al, 1977, Week et al, 1981). In light of this, and although there is 
no published evidence of antiviral activities induced by human interferon a in rats, it seems likely 
that this cross-species effect might occur.
If the suppressive action of human interferon a on rat CYP4A1 is governed by the same 
criteria as that for its antiviral activity, then the pattern of species specificity of the two properties 
of interferon a would be expected to be similar (Stanley et al, 1991, Moochhala et al, 1989). This 
hypothesis is supported by the studies conducted by Parkinson and coworkers (1982) who showed a 
strong correlation between three human recombinant a-interferons and their ability to suppress 
cytochrome P450 in mouse liver. However, with the use of hybrid human recombinant a-interferons 
in mice, Renton and cowOrkers (1984) later demonstrated that the antiviral and P450 suppressive 
properties are separable, suggesting that the mechanisms of interferon action governing these 
properties might be distinct. Clearly, the species specificity of interferon a  with respect to its 
suppression of cytochrome P450 remains to be clarified.
The results presented thus far strongly suggest that the inhibitory effect of poly IC on the 
clofibrate-induced level of CYP4A1 is due to the action of the endogenous interferons it induces, 
rather than due to an unrelated effect of poly IC. Furthermore, human interferon a  exerts a smaller, 
but significant, suppressive effect on the induced level of rat hepatic CYP4A1, demonstrating that, 
with respect to its effect on drug metabolism, human interferon a  may not be highly species specific.
The induction of CYP2E1 by small organic molecules has been shown to occur through 
stabilization of the protein rather by an increase in transcription of the CYP2E1 gene (Khani et al,
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1987, Song et al, 1989). Therefore, the four-fold induction of CYP2E1 in response to isoniazid 
treatment, in this investigation, may be attributed to the stabilization of the isoenzyme.
While administration of isoniazid to rats did not change the liver/body weight ratio, the 
microsomal cytochrome P450 specific content was significantly decreased to approximately 78% of 
the control level. The probable cause of this suppression is that a significant down-regulation in the 
expression of other cytochrome P450 isoenzymes is associated with the induction of CYP2E1. This 
proposal is supported by the Western blot data (shown in figure 3.17) which shows that the level of 
CYP4A1 is suppressed (relative to control) in isoniazid treated rats. It is interesting to note that the 
level of CYP2E1 is likewise depressed in clofibrate treated rats (figures 3.19 and 3.21). This suggests 
an inter-relationship in the regulation of different cytochrome P450 isoenzymes.
The different effects of poly IC and interferon a  on CYP4A1 and CYP2E1 described above 
appear to strongly suggest that type I interferons differentially down-regulate P450 isoenzymes. 
Moreover, the mechanism(s) governing the interferon-mediated down-regulation may be linked to the 
transcriptional inducibility of the P450 isoenzymes since this is the primary difference between the 
modes of regulation of CYP4A1 and CYP2E1.
Administration of poly IC had no effect on the control level of cytochrome bg or NADPH- 
cytochrome c reductase activity (figures 3.25 and 3.26). In contrast to this observation, Morgan and 
Norman (1990) have shown that the rat hepatic content of these proteins were suppressed 24 hours 
after poly IC administration to Sprague-Dawley rats. However, the effects of poly IC on cytochrome 
bg and NADPH-cytochrome c reductase may differ between this rat strain and the Wistar rats which 
were used in the present investigation.
In summary, the type I interferon-mediated suppression of clofibrate-induced CYP4A1 
strongly suggests that the inhibitory mechanism(s) governing the down-regulation is directed at the 
process of CYP4A1 induction. Since the induction of CYP4A1 by clofibrate occurs by the 
transcriptional activation of the CYP4A1 gene, these results suggest that an interferon-mediated
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mechanism inhibits this process. This is supported by the fact that the constitutive level of CYP4A1 
was not affected by poly IC treatment. The inability of poly IC or interferon a  to suppress CYP2E1, 
which is post-transcriptionally induced, suggests that interferons may specifically inhibit the induction 
of those P450 isoenzymes which are transcriptionally inducible. The implications arising from the 
studies discussed thus far have been further explored by the analysis of mRNA and the transcriptional 
activity of CYP4A1 described in the remainder of this thesis.
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CHAPTER 4
THE EFFECTS OF POLY 10 AND INTERFERON a 
ON THE mRNA LEVELS OF CYP4A1 AND CYP2E1
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4.1 INTRODUCTION
The results presented in the previous chapter demonstrate that poly IC suppressed the 
clofibrate-induced protein content and lauric acid w-hydroxylase activity of CYP4A1 in rat hepatic 
microsomes. In addition, it was shown that interferon a, administered at 2.5 x 10^  lU/kg, suppressed 
the clofibrate-induced level of CYP4A1 protein content. The interferon-mediated inhibitory effects 
responsible for the observed down-regulation might act at any of the stages of gene expression listed 
below (each is explained in more depth in section 1.3.3).
(i) Initiation, elongation or termination of transcription of the CYP4A1 gene.
(ii) Processing of pre-RNA to CYP4A1 mRNA.
(iii) Stability of CYP4A1 mRNA.
(iv) Initiation, elongation or termination of translation of CYP4A1 mRNA.
(v) Formation of the CYP4A1 apoprotein-haem complex.
(vi) Stability of the CYP4A1 apoprotein.
Renton and coworkers had demonstrated that the in vitro translation of clofibrate-induced 
CYP4A1 mRNA was significantly suppressed in the hepatic microsomes of rats cotreated with poly 
IC (Renton et a/, 1987). This result strongly suggested that the latter two stages of gene expression 
(iv and vi in the list above) were not targets for the inhibitory mechanism(s) induced by interferon. 
More recently, it was shown that the clofibrate-induced level of CYP4A1 mRNA was suppressed by 
the coadministration of poly IC (Renton and Knickle, 1990). Therefore, the probable stages of 
CYP4A1 expression which may be down-regulated by an interferon-mediated mechanism(s) can be 
narrowed further to one (or more) of the earlier stages of gene expression (i to iii in the list above). 
It was suggested in the previous chapter that since poly IC suppresses CYP4A1 induction but
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not its constitutive expression, the interferon-mediated inhibitory effect may be directed at the 
mechanism governing that transcriptional induction of the CYP4A1 gene. If this is the case, then the 
possible stages of CYP4A1 gene expression most likely to be down-regulated by interferons could 
be reduced to (i) in the list above. This reasoning is explored in the next chapter. Whichever of the 
pretranslational stages of gene expression is actually down-regulated by interferons, one would expect 
the suppression of CYP4A1 protein and catalytic activity levels to reflect a reduction in the level of 
CYP4A1 mRNA. By the same token, since CYP2E1 induction by isoniazid occurs through protein 
stabilization rather than by regulation at a pretranslational stage of CYP2E1 expression, and 
coadministration with either poly IC or interferon a does not affect the induced level of CYP2E1 
protein, then one would expect to see no difference in the hepatic CYP2E1 mRNA levels in control 
and isoniazid treated rats.
Analysis of the effects of poly IC and interferon a on CYP4A1 and CYP2E1 mRNA was 
achieved by probing hepatic RNA (applied to nylon membranes by Northern-blotting or slot-blotting) 
with ^^-labelled 2.1kb CYP4A1 and l.lkb CYP2E1 cDNA probes. Total RNA was isolated from 
the hepatic tissue which had been retained from the studies described in the previous chapter.
Specific hybridization of the cDNA probe with CYP4A1 mRNA was detected by 
autoradiography which records the reaction of /3-particles emitted from a specifically bound ^^ P- 
labelled probe with silver halide grains in the emulsion layer of X-ray film. This localized reaction 
forms a latent image which is rendered visible by the action of developing agents generating a 
spectrum of intensities ranging from very faint to intense black depending on the level of /3-emission 
and duration of exposure to the X-ray film. Although the (series of concentrations oQ RNA samples 
from different treatment groups of rats in each study were applied to several separate nylon 
membranes, these membranes were subjected to the same hybridisation, washing and autoradiography 
conditions.
To standardize the process, in order to compensate for any errors in the amount of total RNA
113
loaded, the membranes were stripped of previously hybridized probe and reprobed with a ^ ^P-labelled 
2.1kb human actin cDNA. The expression of the actin gene, one of a number of ’housekeeping’ 
genes which are constitutively expressed in all cell types, is routinely used as an RNA ’loading 
control’ since its level is not usually affected by drug treatments (Morgan, 1991, Morgan and 
Norman, 1990).
Until recently this type of control remained a qualitative one whereby the constant level of 
actin mRNA between samples was confirmed by visual inspection of the autoradiograph. Similarly, 
a difference in the level of specific mRNA species in different treatment groups was also determined 
by visual inspection of the relative intensities of the bands on the autoradiograph. The recent 
introduction of densitometric scanning has enabled an accurate measurement of the intensities of the 
bands, providing a means for quantifying the data generated from this type of experiment. This 
method of data analysis has also presented the possibility of determining the statistical significance 
of differences encountered in the data. However, the application of densitometry to the results 
presented in this chapter has highlighted some weaknesses in the experimental techniques which were, 
until now, assumed to produce consistent and reliable results. These will be discussed more fully in 
section 4.3.
4.2 The suppression of clofibrate-induced hepatic CYP4A1 mRNA by poly IC
The level of hepatic CYP4A1 mRNA in clofibrate treated rats was significantly higher 
compared with that in control rats treated with saline (figures 4.1 to 4.4). Although the steady state 
level of CYP4AI mRNA was visually discernible as a faint band on the Northern blot (figure 4.1), 
this level was too low to be quantified by densitometry. Therefore, in this instance it was difficult 
to evaluate the extent of CYP4A1 mRNA induction by clofibrate. However, the basal level of 
CYP4A1 mRNA was clearly detected by slot blot analysis (figure 4.3).
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Figure. 4.1
Northern blot analysis of the effect of poly IC on the clofibrate-induced level of 
CYP4A1 mRNA
Track Treatment
1 Control 0.9% saline X 3 days
2 Clofibrate 250mg/kg X 3 days
3 Clofibrate + poly 1C (as for 2 and 4)
4 Poly IC 10 mg/kg 24 hours before sacrifice
Each band represents a treatment group sample which was prepared 
by pooling the total RNA of intra-group samples on the basis of an 
equivalent RNA concentration. 20pg fü l^A was loaded per well.
The RNA was probed with a 2.1 kb rat CYP4A1 cDNA.
Washing stringency:
5 X SSC -H 0.1% SDS for 30’ at 42°C
1 X SSC + 0.1% SDS for 20’ at 42°C twice
0.5 X SSC + 0.1% SDS for 30’ at 42 T
0.1 X SSC + 0.1% SDS for 20’ at room temperature
5 X SSC for 30’ at room temperature
Exposed to film for 48 hours at -70°C
Figure. 4.2
The effect of poly IC on the clofibrate-induced level of hepatic CYP4A1 mRNA
cc
l i
1201
100
6 0 -
40 -
2 0 -
CLOHBRATE CLOFIBRATE 4- POLY 1C
TREATMENT GROUP
Values, expressed as a percentage of the control level, were obtained 
by densitometric scanning of the Northern blot bands in figure 4.1.
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Figure. 4.3
Slot blot analysis of the effect of poly IC on the clofibrate-induced level of 
CYP4A1 mRNA (see overleaf for legend)
ACTIN CYP4A1
RNA i\ig) 20 20 10 5 2.5 1.25 0.625
RAT
1
2
3
4
5
6
B
7
8
9
10
C
11
12
13
14
D
15
16
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Legend for figure 4.3
Group Rat number Treatment
A 1-4 Control 0.9% saline X 3 days
B 5-8 Poly IC 10 mg/kg 24 hours sacrifice
C 9-12 Clofibrate 250 mg/kg X 3 days
D 13-16 Clofibrate
and poly IC (as for B and C)
! The RNA was probed with a 2.1kb rat CYP4A1 cDNA and a 2.1kb cDNA of the human 
I actin gene. [ ^ :
Washing stringency:
5 X SSC + 0.1% SDS for 30’ at 42°C
1 X SSC + 0.1% SDS for 20’ at 42°C twice
0.5 X SSC + 0.1% SDS for 30’ at 42°C
0.1 X SSC + 0.1% SDS for 20’ at room temperature*
5 X SSC for 30’ at room temperature
Exposed to film for 48 hours at -70°C
(* 0.2 X SSC instead of 0.1 x SSC for the actin probing)
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Figure 4.4
The effect of poly IC on clofibrate-induced hepatic CYP4A1 mRNA
500 n
400-
Iy g 300-  
* 1
il ■
H fe 200 - 
n-3 O
100-
POLYIC CLOFIBRATE CLOFIBRATECONTROL
+ POLY IC
TREATMENT GROUP
* p< 0.01 significant difference from the control group
The intensities of the bands in figure 4.3, which represent the levels of actin and 
CYP4A1 mRNA, were measured by densitometric scanning. The levels of CYP4A1 
mRNA were normalised by dividing the intensities of the ‘CYP4A1 bands’ (in the 
20pg RNA column) by those of the corresponding ‘actin bands’. The histogram 
bars represent the mean of each treatment group ± the standard deviation where n = 4 
(except for clofibrate and poly IC treated group where n = 3), expressed as a percentage 
of the control (saline treated) group.
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This analysis showed that the clofibrate-induced level of CYP4A1 mRNA was approximately 3 times 
greater than the steady state level in saline treated rats (figure 4.4).
The Northern blot shows that the clofibrate-induced level of CYP4A1 mRNA was markedly 
suppressed by poly IC to approximately 40% of the induced level (figure 4.1). However, slot blot 
analysis did not show a statistically significant suppression although the mean level of CYP4A1 
mRNA in the group cotreated with clofibrate and poly IC was approximately 40% lower than that 
in the clofibrate treated group (figure 4.4).
In the clofibrate and poly IC treated group, the data representing the level of hepatic CYP4A1 
mRNA in rat 16 (figure 4.3) was omitted from the calculations since this was clearly an anomalous 
result possibly arising from the non-responsiveness of the rat to poly IC treatment or due to an error 
in poly IC dosing. Although there is a considerable variation in the band intensities in the clofibrate 
treated group (samples 9 to 12), none of the samples in this group stands out as distinctly anomalous. 
The variations within the treatment groups were not due to an inaccuracy in RNA loading since the 
level of actin mRNA detected in each of the samples appeared to be constant (figure 4.3). The RNA 
sample from rat 16 was also excluded from the clofibrate and poly IC ’group’ RNA sample analyzed 
by Northern blotting.
The discrepancy between the results produced by Northern blot and slot blot analysis of the 
same samples was probably due to the problems encountered with the quantitation and statistical 
analysis of slot blot results. These are discussed below and in section 4.7. Since the suppression of 
clofibrate-induced CYP4A1 mRNA by poly IC has been demonstrated by another group (Renton and 
Knickle 1990), the suppression seen in the Northern blot experiment in this study was considered to 
be a valid result.
While the clofibrate-induced level of CYP4A1 mRNA was suppressed by poly IC, the 
untreated level of CYP4A1 mRNA refiecting the constitutive expression of CYP4A1 was not affected 
by poly IC treatment (figures 4.3 and 4.4).
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4.3 The limitations of slot blotting for the quantitative analysis of mRNA
Until the introduction of densitometric scanning, several assumptions had been made about 
the results generated by the slot blotting procedure. It had been assumed that with a decrease in the 
concentration of total RNA (which had been serially diluted and applied to a nylon membrane), the 
hybridisation of a cDNA probe with specific mRNA species (following highly stringent washing) 
decreases in a linear manner. Accordingly, a direct relationship should exist between the 
concentration of total RNA loaded and the intensity of the corresponding bands on the 
autoradiograph. Visual inspection of slot blot autoradiographs appeared to support this assumption 
since the bands did become less intense with a decrease in the amount of total RNA probed (see 
figure 4.3 for example). However, quantitation of the band intensities by densitometry revealed that 
the actual relationship does not concur with the assumed relationship.
The non-linearity is demonstrated in figure 4.5 which shows the correlation between the 
concentration of total RNA probed and the corresponding band intensities representing CYP4A1 
mRNA in samples 1,5,9 and 13 on the autoradiograph shown in figure 4.3. The graph in figure 4.5 
shows that at the lowest concentration of total RNA (1.25/ig) at which a signal could be accurately 
detected by densitometric scanning, there appears to be little difference in the level of CYP4A1 
mRNA between the different samples. With an increase in the concentration of total RNA, the 
difference in band intensity between the samples also increases and is greatest at 20^g total RNA. 
However, the correlation between the amount of total RNA probed and the band intensity was not 
linear for any of the samples.
Clearly, in light of the technology now available to quantitate autoradiographic results, the 
currently used slot blotting procedure needs to be re-examined so that its effectiveness as a tool for 
the analysis of mRNA levels can be improved.
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Figure 4.5
Hybridisation of the CYP4A1 cDNA probe with serially diluted rat liver RNA
Control
PolylC
*I
<Î
fe 40000- o
g
Clofibrate
60000- Clofibrate 
+ Poly IC
I 20000-
0 5 10 15 20 25
TOTAL RNA LOADED (ug)
The plot presents a correlation between the intensities of the ‘CYP4A1 mRNA bands’ 
for samples 1 , 5 , 9  and 13 in Figure 4.3 and the concentrations of total RNA 
loaded.Each sample is a representative of the treatment group from which they have 
been selected.
*The units are arbitrary and represent the areas under the peaks from a graphical 
representation of the band intensities detected at 550nm on a scanning densitometer.
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The ’CYP4A1 mRNA band’ intensities were divided by those produced by probing the same 
RNA with the actin cDNA probe to generate normalised data. If the relationship between the 
CYP4A1 mRNA and actin mRNA band intensities and the amount of total RNA being probed was 
linear, irrespective of the concentration of total RNA, the CYP4A1: actin mRNA band intensity ratios 
would be constant for each sample. In effect, the normalised data (expressed as CYP4A1: actin 
mRNA band intensity ratios) for the six RNA concentrations within each sample should act as 
replicates. However, when the data which is presented graphically in figure 4.5 was manipulated 
in this way, the CYP4A1:actin mRNA band intensity ratios varied considerably (figure 4.6). This 
departure from the expected behaviour of the data supports the earlier conclusion that a revaluation 
of the slot blotting method is needed.
4.4. Alternative approaches to the statistical analysis of slot blot results
Since the quantitation of slot blot results has become a relatively recent possibility, such 
results have not previously been statistically analyzed. Therefore, a published model on which to base 
the statistical analysis of the results presented in this chapter does not exist. Several approaches were 
considered for the analysis of the data.
In the first approach, each of the CYP4A1:actin mRNA band intensity ratios within a 
treatment group were treated as replicates. That is, the ratios for each of the four samples (within 
a treatment group) at the six RNA concentrations acted as replicates. Therefore, unless some bands 
were too faint to detect, each group had 24 ratios (replicates). The normal distribution of the the data 
within each group was confirmed by using the Komolgorov-Smimov goodness of fit test (Ott, 1988). 
However, there was considerable variation of data in each treatment group. The statistical 
significance of differences in the data between different treatment groups was then assessed by using 
a one way analysis of variance and Duncan’s multiple range test (Ott, 1988, see section 2.6).
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Figure 4.6
Variations in the normalised levels of CYP4A1 mRNA detected in a series of 
concentrations of total hepatic RNA
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TOTAL RNA LOADED (ug)
The intensities of the ‘CYP4A1 mRNA bands’ for samples 1, 5, 9 and 13 in figure 
4.3 at a series of total RNA concentrations were normalised by expressing them as a 
ratio of the corresponding intensities of the ‘actin mRNA bands’. Each sample is a 
representative of the treatment group from which they have been selected.
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In view of the non-linearity of the results of slot blotting (outlined in section 4.3), it cannot 
be assumed that the six ratios (derived from the CYP4A1 and actin mRNA band intensities at the six 
concentrations of RNA probed) within each sample can be treated as replicates. Therefore, this 
method of statistical analysis was deemed inappropriate.
An alternative, more simple approach was adopted to analyze the results. For each sample 
only one ratio, which was derived from the CYP4A1 and actin mRNA band intensities at 20;ig total 
RNA, was used. The differences between the levels of CYP4A1 mRNA in the different treatment 
groups appear to be greatest for the 20^g total RNA samples (figure 4.5). Each treatment group, 
therefore, contained four ratios representing the normalised level of hepatic CYP4A1 mRNA in the 
individual rats. The normally distributed data (determined using the Komolgorov-Smimov goodness 
of fit test) was then analyzed using a one way analysis of variance and Duncan’s multiple range test. 
This procedure was subsequently used to analyze the results from each study irrespective of which 
cDNA probe had been used. In several of the studies, where the group data was heteroscedastic 
(having unequal variances), homoscedasity was obtained by logarithmic transformation (see section 
2 .6).
Ideally, this method of analysis also requires a linear relationship between the slot blot band 
intensities and the amounts of total RNA probed. However, the use of band intensities at just one 
RNA concentration reduces the degree to which this source of error (non-linearity) will affect the 
analysis. If the slot blot procedure can be improved such that linear results are obtained, either of 
the approaches outlined above would be appropriate.
4.5 The effects of interferon a on the clofibrate-induced level of hepatic CYPP4A1 mRNA
Following the analysis of the effect of poly IC on the clofibrate-induced level of rat hepatic 
CYP4A1 mRNA by Northern blotting, further Northern blotting was hampered by technical problems
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encountered with this technique. These will be detailed in section 4.7. As a result, subsequent 
analysis of mRNA by Northern blotting was not possible in the time available and was therefore 
carried out exclusively by slot blotting.
The induction of CYP4A1 mRNA by clofibrate (figures 4.7 and 4.8) appears to be greater 
in this study compared with that in the previous study (figure 4.3). However, the difference in 
clofibrate-induction of CYP4A1 mRNA between the two studies was not statistically significant. In 
contrast to the suppression of clofibrate-induced CYP4AI mRNA by poly IC, cotreatment with 
interferon a did not appear to have an effect on the induction of CYP4A1 mRNA by clofibrate.
4.6 Effects of isoniazid alone and in combination with poly IC or interferon a  on the level
of hepatic CYP2E1 mRNA
The steady state level of CYP2E1 mRNA, representing the constitutive expression of the 
CYP2E1 gene, was not modified by isoniazid treatment (figures 4.9 and 4.10). This is in contrast to 
the significant induction of CYP2E1 protein content and catalytic activity by isoniazid treatment 
(figures 3.17 and 3.23 respectively) demonstrated in the previous chapter. These observations agree 
with the evidence that the induction of CYP2E1 protein content and catalytic activity by isoniazid 
occurs through protein stabilisation rather than by an elevation of CYP2E1 mRNA expression (Song 
et al y 1986).
The steady state level of CYP2E1 mRNA was not significantly affected by treatment with 
either poly IC or interferon a. However, poly IC treatment appeared to cause a slight, but not 
statistically significant, decrease in the steady state levels of CYP2E1 mRNA (figure 4.10), protein 
content (figure 3.17) and activity (figure 3.23). While this effect appears to be consistent at the 
various stages of CYP2E1 expression, the lack of statistical significance for the suppression makes 
the interpretation of this observation difficult. A possible explanation is suggested in section 4.7).
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Figure. 4.7
The effect of interferon a on the clofibrate-induced level of CYP4A1 mRNA
CONTROL CLOFIBRATE CLOFIBRATE CLOFIBRATE CLOFIBRATE
+ IFN (1) +IFN  (2) +IFN (3)
CYP4A1
mRNA
ACTIN
mRNA
The 4 bands in each group represent hepatic mRNA from 4 individual rats within each 
treatment group. The RNA, at a total concentration of lOpg, was probed with a 2,lkb rat CYP4A1 
cDNA and a 2.1kb cDNA of the human actin gene.
Treatments:
Control 
Clofibrate 
IFN (1)
IFN (2)
IFN (3)
0.9% saline 
250 mg/kg
2.5 X 104 lU/kg
2.5 X 105 lU/kg
2.5 X 106 lU/kg
Washing stringency:
5 X SSC + 0.1% SDS for 30’ at 42°C 
1 X SSC + 0.1% SDS for 20’ at 42^C twice 
0.5 X SSC + 0.1% SDS for 30’ at 42°C 
0.1 X SSC + 0.1% SDS for 20’ at room temp*
5 X SSC for 30’ at room temperature
Exposed to film for 48 hours at -70°C
(* 0.2 X SSC instead of 0.1 x SSC and exposure for 72
hours for the actin probing)
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Figure 4.8
The effect of interferon a on clofibrate-induced rat hepatic CYP4A1 mRNA
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CONTROL CLOFIB CLOFIB CLOFIB CLOFIB
+ IFN(1) +IFN (2) +IFN(3)
TREATMENT GROUP
* p< 0.01 significant difference from the control group
The intensities of the bands in figure 4.7, which represent the levels of actin and CYP4A1 
mRNA, were measured by densitometric scanning. The levels of CYP4A1 mRNA were 
normalised by dividing the intensities of the ‘CYP4A1 bands’ by those of thecorresponding ‘actin 
bands’. The histogram bars represent the mean of each treatment group i  standard deviation 
where n =4, expressed as a percentage of the control (saline treated) group.
Treatment
Control 
Clofibrate 
IFN (1) 
IFN (2) 
IFN (3)
0.9% saline 
250 mg/kg
2.5 X 104 lU/kg
2.5 X 105 lU/kg
2.5 X 106 lU/kg
X 3 days 
X 3 days
24 hours before sacrifice 
24 hours before sacrifice 
24 hours before sacrifice
N.B. Analysis of the raw data revealed that it was markedly heteroscidastic. Logarithmic 
transformation of the data produced homoscidasity and enabled statistical analysis of the data as 
described in section 2.6. The histogram depicts the arithmetic mean and SD values although the 
(transformed) geometric mean and SD values were used for statistical analysis of the data.
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Figure. 4.9
Slot blot analysis of tbe effects of isoniazid, poly IC and interferon a on tbe level of
hepatic CYP2EI mRNA
CONTROL POLY IC IFN INK INK 
+ POLY IC
INK 
+ IFN
a
(a) CYP2E1 mRNA
(b) ACTIN mRNA
The 4 bands in each group represent hepatic mRNA from 4 individual rats within each treatment group. 
The RNA, at a total concentration of 20pg, was probed with a l.lkb rat CYP2E1 cDNA and a 2.1kb 
cDNA of the human actin gene.
Treatment
Control
Isoniazid (INH) 
Poly IC 
IFN
0.9% saline 
100 mg/kg 
10 mg/kg 
2.5 X 106 lU/kg
Washing stringency
5 X SSC + 0.1% SDS for 30’ at 55°C
1 X SSC + 0.1% SDS for 20’ at 4 2 T  twice
0.1 X SSC + 0.1% SDS for 30’ at room temperature*
5 X SSC for 30’ at room temperature 
Exposed to film for 72 hours at -70°C 
(* 0.2 X SSC instead of 0.1 x SSC for the actin probing)
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Figure 4.10
The effects of isoniazid, poly IC and interferon a on hepatic CYP2E1 mRNA
200 n
150-
100 -
5 0 -
CONTROL POLY IC IFN INH INK INK
+ POLY IC + IFN
TREATMENT GROUP
* p< 0.05 significant difference from the control and isoniazid groups
The intensities of the bands in figure 4.9, which represent the levels of actin and 
CYP2E1 mRNA, were measured by densitometric scanning. The levels of CYP2E1 
mRNA were normalised by dividing the intensities of the CYP2E1 bands’ by Jhose of 
the corresponding ‘actin bands’. The histogram bars represent the mean of each 
treatment group ± standard deviation where n = 4, expressed as a percentage of the 
control (saline treated) group.
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Unexpectedly, the level of hepatic CYP2E1 mRNA was significantly less in rats treated with 
a combination of poly IC and isoniazid compared with that in rats treated with isoniazid alone. This 
difference was not observed for CYP2E1 protein content or catalytic activity.
4.7 Discussion
The suppression of clofibrate-induced CYP4A1 mRNA by concomitant treatment with poly 
IC agrees with the observation of Renton and Knickle (1990) and supports their proposal that the 
interferon-mediated suppression of CYP4A1 induction by clofibrate occurs at a pretranslational level. 
Poly IC appears to have a differential effect on the constitutive and induced expression of CYP4A1 
mRNA. While poly IC suppressed the induction of CYP4A1 mRNA by clofibrate, it did not affect 
the steady state level of CYP4A1 mRNA. These observations are consistent with the effects of poly 
IC on the steady state and clofibrate-induced levels of CYP4A1 protein content and catalytic activity 
demonstrated in the previous chapter.
Collectively, these findings strongly suggest that the interferon-mediated molecular 
mechanism(s) which down-regulate the induction of CYP4A1 by clofibrate act at one or more of the 
pretranslational stages of gene expression. Moreover, since the constitutive expression of CYP4A1 
mRNA was unaffected by poly IC, the interferon-mediated inhibitory mechanism(s) appear to be 
directed at the molecular mechanisms which govern the modulation of CYP4A1 mRNA. CYP4A1 
mRNA induction by clofibrate is known to occur through the transcriptional activation of the CYP4A1 
gene (Hardwick et al y 1987). Therefore, on the strength of the evidence accumulated thus far in this 
thesis, it is proposed here that the interferon-mediated inhibitory activities responsible for suppressing 
the induction of CYP4A1 interfere directly with the molecular processes governing the transcriptional 
induction of the CYP4A1 gene. This hypothesis has been tested by conducting nuclear run-on 
experiments (see chapter 5).
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Although it was shown in the previous chapter that the clofibrate-induced level of CYP4A1 
apoprotein was suppressed by the highest dose level (2.5 x 10^  lU/kg body weight) of human 
interferon a  (figures 3.8, 3.9 and 3.16), interferon a  appeared to have no statistically significant 
effect on the induction of CYP4A1 mRNA by clofibrate. One interpretation of this result might be 
that the suppression of rat hepatic CYP4A1 by human interferon a  was due to an inhibitory effect 
directed at the translational or post-translational levels. In other words, that poly IC-induced 
endogenous type I interferons and exogenous human interferon a  might suppress the induction of 
CYP4A1 by different mechanisms. However, this interpretation is unlikely since the similarity 
between the human and murine type I interferons (see section 1.2.2) suggest that they may recognise 
the same cell surface receptor and may activate common signal transduction mechanisms (Branca 
and Baglioni, 1981). Therefore, one would expect the induction of CYP4A1 to be suppressed by poly 
IC and human interferon a  via the same inhibitory mechanism.
Elucidation of the effect of interferon a  on the induction of CYP4A1 has been complicated 
by the unexpected lack of an effect of human interferon a  (at any of the dose levels) on the 
clofibrate-induced lauric acid co-hydroxylase activity of CYP4A1 (figure 3.16). In light of these 
results and the lack of an effect of interferon of on the induction of CYP4A1 mRNA by clofibrate, 
it is not clear whether the expression of cytochrome CYP4A1 in the rat can be modulated by human 
interferon a. The causes of the disparate observations reported here are as yet unknown and further 
work with human interferon a  is needed to elucidate any species differences in CYP4A1 modulation.
It is clear that, unlike the effects of poly IC on drug metabolism, analysis of the effects of 
administering exogenous human interferon a is complicated by a variety of factors. Such 
considerations as the species specificity of the effect of human interferon a on drug metabolism, the 
differential effects of human interferon a  on rat hepatic P450 isoenzymes and their implications on the 
interferon-mediated down-regulation of CYP4A1 will be discussed extensively later in chapter 6.
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It was previously shown that, at the levels of protein content and catalytic activity, poly IC 
and interferon a  had no significant effect on the constitutive expression of CYP2E1 or on the 
isoniazid-induced expression of CYP2E1. These observations appeared to reinforce the differential 
effects of poly IC and interferon a on cytochromes CYP4A1 and CYP2E1. However, the results 
presented in this chapter showed a significant suppression of CYP2EI mRNA in rats cotreated with 
isoniazid and poly IC relative to mRNA level in rats treated with isoniazid alone.
This finding is difficult to interpret. A possible explanation could be that the suppression of 
CYP2E1 mRNA by poly IC was compensated by the isoniazid-induced stabilisation of the CYP2E1 
protein. If down-regulation of CYP2E1 occurred at the transcriptional level, the interferon-mediated 
molecular mechanism might affect regulatory elements distinct from those controlling constitutive 
expression of the CYP2E1 gene. This would explain the lack of an effect of poly IC on the steady 
state level of CYP2EI mRNA, protein and catalytic activity in control (saline treated rats) rats. 
However, this explanations is speculative and further work is required to clarify these findings.
It was mentioned earlier that ideally the rat liver RNA from each study would have been 
analyzed by Northern blotting as well as by slot blotting. The main advantage of the latter technique 
is that it allows for the analysis of many samples, while Northern blotting is restricted to the smaller 
number of wells in a gel. However, gel electrophoresis enables the separation of RNA species so 
that, following Northern blotting and hybridisation with a cDNA probe, specific mRNA species can 
be more accurately detected. In contrast, since slot blotting involves the direct application of total 
RNA to nylon membranes, one RNA species may be masked by others.
Although the first Northern blot was successfully probed (figure 4.1), subsequent Northern 
blotting conducted by myself and colleagues in the laboratory was unsuccessful during the period that 
these later investigations were undertaken. The separation of RNA by gel electrophoresis, visualised 
by ethidium bromide staining, appeared to be successful as was the transfer procedure. However, no 
signal was detected following hybridisation and autoradiography. This was due to problems with the
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formaldehyde used in the denaturing agarose gels. The technique requires that the stock solution be 
at pH 7, however, for unknown reasons (possibly changes of supplier or storage) values as low as 
pH 4 were occurring. Once this problem was recognised (after completion of this work), deionisation 
of the stock formaldehyde with resin (obtained from BioRad) prior to use was incorporated into the 
operating procedure.
The introduction of densitometric scanning has proved to be a major innovation enabling the 
analysis of results which, until recently, could only be presented in a qualitative manner. However, 
the quantitation of slot blots in the present investigations has highlighted some problems which need 
to be addressed. One of the primary considerations in improving the slot blotting technique for the 
quantitative analysis of mRNA is to determine the range of linearity of the X-ray film used for 
autoradiography. At low and high levels of j3-emission, the response of the X-ray film is not linear. 
However, a linear response is expected within a range between these levels. Therefore, in order to 
determine the intensities of bands which fall within the linear response of the X-ray film, calibration 
standards (commercially available) should be used.
The non-linearity of the relationship between the slot blot band intensities (representing degree 
of specific hybridisation with the cDNA probe) and the concentration of total RNA loaded observed 
here might be explained by a number of possible flaws in the currently used slot blotting procedure. 
First, since the total RNA is applied directly to the nylon membrane in a concentrated area, some 
of the RNA species may be masked by others which may lead to the prevention of complete 
hybridisation of the cDNA with complementary mRNA species. This problem is circumvented by 
Northern blotting where different RNA species are electrophoretically separated (in an agarose gel) 
on the basis of their molecular size prior to blotting and hybridisation. To resolve this problem, the 
amount of total RNA which can be applied to the membrane before overloading needs to be 
evaluated. Preliminary investigations conducted recently in this laboratory indicate that only up to 
5fig total RNA should be applied (personal communication with Dr. P.S. Goldfarb). Another
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technical disadvantage to the current slot blot method is that due to the suction applied to the slot blot 
apparatus, some of the RNA applied is drawn through the membrane and lost. This was demonstrated 
(unpublished) by another group when two nylon membranes were placed in the slot blot assembly 
(personal communication with Dr. P.S. Goldfarb). After the total RNA was applied in the usual 
manner, both nylon membranes were incubated with a cDNA probe and a signal indicating specific 
hybridisation was detected on both membranes. This problem would explain the apparent lack of 
difference between band intensities at the lower range of total RNA concentration (between 0.625 
and 5fig) shown in figure 4.5. Prior to the development of the slot blotting technique, RNA samples 
were applied to nitrocellulose membranes by ’spotting*. The membranes were then air-dried and 
baked for 2 hours at 80*C to bond the RNA to the nitrocellulose. Although this system of application 
would not produce consistent RNA ’spot’ sizes making the qualitative assessment of the relative 
levels of specific hybridisation difficult, the precise spot intensities (on the corresponding 
autoradiograph) can now be quantified by scanning densitometry. Nylon membranes are preferred 
now as they are more robust (to handling, stripping and reprobing) than nitrocellulose. However, a 
comparison of the suitability of the two types of support for this technique would be worthwhile to 
further improve the slot blotting method for mRNA analysis.
Pre-flashing the X-ray film can be used in future studies to optimize the autoradiographic 
image. A short, uniform, low-level pre-exposure of the X-ray film to high-intensity light before 
exposure to the radioactive signal has been shown to enhance the image such that less exposure to 
the signal is required (Laskey and Mills, 1975). That is, the same intensity of image can be obtained 
with a lower level of radioactivity or a shorter exposure time as that without pre-flashing. In addition, 
pre-flashing makes the responsiveness of the film more linear.
The use of actin mRNA as an RNA ’loading control’ was questioned in a recent report 
(Morgan, 1991). In his study, using 5’-^^P-labelled oligo-d(T)i6 as the control probe to measure the 
amount of poly (A)"*" RNA in the hepatic tissue of female Sprague-Dawley rats, Morgan found that
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the suppression of CYP2C12 mRNA by poly IC was accompanied by an elevation in the level of 
actin mRNA. Male Wistar rats were used in the present investigations, and the same effect was not 
apparent. However, since a radiolabelled oligo-d(T) probe was not used in the present investigations, 
the effects of poly IC or human interferon a  on actin mRNA could not be conclusively determined. 
Clearly, the result of Morgan’s study indicates that a reassessment of the nature and validity of RNA 
’loading controls’ is needed in future studies.
A problem encountered with using radiolabelled oligo-dT as an RNA loading control is that 
it is very difficult to strip off the membrane for reprobing (personal communication with K.W. 
Renton). To circumvent this, two identical slot blot membranes can be produced with RNA loaded 
from the same preparation. One membrane can be hybridized with the radiolabelled cDNA probe of 
interest and the other membrane probed with radiolabelled oligo-dT. Alternatively, the oligo-dT can 
be used after the RNA has been probed with all cDNA probes of interest.
The level of albumin mRNA was considered as an alternative RNA loading control since 
albumin is the major secretory protein of mammalian liver, comprising about 10% of the proteins 
synthesized. Indeed, a mouse serum albumin cDNA was available for probing Northern and slot 
blots. However, the use of such a probe in the present investigations is inappropriate since serum 
albumin levels are known to decrease after rats are treated with interferon-inducing agents (Renton 
and Mannering, 1976).
In addition to the above considerations, the effects of poly IC on other hepatic RNA species 
may need to be taken into account. In their studies on the effects of poly IC on drug metabolism in 
mice, Gooderham and Mannering found that the level of total hepatic RNA was considerably elevated 
(by approximately 20%) by poly IC treatment (Gooderham and Mannering, 1986). It was postulated 
that the induction of RNA was due to the establishment of an antiviral state within the hepatocytes. 
In view of this, it would be worthwhile to determine whether this effect is mirrored in poly IC treated 
rats.
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CHAPTER 5
DOWN-REGÜLATION OF CYP4A1 TRANSCRIPTION BY 
POLY IC AND INTERFERON a IN RAT HEPATIC NUCLEI
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5.1 INTRODUCTION
The investigations described so far have shown the effects of poly IC and interferon a  on rat 
hepatic CYP4A1. It was demonstrated that clofibrate-induced levels of CYP4A1 protein content and 
lauric acid co-hydroxylase activity were suppressed by poly IC treatment. Further experiments 
revealed that this suppression was associated with a decrease in the clofibrate-induced level of 
CYP4A1 mRNA. In addition to these findings it was shown that the uninduced, constitutive levels 
of CYP4A1 protein content, catalytic activity and mRNA were not affected by poly IC treatment.
From these results it was deduced that the observed down-regulation of clofibrate-induced 
CYP4A1 was due to an interferon-mediated inhibitory mechanism(s) directed at a pretranslational 
stage of CYP4A1 expression. More specifically, the lack of an effect of poly IC on the constitutive 
expression of CYP4A1 strongly suggests that the mechanism(s) which causes the down-regulation 
of clofibrate-induced CYP4A1 does so by interfering with the process of CYP4A1 induction. It is 
known that the induction of CYP4A1 by clofibrate is due to the transcriptional activation of the 
CYP4A1 gene (Hardwick et al y 1987). Therefore, further investigations were carried out to test the 
hypothesis that the transcriptional induction of the CYP4A1 gene is down-regulated by an interferon- 
mediated mechanism. This was achieved by conducting nuclear run-on experiments which involved 
in vitro transcription reactions with rat hepatic nuclei. Essentially, in vitro transcription involves the 
elongation of RNA transcripts which have already been initiated, incorporating the nucleotide 
substrates (radiolabelled UTP plus cold ATP, CTP and GTP) included in the reaction. Following in 
vitro transcription the RNA transcripts are purified and hybridised with cDNA probes immobilised 
on nylon membranes. The specific hybridisation of RNA transcripts with the cDNA probes is 
detected by autoradiography.
It has been shown that the level of hepatic CYP2E1 protein is suppressed in clofibrate treated 
rats (figure 3.19 and 3.20). Similarly, the level of CYP4A1 protein is suppressed by isoniazid
137
treatment (figure 3.13). A l.lkb CYP2E1 cDNA probe was used in a nuclear run-on experiment to 
determine whether the suppression of CYP2E1 in clofibrate treated rats was due to the transcriptional 
down-regulation of the CYP2E1 gene.
In 1990, Issemann and Green identified the peroxisome proliferator activated receptor (PPAR) 
which has been implicated in the induction of peroxisome proliferator responsive genes (see section 
1.1.5). Since that breakthrough, the accelerated progress in this area of research has generated some 
significant discoveries. PPAR has been shown to bind to a peroxisome proliferator regulatory element 
(PPRE) located in the 5’ flanking region of the acyl CoA oxidase gene. Binding of the PPAR to the 
PPRE is necessary for its transcriptional activation in response to the peroxisome proliferator Wy- 
14,643 (Tugwood et al, 1992).
A PPRE related to that associated with the promoter of the acyl CoA oxidase gene has been 
identified in the 5’ flanking region of the clofibrate-inducible rabbit CYP4A6 gene (Osumi et a l  y 
1991, Muerhoff et a l  y 1992a, Muerhoff et a l  y 1992b). Although a consensus PPRE has not yet been 
identified in the 5’ flanking regions of the rat CYP4A1 gene, the discovery of such a consensus 
regulatory element is anticipated. It was recently reported that the PPAR mRNA is induced in rats 
treated with fenofibrate, a potent peroxisome proliferator and a structural analogue of clofibrate 
(Gebel et a l y  1992).
On the basis of this finding (discussed more fully in section 6.4), one might expect a similar 
induction of PPAR mRNA in rats treated with clofibrate. To investigate this possibility, a 1.8kb 
mouse PPAR cDNA was used to probe the hepatic RNA isolated in this study. In addition, the effects 
of poly IC and interferon a  on the level of PPAR mRNA in clofibrate treated rats was analyzed to 
determine whether the interferon-mediated suppression of clofibrate-induced CYP4A1 is related to 
a suppression of the PPAR.
It has been shown that there is 97% similarity between the mouse and rat PPAR genes 
(Gottlicher et aly 1992). Therefore, it was assumed in these analyses that the mouse PPAR cDNA
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hybridised with rat PPAR mRNA transcripts.
5.2 Studies to confirm the viability of isolated rat liver nuclei and to determine the duration
of a linear rate of in vitro transcription
Prior to conducting nuclear run-on experiments to determine the transcriptional rates of 
specific genes, preliminary in vitro transcription experiments were conducted to confirm the viability 
of the rat hepatic nuclei and also to determine the duration of a linear rate of transcription in each 
sample of nuclei being used. This was necessary to ascertain the optimum period of incubation for 
the in vitro transcription reactions in order to validate the comparison of the results of subsequent 
nuclear run-on experiments.
5.2.1 Accuracy of ^H-labelled UTP measurement for the use in transcriptional analysis
Since the correct measurement of ^H-labelled UTP incorporation into RNA transcripts was 
fundamental in determining the duration of a linear rate of transcription in the preliminary studies, 
it was first necessary to verify the suitability of the scintillant and scintillation counting program for 
this purpose. This was achieved by spotting 5 ^1 of serially diluted ^H-labelled UTP, in duplicate, 
on to glass fibre filters and counting in a LKB Wallace 1217 liquid scintillation counter using 
Optiphase scintillant and an appropriate counting program.
A very strong correlation between the level of radioactivity detected and the amount of ^ H- 
labelled UTP spotted confirmed that the scintillation counting method adopted was suitable (figure 
5.1). In addition, the agreement between the duplicates (represented by the narrow error bars in 
figure 5.1) at each concentration of ^ H-labelled UTP verified the accuracy of pipetting very small 
volumes which was essential for many stages in the in vitro transcription experiments.
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Figure. 5.1
Measurement of 3H-labelled UTP by scintillation counting
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y = 0.26200 + 9.4176x = 0.999
20 1 3
3H-LABELLED UTP (pCi)
3H-labelled UTP was serially diluted and 5pl of each concentration was 
spotted onto duplicate glass fibre filters. The level of 3H was measured by 
scintillation counting as described in Materials and Methods.
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5.2.2 Viability of the nuclei and duration of in vitro transcription
As mentioned earlier, prior to conducting nuclear run-on experiments it was important to 
determine the duration of a linear rate of transcription in each sample of nuclei to establish the 
optimum period of incubation for the in vitro transcription reactions. Since the hepatic nuclei from 
four rats in each treatment group had been pooled (and aliquoted before storage in liquid nitrogen), 
each in vitro transcription reaction contained nuclei representing a treatment group. A detailed 
description of the procedure used is given in section 2.5.5 (Materials and Methods).
The rates of ^H-labelled UTP incorporation into RNA transcripts following in vitro 
transcription in hepatic nuclei from saline treated rats, clofibrate treated rats, rats treated with 
clofibrate and poly IC and rats treated with clofibrate and interferon a. are shown in figures 5.2, 5.3,
5.4, 5.5 respectively. Although there is a certain amount of disagreement (depicted by large range 
bars) between the amount of ^H-labelled UTP incorporated in duplicate transcription reactions at 
some time points, it is evident that, for each treatment group, there is a linear rate of ^ H-labelled 
UTP incorporation up to 20 minutes of incubation.
The significance of this result is two fold. Firstly, the incorporation of ^ H-labelled UTP into 
RNA transcripts isolated from each sample of nuclei confirms that the nuclei were transcriptionally 
viable. Secondly, since each group of nuclei undergoes a linear rate of transcription up to 20 minutes, 
this was used as a fixed incubation time for subsequent in vitro transcription reactions to measure 
transcription rates for specific mRNAs.
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Figure. 5.2
In vitro transcription in hepatic nuclei isolated from rats treated with saline
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Duplicate in vitro transcription reactions containing 5x106 nuclei and 10 pCi 
3H-labelled UTP were incubated at 30°C as described in chapter 2.
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Figure. 5.3
la  vitro transcription in hepatic nuclei isolated from rats treated with clofibrate
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Duplicate m vitro transcription reactions containing 5x106 nuclei and 10 pCi 
3H-labelled UTP were incubated at 30°C as described in chapter 2.
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Figure. 5.4
lû  vitro transcription in hepatic nuclei isolated from rats treated with clofibrate 
and poly IC
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Duplicate m vitro transcription reactions containing 5 x 106 nuclei and 10 pCi 
3H-labelled UTP were incubated at 30°C as described in chapter 2 .
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Figure. 5S
In vitro transcription in hepatic nuclei isolated from rats treated with clofîbrate
and interferon a
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Duplicate in vitro transcription reactions containing 5x106 nuclei and lOpCi 
3H-labelIed UTP were incubated at 30°C as described in chapter 2.
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5.3 Effects of poly IC and interferon a on the clofibrate-induced in vitro transcriptional rate
of the CYP4A1 gene
Total RNA was isolated from a small amount of hepatic tissue retained from each rat in this 
study for slot blot analysis to determine the level of hepatic CYP4A1 mRNA and to confirm the 
previous results (as described in the previous chapter). The results of this procedure, which were 
statistically analyzed in the same way as previous slot blot results (see section 4.4), are shown in 
figures 5.6 and 5.7.
Treatment with clofibrate increased the level of hepatic CYP4A1 mRNA relative to the 
control (saline treated) group, and the mean values for the relative levels of CYP4A1 mRNA 
appeared to confirm the expected interferon-mediated suppression of the clofibrate-induced level of 
CYP4A1 mRNA. However, the large standard deviations in the group data resulted in a lack of 
statistical significance in the differences between the level of clofibrate-induced CYP4A1 mRNA and 
the levels in rats cotreated with poly IC or interferon a.
The outcome of this analysis mirrors that of a previous study where slot blot analysis 
indicated that there was apparently no statistically significant difference between the clofibrate- 
induced level of CYP4A1 mRNA and the level in rats cotreated with poly IC (figure 4.4) even 
though the mean values for the relative levels of CYP4A1 mRNA indicated that suppression of 
clofibrate-induced CYP4A1 mRNA by poly IC was occurring. In each of these studies, the large 
standard deviations of the intra-group data resulting from problems associated with the analysis of 
quantitative slot blots (discussed in section 4.7) may have caused the problem.
The transcriptional rate of the hepatic CYP4A1 gene in rats treated with clofibrate alone and 
in combination with poly IC or interferon cl was examined by nuclear run-on analysis. In rats treated 
with clofibrate, the transcriptional rate of the CYP4A1 gene was markedly elevated relative to the 
control group (figures 5.8 and 5.9).
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Figure. 5.6
The effect of poly IC and interferon a on the clofibrate-induced level
of CYP4AI mRNA
TREATMENT GROUP
CONTROL CLOFIBRATE CLOFIBRATE 
+ POLY IC
CLOFIBRATE 
+ IFN
CYP4AI
mRNA
ACTIN
mRNA
The 4 bands in each group represent hepatic mRNA from the 4 individual rats within each 
treatment group. The RNA, at a total concentration of 20ji.g was probed with a 2.1 kb rat CYP4A1 
cDNA and a 2.1 kb cDNA of the human actin gene.
Treatment
Control 
Clofibrate 
Poly IC 
IFN
0.9% saline 
250 mg/kg 
10 mg/kg 
2.5 X 106 lU/kg
Washing stringency
5 X SSC + 0.1% SDS for 30’ at 42®C
1 X SSC + 0.1% SDS for 20’ at 42°C twice
0.25 X SSC + 0.1% SDS for 20’ at 42°C twice
0.1 X SSC + 0.1% SDS for 20’ at room temperature*
5 X SSC for 30’ at room temperature
Exposed to film for 48 hours at -70°C
(* 0.2 X SSC instead of 0.1 x SSC and exposure for
72 hours for the actin probing)
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Figure 5.7
The effect of poly IC and interferon a on the clofibrate-induced level of rat
hepatic CYP4AI mRNA
800 n
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CONTROL CLOFIBRATE CLOFIBRATE CLOFIBRATE
+ POLY IC + IFN
TREATMENT GROUP
* significant difference from the control group p< 0.05
The intensities of the bands in figure 5.6, which represent the levels of actin and CYP4A1 
mRNA, were measured by densitometric scanning. The levels of CYP4A1 mRNA were 
normalised by dividing the intensities of the ‘CYP4A1 bands’ by those of the corresponding 
‘actin bands’. The histogram bars represent the mean of each treatment group ± standard 
deviation (SD), where n = 4, expressed as a percentage of the control (saline treated) group. 
Treatment
Control 0.9% saline
Clofibrate 250 mg/kg
Poly IC 10 mg/kg
IFN 2.5xl06RJ/kg
N.B. Analysis of the raw data revealed that it was markedly heteroscidastic. Logarithmic 
transformation of the data produced homoscidasity and enabled statistical analysis of the data as 
described in section 2.6. The histogram depicts the arithmetic mean and SD values although the 
(transformed) geometric mean and SD values were used for statistical analysis of the data.
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Figure 5.8
Nuclear run-on analysis of the effects of poly IC and interferon a  on the clofibrate-
induced transcription rate of the rat hepatic CYP4A1 gene
linearized 
cDNA probe
CONTROL
TREATMENT GROUP
CLOFIB CLOFIB 
+ POLY IC
CLOHB 
+ IFN
(a)
CYP4A1 
in pUC19
actin
in pUC19 
pUC19
(b)
CYP4A1 
in PÜC19
actin
in PÜC19 
PÜC19
Nuclei were isolated from the pooled liver of 4 rats in each treatment group. For each group of nuclei, an 
in vitro transcription reaction was set up in duplicate containing 5 x 10^  nuclei and 150 pCi 32p_iabelled 
UTP as described in chapter 2 (Materials and Methods). Following in vitro transcription at 30°C for 20’, 
the nuclear RNA was isolated and purified. The amount of radiolabelled RNA in each reaction mixture
was standardised by scintillation counting a small aliquot. The RNA was then incubated for hybridisation
with cDNA probes immobilised on nylon membranes. The bands in the autoradiograph shown above 
represent the levels of specific 32p-iabelled RNA transcripts.
(a) 1.5 X 10^  pCi cpm/ml hybridisation mixture 
^) 2.5 X 106 pCi cpm/ml hybridisation mixture 
Treatment:
Control 0.9% saline 3 days
Clofibrate 250 mg/kg 3 days
Poly IC 10 mg/kg 24 hours before sacrifice
IFN 2.5 X 106 lU/kg 24 hours before sacrifice
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Figure 5.9
The effect of poly IC and interferon a on the clofibrate-induced
transcription rate of the CYP4A1 gene in rat hepatic nuclei
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The intensities of the bands in figure 5.8 were measured by densitometric scanning. 
The levels of CYP4A1 RNA transcripts were normalised by dividing the intensities of 
the ‘CYP4A1 bands’ by those of the corresponding ‘actin bands’.
The histogram bars represent the mean of the data from the duplicate nuclear run-on 
reactions ((a) and (b)) corrected for the amount 32p_iabelled RNA used for 
hybridisation, expressed as a percentage of the control (saline) group.
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Furthermore, cotreatment with either poly IC or interferon a suppressed the clofibrate-induced 
transcriptional rate of CYP4A1. The suppression elicited by interferon a appears to be greater than 
that caused by poly IC (figure 5.9). Since the data for each treatment group represents duplicate 
reactions, statistical analysis of these results was not possible. This result strongly suggests that the 
interferon-mediated inhibitory mechanism(s) which causes the down-regulation of clofibrate-induced 
CYP4A1 interferes with the transcriptional activation of the CYP4A1 gene.
5.4 Effect of poly IC and interferon a on PPAR mRNA and on the in vitro transcriptional 
rate of the PPAR gene
The effect of clofibrate on the level of rat hepatic PPAR mRNA was examined by using a 
1.8kb mouse PPAR cDNA probe. The outcome of the slot blot analysis is shown in figure 5.10. 
Although the faint bands on the autoradiograph are difficult to distinguish by visual inspection of the 
photograph, they were discernible by densitometric scanning. This showed that although the mean 
level of PPAR mRNA in the control group appeared to be elevated by clofibrate treatment (figure 
5.11), the result was not statistically significant. Similarly, the PPAR mRNA levels in the groups 
which were treated with a combination of clofibrate and either poly IC or interferon a  were not 
significantly different from those in the control (saline treated) or clofibrate treated groups although 
the mean levels appeared to be reduced.
A second nuclear run-on experiment including the PPAR cDNA probe was carried out to 
determine the effects of clofibrate, poly IC and interferon a on the transcriptional rate of CYP4A1. 
In addition to the PPAR cDNA insert in pBluescript and pBluescript alone (as a negative control), 
all the other available cDNA probes (CYP4A1, CYP2E1 and actin cDNA inserts in pUC19 and 
pUC19 alone) were used in this nuclear run-on to confirm and extend the previous findings (outlined 
above in section 5.3). In addition, two extra samples of nuclei were used to extend the investigations.
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Figure. 5.10
Analysis of the effects of clofibrate, poly IC and interferon a on the level of rat
hepatic PPAR mRNA
TREATMENT GROUP
CONTROL CLOFIBRATE CLOFIBRATE CLOFIBRATE
+ POLY IC + IFN
The 4 bands in each group represent hepatic mRNA from the 4 individual rats within each 
treatment group. The RNA, at a total concentration of 20|ig was probed with a 1.8kb PPAR cDNA 
probe.
Treatment
Control 
Clofibrate 
Poly IC 
IFN
0.9% saline 
250 mg/kg 
10 mg/kg 
2.5 X 106 lU/kg
Washing stringency
5 X SSC + 0.1% SDS for 30’ at 42°C 
1 X SSC + 0.1% SDS for 20’ at 4 2 T  twice 
0.25 X SSC + 0.1% SDS for 20’ at 42°C twice 
0.1 X SSC + 0.1% SDS for 20’ at room 
temperature*
5 X SSC for 30’ at room temperature 
Exposed to film for 48 hours at -70°C
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Figure 5.11
The effects of clofibrate, poly IC and interferon a on the level of rat hepatic
PPAR mRNA
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TREATMENT GROUP
No two pairs of groups are significantly different
The intensities of the bands in figure 5.10, which represent the levels of actin and 
PPAR mRNA, were measured by densitometric scanning. The levels of PPAR 
mRNA were normalised by dividing the intensities of the ‘PPAR bands’ by those of 
the corresponding ‘actin bands’ in figure 5.6. The histogram bars represent the mean 
of each treatment group ± standard deviation (SD), where n = 4, expressed as a 
percentage of the control (saline treated) group.
Treatments
Control
Clofibrate
PolylC
IFN
0.9% saline 
250 mg/kg 
10 mg/kg
2.5 X 106 lU/kg
3 days 
3 days
24 hours before sacrifice 
24 hours before sacrifice
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One of the new samples of nuclei was isolated from rats treated with poly IC alone and the other 
sample was from rats treated with interferon a alone. Comparison of the transcriptional rate of the 
CYP4A1 gene in these nuclei with that in control nuclei (from saline treated rats) was expected to 
reveal whether the constitutive expression of this gene was affected by interferon. Finally, the 
CYP2E1 cDNA probe was included in order to determine whether the suppression of hepatic 
CYP2E1 protein in clofibrate treated rats (figure 3.21) was due to a transcriptional down-regulation 
of the CYP2E1 gene.
However, the outcome of the nuclear run-on experiment, shown in figure 5.12, was obscured 
by a technical problem. Longer nylon membrane strips were used in order to accommodate all the 
cDNA probes plus the negative controls. However, due their length, parts of membrane strips 
overlapped when they were rolled up to fit into scintillation vials for hybridisation with the 
radiolabelled RNA transcripts. To overcome this problem the membranes were sandwiched in strips 
of nylon mesh (125^m) and then rolled up for insertion into the scintillation vials. Separation of the 
overlapping regions of the membrane by the nylon mesh was expected to allow a uniform flow of 
the hybridisation mixture to all parts of the membranes. This proved to be counterproductive since 
the narrow diameter of the scintillation vials caused the nylon mesh to pucker resulting in the striated 
effect seen on the autoradiograph (figure 5.12). In future nuclear run-on assays, the problem of 
overlapping nylon membrane strips could be avoided by using a vial with a wider diameter to 
accomodate the length of the nylon strip. The only restrictions on the size of the larger vial would 
be the diameter of the Hybaid™ bottle into which the vial is inserted and the very small volume of 
the hybridisation buffer (2ml).
154
Figure 5.12
Nuclear run-on analysis of the effect of clofibrate, poly IC and interferon a on the
transcription rate of the rat PPAR gene
TREATMENT GROUP
CONTROL CLOFIB CLOFIB CLOFIB POLY IC IFN
+ POLY IC + IFN
a
b
c
d
cDNA probes Treatment
(a) CYP4A1 cDNA in pUC19 Control 0.9% saline 3 days
(b) CYP2E1 cDNA in pUC19 Clofibrate 250 mg/kg 3 days
(c) actin cDNA in pUC19 Poly IC 10 mg/kg 24 hours before sacrifice
(d) PÜC19 IFN 2.5xl()6lU/kg 24 hours before sacrifice
(e) PPAR cDNA in pBluescript
(f) pBluescript
Nuclei were isolated from the pooled liver of 4 rats in each treatment group. For each group of nuclei, an 
in vitro transcription reaction was set up in duplicate containing 5 x 10^  nuclei and 150 pCi 32p_iabelled 
UTP as described in chapter 2 (Materials and Methods). Following in vitro transcription at 30°C for 20’, 
the nuclear RNA was isolated, purified. The amount of radiolabelled RNA in each reaction mixture was 
standardised by scintillation counting a small aliquot. The RNA (1 x 10  ^ cpm/ml per hybridisation 
mixture) was then incubated for hybridisation with cDNA probes immobilised on nylon membranes. The 
bands in the autoradiograph shown above represent the levels of specific 32p-iabelled RNA transcripts.
The PPAR cDNA probe used was that for the mouse PPAR gene. It is assumed that the RNA transcripts 
which hybridise with this cDNA probe are expressed by the rat orthologue of the PPAR gene which has 
been shown to be 97% similar to the mouse PPAR gene (Gottlicher et al, 1992).
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Due to the striated appearance of the autoradiographs, it was not possible to accurately 
determine the intensities of the bands of interest on the autoradiograph. Since the ’actin band’ was 
not clearly visible for several of the treatment groups, normalised band intensities could not be 
determined and a qualitative answer was not possible simply by visual inspection of the 
autoradiograph. Time did not permit a repetition of this final experiment. However, it is included to 
illustrate the technical difficulties associated with the quantitation of autoradiographic data. It also 
demonstrates that it is often only the ’best’ result that appears in the literature.
5.5 Discussion
Nuclear run-on analysis of the in vitro transcriptional rate of CYP4A1 in rat hepatic nuclei 
confirmed that this gene is transcriptionally induced by clofibrate treatment (Harwick et al, 1987). 
Furthermore, the clofibrate-induced transcriptional rate was suppressed by concomitant treatment with 
either poly IC or human interferon a. These results indicate that the inhibitory mechanism(s) which 
causes the interferon-mediated down-regulation of CYP4A1 is directed at the transcriptional induction 
of the CYP4A1 gene.
While the effects of poly IC and interferon a  on the constitutive transcriptional rate of 
CYP4A1 were not clarified, the fact that poly IC did not affect the constitutive levels of CYP4A1 
protein, its lauric acid w-hydroxylase activity and CYP4A1 mRNA strongly suggests that the 
constitutive transcriptional rate of CYP4A1 is not affected by poly IC treatment. Further nuclear run- 
ons are needed to confirm this.
Transcriptional induction involves the interaction of an inducer molecule, regulatory proteins 
(such as receptors and transcription factors), and regulatory sequences (such as the initiator element, 
enhancer elements and upstream regulatory elements) associated with the gene promoter resulting in 
an enhanced rate of transcription at the start site. In view of this, it is likely that the interferon-
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mediated molecular mechanism(s) which suppresses the transcriptional induction of CYP4A1 does so 
by interfering with the molecular processes governing enhanced transcriptional initiation of the 
CYP4A1 gene. A number of hypothetical models for such inhibitory interactions are proposed in 
chapter 6.
In the previous chapters it was shown that, while poly IC caused a significant suppression of 
the induced levels of CYP4A1 apoprotein, catalytic activity and mRNA, human interferon ot appeared 
to cause a relatively smaller suppression. This was attributed to the species specific nature of 
interferon action. Therefore, while the endogenous interferons induced in poly IC treated rats would 
be expected to have a highly specific regulatory effect on the induction of CYP4A1 by clofibrate, 
human interferon a. treatment would be expected to elicit a relatively smaller response.
However, the nuclear run-on analysis indicated that interferon a. had a greater suppressive 
effect than poly IC on the transcriptional induction of the CYP4A1 gene. This was not reflected in 
the relative levels of CYP4AI mRNA in the corresponding treatment groups which apparently 
showed that cotreatment with poly IC or interferon ot had no statistically significant effect on the 
clofibrate-induced level of CYP4A1 mRNA. Although the exact cause of this discrepancy is not 
clear, it is possible that the actual effects of poly IC and interferon a  on the induction of CYP4A1 
mRNA were masked by the limitations of quantitating the slot blot results. However, this does not 
explain the greater suppression of the clofibrate-induced transcriptional activation of CYP4A1 caused 
by interferon a relative to that caused by poly IC.
Although, the effect of clofibrate on the transcriptional rate of the PPAR gene could not be 
clarified, the absence of a clear effect of clofibrate treatment on the level of hepatic PPAR mRNA 
suggests that transcription of the PPAR gene may not be influenced by clofibrate treatment. These 
results do not agree with the results of a study conducted by Gebel and coworkers. They 
demonstrated that in rats treated with fenofibrate, a potent peroxisome proliferator and an analogue 
of clofibrate, the levels of PPAR protein and mRNA were induced relative to the low steady state
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levels in untreated rats (Gebel et al, 1992).
A possible explanation for the difference between this result and the outcome of the present 
investigations is that the latter was obscured by the limitations of the statistical analysis of the slot 
blot results. The large standard deviations in the group data (figure 5.11) may have masked the 
induction of PPAR mRNA by clofibrate. This is supported by the relative mean levels of PPAR 
mRNA which also suggest that the clofibrate-induced level of PPAR mRNA may be down-regulated 
by cotreatment with poly IC. The difficulty encountered in analyzing this data was compounded by 
the faintness of the bands. Further nuclear run-ons and analysis of the RNA samples by Northern 
blotting using a lower washing stringency following hybridisation are required to clarify these 
equivocal results, however, time constraints restricted the repetition of this study. An alternative 
explanation for the difference between the results of Gebel’s study and those presented here would 
be that PPAR expression is genuinely up-regulated by fibrate groups, but that reproducible results 
can only be obtained with the more potent inducers.
While the effects of clofibrate, poly IC and interferon a  on the expression of PPAR remain 
unclear, the implications of the important recent discoveries (outline in sections 1.1.5 and 5.1) on 
the proposed mechanisms for the interferon-mediated down-regulation of the clofibrate-induced 
transcriptional rate of CYP4A1 are discussed in the following chapter.
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CHAPTER 6 
DISCUSSION
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6 DISCUSSION
6.1 The effects of poly IC on CYP4A1
The primary objectives of these investigations were firstly, to confirm the previous reports 
of the suppression of clofibrate-induced CYP4A1 apoprotein and mRNA by poly IC and secondly, 
to progress this area of research by attempting to elucidate the molecular mechanism(s) which 
underlies the interferon-mediated inhibitory effect (Renton et al, 1987, Renton and Knickle, 1990).
With respect to the first objective, the results presented in this thesis support the observations 
of Renton and Knickle. In addition, it was shown that the interferon-mediated suppression of 
CYP4A1 catalytic activity was not due to an indirect effect on two other enzymes involved in the 
monooxygenase system. Neither poly IC nor human interferon ol affected the levels of NADPH- 
cytochrome c reductase activity or cytochrome bg content.
Nuclear run-on analysis of the in vitro transcriptional rate of CYP4A1 in rat hepatic nuclei 
(see chapter 5) confirmed that this gene is transcriptionally induced by clofibrate treatment (Hardwick 
et al, 1987), a finding that had not previously been substantiated. Moreover, this study has shown 
that the clofibrate-induced up-regulation of CYP4A1 transcription is suppressed by cotreatment with 
either poly IC or human interferon a. Since the induction of CYP4A1 occurs by the transcriptional 
activation of the CYP4A1 gene, the results presented here confirm the suggestion made previously 
that this event (rather than mRNA turnover) is the target of the inhibitory mechanism(s) which causes 
the interferon-mediated down-regulation of CYP4A1.
In addition to these observations, it has been demonstrated here that poly IC treatment alone 
does not affect the constitutive levels of CYP4A1 apoprotein content, catalytic activity or mRNA, 
strongly suggesting that the constitutive transcription rate of CYP4A1 is not susceptible to interferon- 
mediated inhibition, although this was not clarified in the present investigations. These results support
160
the proposal that the interferon-mediated suppression of CYP4A1 is due to an inhibitory mechanism 
directed at the transcriptional induction of CYP4A1.
Although the molecular mechanism and upstream regulatory sequence(s) governing the 
transcriptional induction of CYP4A1 have not yet been fully defined, hypotheses can be postulated 
based on the identification of the PPAR and peroxisome proliferator response elements (PPREs) in 
the 5’ flanking regions of the rat acyl Co A oxidase and rabbit CYP4A6 genes (Issemann and Green, 
1990, Tugwood et al, 1992, Muerhoff et al, 1992a). These hypotheses and further theories to explain 
the interferon-mediated down-regulation of CYP4A1 transcriptional induction are presented in section 
6.5.
6.2 Comparison of the effects of poly IC and human interferon a on drug metabolism in rats
Preliminary experiments to determine the effect of human interferon a on the induction of 
CYP4A1 in rats indicated that the clofibrate-induced apoprotein content of this isoenzyme was 
suppressed by the highest dose level of interferon a  (2 x 10^  lU/kg). The lack of an effect by the 
lower interferon a  doses suggests that the suppression of clofibrate-induced CYP4A1 apoprotein by 
human interferon a might be dose-dependent although a distinct dose response relationship was not 
apparent. Unexpectedly, the suppression of clofibrate-induced CYP4A1 apoprotein by the highest 
interferon a dose was not reflected in subsequent analyses of the levels of CYP4A1 catalytic activity 
and mRNA. Further studies are needed to clarify this discrepancy.
A comparison of the effects of interferon a  and poly IC on CYP4A1 was complicated by the 
question of the species specificity of the interferon-mediated suppression of drug metabolism. It might 
be expected that the administration of exogenous human interferon a would elicit a relatively weaker 
effect on drug metabolism in rats compared with the effects of poly IC treatment since poly IC would 
induce endogenous, species specific type I interferons. This would account for the smaller (but
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significant) suppressive effect of the highest human interferon a dose (2 x 10^  lU/kg) on the 
clofibrate-induced levels of total P450 and CYP4A1 apoprotein compared with the suppression caused 
by poly IC.
However, a recent study conducted by Craig and coworkers suggests that, whereas human 
interferon a is able to induce antiviral activities in the cells of other species (see section 1.2.4.3), 
the suppression of drug metabolism by interferons is highly species specific (Craig et al, 1989). They 
showed that while rat interferon y  significantly suppressed the level of total P450 content and 
theophylline clearance in rats, human interferon a did not affect either parameter. The 
biotransformation of theophylline to 1,3-dimethyluric acid has been attributed to the 8-hydroxylase 
activity of CYP1A2 and is the major metabolic pathway although other cytochrome P450 isoenzymes 
are thought to be involved in generating minor metabolites (Fuhr et al, 1992). Although this 
observation appears to be at variance with the results of the present investigations, several 
considerations may account for this.
Firstly, the present investigations were concerned with determining the effects of human 
interferon a on the induction of CYP4A1 (by clofibrate) while the experiments conducted by Craig 
and coworkers examined the effect of human interferon a on the steady state level of theophylline 
metabolism in rats. As will be discussed later (in section 6.3), interferons appear to have different 
effects on the constitutive and induced expression of different P450 isoenzymes. In addition, the 
highest dose of human interferon a used in the present investigations, was approximately 2.5 times 
greater than the highest dose (7.5 x 10^  lU/kg) used in the study conducted by Craig and coworkers. 
It is possible that a higher dose level of human interferon a might suppress the rate of theophylline 
clearance in rats.
It is interesting to note that the constitutive expression of the mouse Cypla-2 protein has been 
shown to be suppressed by human interferon a suggesting that human interferon a  has a differential 
effect on the mouse Cypla-2 and rat CYP1A2 isoenzymes (Stanley et al, 1991). Based on this
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observation, it could be proposed that human interferon a has a differential effect on orthologdus 
P450 isoenzymes in different species. Clearly, an analysis of the effects of interferons on orthologous 
P450 isoenzymes in different species of experimental animals will be required to test this suggestion.
The species specificity of the interferon-mediated suppression of drug metabolism, and the 
suppression of CYP4A1 in particular, might be clarified by a study in which the effects of 
administering a higher dose range (than that used in the present investigation) of exogenous human 
interferon a to clofibrate treated rats are compared with the effects of administering the same dose 
range of rat interferon a  to clofibrate treated rats. Since the present investigations did not reveal a 
distinct relationship between the interferon a dose and the suppression of CYP4A1 induction, such 
a study would also serve to reexamine the dose-response relationship of the interferon-mediated 
down-regulation of CYP4A1 induction.
A more accurate comparison of the effects of poly IC and human interferon a  on drug 
metabolism in rats would be achieved by standardising the dose of exogenous human interferon a 
and the dose of poly IC which would induce a comparable level of type I interferons. This could be 
achieved by administering one group of rats with a series of human interferon a doses and another 
group with a range of poly IC doses. The serum interferon concentration in blood samples, taken at 
half hour intervals up to 24 hours, could then be measured by an assay of antiviral activity or by an 
immunodetection assay (such as ELISA) using commercially available antibodies raised against 
interferons a  and /3. This type of experiment would provide additional information about the 
pharmacokinetics of exogenous human interferon a and the type I interferons induced by poly IC in 
rats. In addition, such experiments would indicate the relative levels of interferon a and /3 induced
by poly IC - Although the plasma and
tissue pharmacokinetics of human interferon a in rats after intravenous administration has been 
studied (Greig et al, 1988), a similar investigation following the intraperitoneal injection of poly IC 
and interferons has not yet been conducted.
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The route of administration is an important consideration when comparing the effects of 
exogenous interferons and poly IC on drug metabolism. Poly IC has consistently been administered 
intraperitoneally at a dose level of lOmg/kg body weight (El Azhary et al, 1979, Renton et al, 1979, 
Renton and Singh, 1984, Renton and Dickson, 1984, Gooderham and Mannering, 1986, 
Ischiropoulos et al, 1989, Moochhala et al, 1989, Gooderham and Mannering, 1990, Morgan, 1991, 
Morgan and Norman, 1990). Intraperitoneal injection was also the preferred route in many similar 
studies with interferons (Ansher et al, 1992, Franklin and Finkle, 1985, Parkinson et al, 1982, 
Stanley et al, 1991). Interferons have also been injected intramuscularly in rats, however, the reason 
for choosing intramuscular injection was not explained in these reports (Craig et al, 1990, Craig et 
al, 1992). In each case, the animals were killed 24 hours post dose.
It is interesting to note that interferons a and y  have been administered mainly by 
intramuscular and subcutaneous injection in humans as absorption was found to be most efficient and 
the catabolism less rapid by these routes (Wills, 1990). These may have been the reasons for using 
this method of administration to rats in the studies conducted by Craig and coworkers (Craig et al, 
1990, Craig et al, 1992). While alternative routes have been used for interferon treatment, these have 
been an attempt to improve the delivery of the interferon to sites which are not easily accessible. For 
example, interferon y  was administered intraperitoneally to treat ovarian carcinoma in a phase I 
clinical trial (D’Acquisto et al, 1988).
In view of the preferred routes of administration in humans, the intraperitoneal injection of 
poly IC and interferons may not be the most efficient route of administration in rats. Further studies 
are needed to explore the pharmacokinetics of interferons in rats following different routes of 
administration.
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6.3 The differential effects of interferons on cytochrome P450 isoenzymes
The present investigations showed an interferon-mediated down-regulation of the 
transcriptional induction of CYP4A1 while the constitutive expression was unaffected. In view of this 
result it could be postulated that interferons down-regulate the induction of those P450 isoenzymes 
which are transcriptionally inducible but do not affect their constitutive expression, implying that the 
interferon-mediated inhibitory mechanism is directed at the process of transcriptional induction of 
these P450 isoenzymes. To test this hypothesis, the suppression of CYP4A1 induction by poly IC and 
interferon a was compared with the effects of poly IC and interferon a on cytochrome CYP2E1. The 
latter P450 isoenzyme was chosen for comparison because it is induced by isoniazid through protein 
stabilisation (Song et al, 1989), whereas CYP4A1 is transcriptionally induced by clofibrate (Hardwick * 
et al, 1987).
Initial analyses showed that neither the constitutive nor induced levels of CYP2E1 apoprotein 
and catalytic activity were affected by poly IC or interferon a. Although the slot blot analysis of ' 
mRNA appeared to indicate that poly IC down-regulated the level of CYP2E1 mRNA in isoniazid < 
treated rats relative to that in rats treated with isoniazid alone, these results were not clear-cut due 
to the problems encountered with quantitation of the slot blot results. The fact that this suppression 
was not observed at the level of CYP2E1 protein and catalytic activity casts doubt on the validity of 
the slot blot result. On the basis of these results it would be tempting to deduce that the inability of 
poly IC or interferon a to suppress the isoniazid-induced levels of CYP2E1 protein and catalytic 
activity confirms the hypothesis that interferons only down-regulate the induction of those P450 
isoenzymes that are transcriptionally inducible.
However, recent reports of the effects of poly IC and interferons on other cytochrome P450 
isoenzymes (discussed below) do not conform to this generalisation. The identification of the factors 
which govern the suppression of P450 isoenzymes by interferons is vital in determining the various
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molecular mechanisms causing the inhibitory effect. To begin with, it would be worthwhile to 
compare the characteristics of the P450 isoenzymes which are down-regulated by interferons to 
identify any common features, such as the mechanisms of constitutive and, or inducible expression, 
which might have a bearing on their susceptibility to down-regulation.
Contrary to the hypothesis proposed earlier in which the interferon-mediated inhibitory 
mechanism only targets the induction of transcriptionally inducible CYP genes, the constitutive 
expression of certain P450 isoenzymes are down-regulated by interferons. CYP2C11 and CYP2C12 
are also constitutively expressed in the liver in a sex specific manner such that CYP2C11 is male 
specific and CYP2C12 is female specific (Soucek and Gut, 1992). The modulation of both of these 
isoenzymes, by growth hormones and diabetes, is by transcriptional activation and neither isoenzyme 
is inducible by xenobiotics. The steady state mRNA level of both CYP2C11 and CYP2C12 have been 
shown to be suppressed by poly IC treatment (Morgan and Norman, 1990, Morgan, 1991). The 
constitutive expression of CYP3A2, another male specific isoenzyme, is transcriptionally modulated 
by growth hormones, diabetes and starvation. The steady state level of CYP3A2 mRNA was 
suppressed by type I and II rat interferons (Craig et al, 1990). The constitutive expression of 
CYP2C6 is also modulated by transcriptional activation and its protein level and catalytic activity have 
been shown to be suppressed by interferon a  (Craig et al, 1992).
These observations suggest that the molecular mechanisms governing the constitutive 
transcription of the CYP2C11, CYP2C12, CYP3A2 and possibly CYP2C6 genes are down-regulated 
by an interferon-mediated mechanism. Based on these observations, one could speculate that 
interferons also transcriptionally down-regulate the constitutive expression of those CYP genes which 
are modulated by transcriptional activation. However, this does not extend to all CYP genes since 
the present investigations have shown that the constitutive steady state levels of CYP4A1 protein, 
catalytic activity and mRNA were not affected by poly IC. Furthermore, interferon a  has been shown 
to suppress the constitutive expression of the mouse Cypla-2 protein, although the effect of interferon
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Ci on the level of Cypla-2 mRNA is not known (Stanley et al, 1991). Since the constitutive 
expression of Cypla-2 is modulated by both transcriptional activation and mRNA stabilisation, there 
is a possibility that the reduced level of Cyp-la2 was also due to an interferon-mediated effect on the 
stability of Cypla-2 mRNA.
Clearly, the interferon-mediated down-regulation of P450 isoenzymes is more complex than 
the results of the present investigations suggest and is probably governed by a combination of factors 
which have yet to be identified. A comparison of the P450 isoenzymes which are down-regulated by 
interferons does not reveal a common feature which might indicate the nature of the interferon- 
mediated molecular mechanism(s) involved.
In view of the interferon-mediated transcriptional down-regulation of CYP4A1 induction 
demonstrated in the present investigations, it is tempting to speculate that all P450 isoenzymes that 
are suppressed by interferons are down-regulated at the transcriptional level. While the information 
(reviewed above) does not support this hypothesis, it does not preclude it either. Where studies have 
only demonstrated an interferon-mediated suppression of the protein content and, or catalytic activity 
of certain P450 isoenzymes (Craig et al, 1989, Stanley et al, 1991, Craig et al, 1992), this could be 
the result of a transcriptional down-regulation of the CYP genes. The transcriptional down-regulation 
of CYP genes could also explain the suppression of specific P450 mRNA levels (Morgan and 
Norman, 1990, Morgan, 1991, Craig et al, 1990, Renton and Knickle, 1990).
Clearly, further information about the effects of interferons on other P450 isoenzymes is 
required to expand these investigations. It has been assumed thus far that a single, common 
interferon-mediated mechanism causes the down-regulation of different P450 isoenzymes. However, 
given the complexity of other interferon-mediated activities, for example in immunomodulation and 
in the antiviral response (see section 1.2.4.1 and 1.2.4.3), it is possible that the differential effects 
of interferons on P450 isoenzymes might be the result of different inhibitory mechanisms elicited by 
interferons.
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6.4 The proposed role of the PPAR in the transcriptional induction of CYP4A1
Since the PPAR has been implicated in the transcriptional induction of peroxisome prolferator 
responsive genes such as CYP4A1, the receptor is a potential target for the interferon-mediated 
inhibitory mechanism that causes the down-regulation of clofibrate-induced CYP4A1 transcription.
To put the hypothetical molecular models for the interferon-mediated suppression of CYP4A1 
induction (described in section 6.5) into context, molecular models for the induction of CYP4A1 are 
presented below. These models are based on the current information about the PPAR, PPREs and 
peroxisome proliferator inducible genes including CYP4A1.
The peroxisome proliferator inducible genes examined thus far {CYP4A1, CYP4A2, CYP4A6 
and the acyl Co A oxidase gene) do not contain a consensus TATA box in their promoter sequence ' 
(Kimura et al, 1989a, Osumi et al, 1991, Muerhoff et al, 1992a). However, several putative 
regulatory sequences have been identified in the 5’ flanking regions of these genes. Two highly 
conserved sequences have been identified in the upstream regions of CYP4A1 and CYP4A2. These ?
are a 19bp sequence located 42 and 48bp upstream and a 6bp (GATTTA) sequence located 20 and i
25bp upstream of the transcription start sites of CYP4A1 and CYP4A2 respectively (Kimura et al, 
1989a). The functions of these sequences are not yet known.
A consensus GC rich sequence, the core binding site for the transcription factor Spl, has been 
identified in the 5’ flanking regions of the CYP4A1 and CYP4A6 (Kimura et al, 1989a and Muerhoff 
et al, 1992a). In addition, an llbp sequence (the function of which is not known) is strongly 
conserved between CYP4A1 and CYP4A6 (Muerhoff et al, 1992a). The CYP4A6 gene has two 
CCAAT boxes and a 17bp sequence which bears a strong similarity to the reverse orientation of one 
of the two regulatory sequences in the acyl CoA oxidase gene which are known to be protected by 
proteins following ciprofibrate treatment (Osumi et al, 1991 and Muerhoff et al, 1992a). In vitro 
expression studies showed that this conserved sequence in the promoter of the acyl CoA oxidase gene
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acted as positive regulatory element which was essential for transcriptional induction by ciprofibrate 
whereas the other sequence acted as a negative regulatory element (Osumi et al, 1991). The positive 
regulatory element, located between 578 to 553bp upstream of the transcription start site of the acyl 
CoA oxidase gene, was subsequently shown to contain two 6bp motifs (TGACCT and TGTCCT) 
which are important for PPAR binding (Tugwood et al, 1992). These DNA motifs have been denoted 
the collective term the ’peroxisome proliferator response element’ (PPRE).
Similar expression studies to those conducted by Tugwood and coworkers have shown that 
the regulatory sequence 723 bp upstream of the CYP4A6 gene which resembled the acyl CoA oxidase 
PPRE was able to bind clofibrate-activated PPAR and stimulate transcriptional activity, confirming 
that it is also a PPRE (Muerhoff et al, 1992b). The identification of the CZP44d-linked PPRE 
strongly suggests that the induction by clofibrate of the closely related CYP4A1 gene (both 
isoenzymes are fatty acid w-hydroxylases) also involves PPAR.
The observations outlined above strongly suggest that the PPRE is an inducible enhancer 
element since it appears to be functional in the reverse orientation in the CYP4A6 gene. Moreover, 
the PPRE motifs conform to the definition of an enhancer as a cluster of simple sequence modules 
(Heintz and Desplan, 1991). The fact that enhancers can act at a considerable distance from the 
transcription start site might explain why the PPREs of the CYP4A1 and CYP4A2 have not yet been 
identified. The PPREs of these genes might be located in the 5’ flanking regions further upstream 
to those which have been sequenced thus far. The constitutive expression of peroxisome proliferator 
inducible genes is probably directed by cw-acting constitutive regulatory elements. Separate 
constitutive and inducible enhancer elements have been identified in the upstream sequences of other 
eukaryotic genes such as the mouse and humanmetallothioneini genes (Serfling et al, 1985).
A biphasic induction of the apoprotein content, catalytic activity and mRNA levels of 
CYP4A1 has been observed after a single dose of clofibrate (Milton et al, 1990). The first and 
second peaks of induction were observed at about 30 minutes and 18 hours respectively. However,
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the mRNA levels of acyl CoA oxidase and palmitoyl CoA oxidase were induced in a monophasic 
manner after clofibrate treatment with peaks at about 18 hours and 18 to 24 hours post dose 
respectively (Milton et al, 1990). In addition, the clofibrate-induced level of CYP4A1 mRNA 24 
hours after clofibrate treatment was not affected by cotreatment with cycloheximide, but the induction 
of acyl CoA oxidase mRNA was abolished by cycloheximide treatment.
If it is assumed that the PPAR is necessary for the transcriptional activation of CYP4A1, the 
results of the study described above suggest that the basal level of the PPAR was sufficient for the 
induction of CYP4A1 while the transcriptional induction of the acyl CoA oxidase gene might require 
the de novo synthesis of an additional regulatory factor. On the basis of the PPREs identified in the 
acyl CoA oxidase and CYP4A6 genes, the PPREs of different peroxisome proliferator inducible genes 
are likely to be similar. However, differences between the PPREs might confer a differential 
susceptibility to the PPAR which might in turn account for the different levels of induction of the 
peroxisome proliferator responsive genes.
If the PPREs of the acyl CoA oxidase and CYP4A6 genes are differentially susceptible to 
PPAR-binding such that the PPAR-PPRE binding in the former gene requires the synthesis of an 
additional transcription factor, then in the absence of that factor, the activated PPAR might bind very 
weakly (or not at all) with the acyl CoA oxidase PPRE. Consequently, in rats cotreated with 
clofibrate and cycloheximide, the activated latent PPAR might bind more strongly to the PPREs of 
some peroxisome proliferator inducible genes (such as CYP4AÏ) while the induction of the acyl CoA 
oxidase gene might be prevented by the inability of the cell to synthesize the additional transcription 
factor. This hypothesis is supported by the apparent lag period of approximately 8 hours post dose 
(during which the additional transcription factor might be synthesized) before the distinct induction 
of acyl CoA oxidase mRNA whereas the first peak of CYP4A1 mRNA induction occurs 1 hour after 
clofibrate treatment (Milton et al, 1990).
The differential regulation of peroxisome proliferator responsive genes by the interactions
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of the PPAR with additional transcription factors is supported by recent investigations involving other 
members of the nuclear hormone receptor superfamily (Green, 1993). These studies have shown that 
the DNA-binding capacity of receptors such as the Drosophila ecdysone receptor (EcR), the thyroid 
hormone receptor (TR) and the vitamin D3 receptor (VDR) with their target response elements is 
potentiated by the heterodimerisation of the receptor with the retinoid X receptor (RXR) (Carlberg 
et al, 1993, Green, 1993, Thomas et al, 1993). These studies also suggest that an additional 
mechanism of differential regulation may be provided by the binding of 9-cw -^retinoic acid with the 
RXR. The ligand may potentiate the RXR-receptor dimérisation or enhance the DNA-binding 
capacity of the heterodimer.
In addition to these putative mechanisms of regulation, it has been suggested that the nature 
of the response elements targeted by nuclear hormone receptors could influence the differential 
regulation of genes responding to the receptors (Umesono et al, 1991). The response elements to 
which the VDR-RXR, TR-RXR and retinoic acid receptor-RXR (RAR-RXR) heterodimers bind are 
direct repeats that are separated by 3, 4 and 5 base pair spaces respectively. The size of the spacing 
between the repeated sequences in theresponseelements appears to be important and may control the 
affinity of heterodimer-DNA binding. Since the PPREs identified to date also consist of direct repeats 
of simple sequence motifs separated by short spaces (for example, the acyl CoA oxidase PPRE 
consists of two 6bp motifs (TGACCT and TGTCCT) separated by 1 base pair (Tugwood et al, 
1992)), this characteristic strongly suggests that the PPAR also forms a heterodimer with RXR. 
Moreover, the slight differences between the PPREs of different peroxisome proliferator responsive 
genes may influence their differential regulation by the PPAR-RXR heterodimer.
Although the effect of clofibrate treatment on PPAR mRNA was not clarified by the 
experiments conducted in the present investigations, the induction of PPAR mRNA in rats treated 
with fenofibrate, a structural analogue of clofibrate, was observed recently (Gebel et al, 1992). After 
a latency period of at least one day, a significant induction of PPAR mRNA and protein was
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observed in the subsequent twelve days. In addition, no PPAR protein was detected in the cytosol 
or nuclear extract in untreated rats but a strong immunoreactivity with the antibody to PPAR was 
observed after seven days of fenofibrate treatmoi.t in both the cytosol and nuclear extracts. This lack 
of the PPAR protein and mRNA in the cytosol and nuclear extracts of untreated rats suggested that 
this receptor is not constitutively expressed. However, PPAR mRNA was detected in untreated rats 
in the present investigations. The strain of rats used by Gebel and coworkers was not specified in 
their publication and this might be the source of the difference between the results of that and the 
present study.
The following is a hypothetical model for the role of the PPAR in the transcriptional induction 
of CYP4A1 based on the information reviewed above and on the presence of PPAR mRNA in 
untreated rats in the present investigations.
(i) In untreated rats, the PPAR gene constitutively expresses an inactive non-dimerising
form of the PPAR molecule. The constant basal level of the inactive PPAR may be 
maintained by the auto-regulation of thé PPAR gene by the intracellular concentration of 
PPAR (figure 6.1). Activation of the PPAR by clofibrate might occur by a number of 
possible mechanisms. PPAR might bind with the clofibrate molecule inducing a 
conformational change in the PPAR molecule. Alternatively, conformational change in the 
PPAR molecule might be caused by an intermediate, clofibrate-activated factor. However, 
the former is the more likely mechanism of activation since recent investigations with 
computer-aided molecular modelling have suggested that, although peroxisome proliferators 
have diverse chemical structures, many peroxisome proliferators share some common 
structural features and functional groups and a putative ligand-binding site which can 
accomodate numerous peroxisome proliferator has been proposed (Lewis and Lake, 1993).
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(ii) A change in the phosphorylation state of the PPAR, perhaps by an intermediate
clofibrate-activated enzyme, is another possible mechanism of activation of the receptor. This 
possibility is explored more fully later (in section 6.5). In an alternative hypothetical 
mechanism, the latent PPAR molecule might be inactive due to its binding to another protein 
such that the dimérisation region of PPAR is masked rendering it unable to bind to the RXR. 
Binding of clofibrate to the PPAR might change the structural conformation of the receptor 
such that it is no longer bound to an inactivating protein. The PPAR would then be able to 
heterodimerise with the RXR and migrate to the nucleus. The glucocorticoid receptor, another 
member of the steroid hormone receptor family, is an example of a receptor which is thought 
to be activated by a similar mechanism. The glucocorticoid receptor resides in the cytoplasm 
in the form of a complex with another protein, HSP90 (Denis et al, 1988, Howard et al, 
1988). It is thought that the glucocorticoid molecule releases HSP90 thereby allowing the 
receptor to migrate to the nucleus, bind the appropriate DNA regulatory element(s) and 
activate transcription. If the PPAR binds to an inhibitory protein, some epitopes of the PPAR 
molecule might be masked and this could explain why the PPAR protein was not observed 
by immunodetection in the hepatic cytosol of untreated rats (Gebel et al, 1992). However, 
this would not explain the absence of PPAR mRNA in the same group of animals.
(iii) Until further information is available, any of the hypothetical mechanisms described 
above might be responsible for the activation of PPAR by peroxisome proliferators. In 
whichever way the PPAR molecule is activated, this might promote dimérisation with the 
RXR and enable the translocation of the heterodimer from the hepatic cytosol to the nucleus 
where it binds to the PPRE associated with the CYP4A1 gene inducing its transcription. 
According to the current model of transcriptional activation by a protein bound at an 
enhancer, the intervening DNA sequence between the enhancer and the promoter loops out
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so that the activator protein (the PPAR in this case) can make contact with the RNA 
polymerase II and the transcription factors which form the transcription initiation complex. 
The hypothetical sequence of events described above is schematically represented in figure 
6.2.
It is possible that, whereas RNA polymerase may bind very weakly at the promoter 
under the control of the regulatory element(s) governing the constitutive transcription of 
CYP4A1, an interaction with the PPAR (bound at the PPRE) might cause the RNA 
polymerase II to bind more strongly and with greater frequency thereby enhancing the rate 
of transcription. In view of the complexity of the initiation of transcription, it may be some 
time before the precise molecular mechanism by which PPAR stimulates the transcription of 
peroxisome proliferator-inducible genes is elucidated.
It is tempting to speculate that the biphasic induction of CYP4A1 observed by Milton and 
coworker (1990) might be explained by some of the hypotheses and observations described above. 
Following clofibrate treatment, the first, small peak of CYP4A1 induction might be due to the 
activation of latent PPAR molecules in the cytoplasmic PPAR pool. As the PPAR molecules enter 
the nucleus and bind with PPREs, the cytoplasmic pool is diminished. This might trigger a positive 
feedback signal causing the transcriptional induction of the PPAR gene which would replenish or 
expand the PPAR pool accounting for the second peak of CYP4A1 induction. This would also 
explain the induction of PPAR mRNA by fenofibrate (Gebel et al, 1992). However, the fact that the 
induction of CYP4A1 was not affected by cycloheximide treatment is inconsistent with these models 
(Milton et al, 1990). According to the models described above, cycloheximide would inhibit the 
synthesis of new PPAR molecules abolishing the second peak of CYP4A1 induction. However, the 
second phase might due to recycling of the PPAR or delayed effects due to dimerization with the 
RXR.
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In an alternative to the ’replenishing’ hypothesis, the activation of the PPAR by binding with 
clofibrate and heterodimerisation might enable the receptor to recognise a PPRE-like element 
associated with the PPAR gene causing auto-induction. However, this theory is weakened by the 
observation that the induction of PPAR mRNA by fenofibrate was observed after a latency period 
of at least one day (Gebel et al, 1992), whereas the maximal induction of CYP4A1 by clofibrate 
occurred at 18 hours post dose (Milton et al, 1990). The difference in routes of administration of the 
two peroxisome proliferators (fenofibrate was given in the diet (0.25% (w/w)) and clofibrate was 
injected intraperitoneally (250 mg/kg)) suggests that the latency period following clofibrate treatment 
might be shorter for reasons related to the route of administration. However, further work on the 
effects of clofibrate on PPAR mRNA is needed to determine whether these findings relate to the 
observations of Gebel and coworkers.
6.5 Models for the type I interferon-mediated suppression of the clofibrate-induced 
transcriptional activation of CYP4A1
The precise molecular mechanism(s) which governs the observed suppression of P450 
isoenzymes by type I and II interferons is as yet unknown. Indeed, one cannot rule out the possibility 
that the differential suppression of P450 isoenzymes is governed by a number of different interferon- 
mediated mechanisms which down-regulate different stages of gene expression. Therefore, it must 
be emphasized that, until further research reveals the actual inhibitory interferon-mediated 
mechanism(s), any theoretical mechanisms for the suppression of P450s will remain speculative.
Earlier it was suggested that the promoters of peroxisome proliferator-inducible genes such 
as CYP4A1 are associated with upstream constitutive and inducible enhancers. The interaction of 
transcription factors, which may be regulated by endogenous signals, with the constitutive enhancer(s) 
might control the constitutive expression of these genes, while transcriptional induction is likely to
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be regulated by the binding of activated PPAR molecules with inducible enhancers (the PPREs). 
Based on this theory for the clofibrate-induced transcriptional activation of CYP4A1 (see section 6.4) 
and the little that is known about the type I interferon-induced signal transduction pathway (see 
section 1.2.5), a number of hypothetical models can be constructed for the type I interferon-mediated 
suppression of CYP4A1 induction.
A number of general models have been proposed for the mechanisms of transcriptional down-- 
regulation based on the transcriptional repression of specific eukaryotic genes (Levine and Manley, 
1989, Renkawitz, 1990, Herr, 1991). The interferon-mediated mechanism causing the transcriptional 
down-regulation of CYP4A1 activation might conform to one of these general models which are 
termed ’competition’, ’direct repression’, ’quenching’ and ’squelching’. The first model simply 
involves the competitive binding of a repressor molecule with a DNA sequence which either overlaps, 
or is closely linked, with the positive regulatory element preventing the binding of the activating 
transcription factor. According to this model, an interferon-induced or activated regulatory protein 
would compete directly with the clofibrate-activated PPAR for binding with the PPRE.
The quenching model would involve the binding of an interferon-mediated inhibitory factor 
(IFN-MIF), which could be a protein that is induced or activated by an interferon mediated 
mechanism, with a DNA sequence adjacent to the PPRE. An interaction between this protein and the 
PPRE-bound PPAR would prevent the appropriate contact between the PPAR and the transcription 
initiation complex at the CYP4A1 promoter, thereby inhibiting transcriptional induction. Alternatively, 
the suppressive mechanism might not involve an interaction or competition with the PPAR molecule. 
Instead, the IFN-MIF might bind with a negative regulatory element associated with the CYP4A1 
promoter causing the direct repression of the gene.
All the models described above involve the recognition of specific DNA sequences by the 
IFN-MIF. However, the squelching mechanism does not require either the recognition of specific 
DNA-binding sites or the presence of a DNA-binding domain in the regulatory protein. There are
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a number of possible scenarios that would fit the squelching mechanism which essentially involves 
an interaction between the IFN-MIF and the PPAR. First, an interaction between the IFN-MIF might 
modify the conformation of the PPAR molecule in such a way that its DNA-binding property is 
abolished. Alternatively, the protein-protein binding might mask the DNA-binding region of the 
PPAR molecule. This hypothetical model could be extended if one assumes that the activated PPAR 
must first form a heterodimer with the RXR for binding with the PPRE. The IFN-MIF might interact 
with the RXR or the PPAR in such a way that their heterodimerisation is inhibited thereby preventing 
the transcriptional activation of the CYP4A1 gene. Another possibility is that an interaction with the 
IFN-MIF might alter the structure of the PPAR such that it can not bind with (and thereby be 
activated by) clofibrate. This inhibitory mechanism might be two fold since the putative auto­
induction of the PPAR (mentioned earlier) would also be prevented potentiating the suppressive effect 
of the IFN-MIF on the transcriptional induction of CYP4A1. A schematic representation of the 
possible sites of CYP4A1 induction that might be affected by an interferon-mediated mechanism are 
shown in figure 6.3.
Clearly there are numerous possible mechanisms by which the interferons suppress the 
transcriptional induction of CYP4A1 each of which might be the actual events occurring in vivo. The 
observations (of the present investigations) that poly IC did not affect the steady state levels of 
CYP4A1 apoprotein, catalytic activity and mRNA strongly suggest that the constitutive transcription 
of CYP4A1 was not affected by interferon. According to the models described above, if the IFN-MIF 
interferes with just the induction of CYP4A1, then the constitutive transcription of CYP4A1 would 
be expected to remain unaffected. However, the interferon-mediated down-regulation of the 
constitutive expression of other P450 isoenzymes (see section 6.3) suggests that the actual inhibitory 
mechanisms might be more complex and diverse than the putative models described for CYP4A1.
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Although there is no evidence for the involvement of phosphorylation in the transcriptional 
activation of P450 isoenzymes, phosphorylation has been shown to play an important role in the post- 
translational regulation of the activities of some cytochrome P450 isoenzymes (Oesch-Bartlomowicz 
and Oesch, 1990). Calcium/phospholipid-dependent protein kinase (PKC) and cAMP-dependent 
protein kinase (PKA) have been shown to directly phosphorylate CYP2B1 and CYP2B2 decreasing 
their catalytic activities (Pyerin et al, 1987). Although interleukin-6 (IL-6) has been shown to 
suppress the PB-inducible level of CYP2B1 mRNA, the effects of other cytokines on CYP2B1 are 
unclear (Craig et at, 1992, Williams et al, 1991). Phosphorylation might play a role in the inhibitory 
mechanism(s) causing the down-regulation of some P450 isoenzymes by interferons. In the specific 
case of the interferon-mediated down-regulation of CYP4A1 induction, a change in the 
phosphorylation state of the PPAR by an IFN-MIF might result in an inhibition of the receptors 
DNA-binding or protein-protein interaction properties. Any effect on the ability of the PPAR to up- 
regulate its own transcription would potentiate this effect on CYP4A1 induction.
Phosphorylation is known to be important in the signal transduction pathway induced by type 
I interferons. A specific isoform of the phosphorylase PKC is known to be involved in the interferon- 
mediated induction of ISGs (Reich and Pfeffer, 1990, Pfeffer et al, 1990, see section 1.2.5). In 
addition, a protein factor, which does not itself interact with a 29bp cis-acting consensus regulatory 
sequence (ICS), has been shown to increase the DNA-binding properties of other nuclear proteins 
by enhancing their capacity to be phosphorylated (Roy and Lebleu, 1990). Such phosphorylated 
nuclear proteins might quench or directly compete with the clofibrate-activated PPAR for binding 
with the PPRE preventing the transcriptional activation of CYP4A1.
It was previously suggested that the interferon-mediated down-regulation of P450s could be 
the result of antiviral activities such as the activation of an endoribonuclease known to digest mRNA. 
It is not known if this endoribonuclease specifically digests viral RNA. Therefore, unless evidence 
to the contrary comes to light, it is also possible that some P450 isoenzymes might be down-regulated
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post-transcriptionally by factors that are involved in the acute phase response to viral infection.
While some of the models described in this section appear to be more plausible than others, 
it must be remembered that they are all hypothetical. There may be more than one interferon- 
mediated inhibitory mechanism and many different IFN-MIFs which may act at different stages of 
cytochrome P450 gene expression.
Apart from the interferons, other cytokines, such as IL-1 and IL-6, have been shown to 
down-regulate cytochrome P450 (Bertini et al, 1988, Pous et al, 1990, Kurokohchi et al, 1992, Pasco 
et al, 1992). IL-1 suppresses the transcriptional activation by TCDD of the CYPlAl and CYP1A2 
genes in rat hepatocytes (Pasco et al, 1992). This cytokine also down-regulates the protein and 
mRNA levels of CYP2D (Kurokohchi et al, 1992). IL-6 down-regulates the PB-induced level of 
CYP2B1 in rat hepatocytes (Williams et al, 1991, Chen et al, 1992). In contrast to the effects of IL-1 
and IL-6 on P450, IL-2 has been shown to induce the expression of rat hepatic CYP2D1 (Kurokohchi 
et al, 1993). However, IL-2 has also been shown to down-regulate the activities of other P450s 
indicating that this interleukin has a differential effect on cytochrome P450 isoenzymes (Ansher et 
al, 1992).
The numerous roles of cytokines in immunomodulation are well documented (e.g. Hamblin, 
1990). For example, a role for IL-2 has been implicated in the production of interferon 7 , mainly 
by T cells and natural killer (NK) cells, in response to mitogen or antigen stimulation. IL-2 is in turn 
produced by T^ cells in response to IL-1 secretion by macrophages. This network also involves the 
interferon 7-mediated induction of some T cell membrane receptors including IL-2 receptors which, 
when stimulated, promote proliferation of the T cells (Male et al, 1991). The tumour necrosis factors 
(TNFa and TNFjg) are cytokines, which are known to induce the production of IL-1 and IL-6 from 
macrophages, have also been shown to modulate the expression of P450 isoenzymes (Li et al, 1988).
The complex interrelationship between cytokines in immunomodulation suggests that the 
cytokine-mediated modulation of the expression of some P450 isoenzymes, and thereby the
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metabolism of some endogenous substrates, might have evolved to confer an advantage to the 
organism against viral infection. However, the clinical complications arising from the cytokine- 
mediated suppression of the metabolism of therapeutic drugs (reviewed in section 1.3.2) render such 
a relationship as counter-productive. An alternative to this theoretical explanation for the modulation 
of cytochrome P450 isoenzymes by cytokines is that the mechanisms causing the modulation may 
have once been innocuous ’side-effects’ of the host defence mechanisms and only became deleterious 
with the advent of chemotherapy. The actual explanation for the cytokine-mediated modulation of 
cytochrome P450 isoenzymes will only emerge when the precise molecular mechanisms governing 
the modulation have been elucidated.
6.6 Suggestions for future work
Continued work on elucidating the mechanism(s) causing the transcriptional down-regulation 
of CYP4A1 induction will be worthwhile as this may provide a model for the interferon-mediated 
suppression of other transcriptionally-inducible P450 isoenzymes, particularly those in man.
As mentioned earlier, determining the effect of clofibrate on the protein and mRNA levels 
of the PPAR and on the transcription rate of the PPAR gene will help to construct a model for the 
transcriptional induction of CYP4A1 and might help to explain the biphasic nature of the induction. 
It would also be worthwhile to confirm the indications of the present investigations which strongly 
suggest that poly IC and interferon a do not affect the constitutive transcription rate of CYP4A1 by 
repeating the second nuclear run-on assay.
Comparing the effects of a higher dose range (than previously used) of human interferon a. 
and rat interferon a on the induction of rat hepatic CYP4A1 would clarify the question of the species 
specificity of the effects of exogenous interferon a on drug metabolism and also ascertain whether 
the effect is dose-dependent (see section 6.2). In addition, the species specificity of the effect of
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interferons on drug metabolism could be explored by evaluating the effects of poly IC and human 
interferon a  on P450 isoenzymes in other animal models such as the mouse, hamster, guinea pig and 
monkey.
An analysis of the pharmacokinetics of poly IC-induced type I interferon and human 
interferon a following intraperitoneal injection in rats would enable a more Confident interpretation 
of the type of experiments presented here. It would also enable a more effective comparison of the 
effects of endogenous and exogenous interferons on drug metabolism (see section 6.2). The relative 
levels of interferons a  and could be evaluated by an immunodetection method (e.g. ELISA) using 
antibodies raised against these interferon types.
The possible involvement of phosphorylation in the PPAR-mediated induction of CYP4A1 and 
in the transcriptional down-regulation by interferons of CYP4A1 induction needs to be examined. 
Preliminary studies might involve an investigation of the effect of staurosporine, a PKC inhibitor, 
on the interferon-mediated suppression of CYP4A1 induction in cultured hepatocytes to determine 
whether the | phosphorylase activity o f PKC is necessary for the down-regulation.
Broadening the investigation to determine the effects of a range of cytokines on numerous 
cytochrome P450 isoenzymes would be worthwhile to clarify the relationship between 
immunomodulatory processes and the suppression of drug metabolism. Such studies might shed some 
light on the molecular mechanisms governing the modulation of cytochrome P450s by cytokines.
In view of the fact that the ultimate aim of conducting the types of experiments presented in 
this thesis and those described by many others is to enable the prediction of the potential toxicological 
risk of chemotherapy with interferons in the treatment of humans, investigations into the effects of 
human interferons on the cytochrome P450 monooxygenase system in cultured human hepatocytes 
would provide valuable information to support the results of investigations based on experimental 
animal models.
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